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Summary 
Apoptosis, as a special form of programmed cell death (PCD) is an essential 
developmental process that is involved in tissue homeostasis and, whose 
deregulation has severe pathological implications for an organism. Thus, the 
evasion of the apoptotic program is one hallmark capability of cancer cells. Tumor 
suppressor genes (TSG) under normal conditions fulfill functions like sensing DNA-
damage or regulating gene expression and they may contribute to the induction of 
apoptosis. In most cancer cells, TSG are mutated, inactivated or their expression 
level is reduced to enable neoplastic outgrowth and tumor cell proliferation. 
Furthermore, inactivation or blockage of TSG function may contribute to activation 
and upregulation of anti-apoptotic oncogenes. The identification and functional 
characterization of novel pro-apoptotic proteins, which can act as tumor suppressors 
themselves, is important in cancer research.  
In this study, the novel APAF-1 binding protein FAM96A, which was discovered in a 
yeast two hybrid screen, was functionally characterized, and its involvement in 
tumorigenesis and Fe-S cluster biogenesis was elucidated. Importantly, the 
endogenous interaction with monomeric APAF-1 was confirmed.  
Furthermore, FAM96A has recently been described to interact with the cytosolic iron 
sulfur assembly protein Ciao1. A combined functional contribution of Ciao1 and 
FAM96A to intrinsic apoptosis was excluded by overexpression and knockdown 
experiments during this study. Ciao1 exhibits a rather anti-apoptotic function, which 
is independent of FAM96A and, most probably, connected to its role in cytosolic Fe-
S biogenesis. However, a scaffolding function of FAM96A during cytosolic iron-sulfur 
assembly might reflect a conserved function of the protein.  
Ciao1 was described to regulate the transcriptional activity of WT1, a tumor 
suppressor in childhood nephroblastoma. Here, a reduction of WT1 mRNA 
expression upon simultaneous Ciao1 overexpression was observed, whereas the 
contribution of FAM96A to the regulation of the WT1 transcription factor was only 
minor. 
The role of FAM96A in intrinsic apoptosis was investigated by stable lentiviral 
protein overexpression in cancer cells. Human colon carcinoma and murine renal 
cancer cells were transduced to upregulate their FAM96A levels. These stable cell 
lines were compared to control vector transduced cells in apoptosis assays 
investigating the effects of FAM96A overexpression on the intrinsic pathway. Upon 
induction of PCD by the chemotherapeutic agents mitomycin C and the second-
generation platinum derivative oxaliplatin, cell killing was enhanced when FAM96A 
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was simultaneously upregulated. Accordingly, when protein levels were diminished 
as a consequence of lentiviral short hairpin RNA (shRNA)-mediated knockdown, a 
significant desensitization of murine fibroblast and RKO cells to the induction of the 
intrinsic apoptosis pathway was observed. Furthermore, the influence of increased 
FAM96A expression levels was investigated in vivo in subcutaneous tumor 
xenograft experiments in NOD/SCID mice. The engraftment potential of colon 
cancer cells was drastically impaired in FAM96A groups compared to controls, and 
tumor growth was reduced in RKO as well as Renca-lacZ tumors. While a regulatory 
influence of FAM96A on intrinsic apoptosis could be observed, the cell cycle 
distribution of Renca-lacZ was not affected by FAM96A upregulation.  
Although several approaches were taken to elucidate the molecular mechanism of 
the pro-apoptotic contribution of FAM96A to intrinsic apoptosis and its putative 
function during apoptosome assembly, it remains unresolved until now. A potential 
scaffolding function of FAM96A during apoptosome assembly or an involvement as 
a nucleotide exchange factor on APAF-1 cannot be excluded. As a pro-apoptotic 
protein, FAM96A resembles a putative tumor-suppressor gene, and losses within 
the FAM96A locus were detected by comparative genomic hybridization. Here, copy 
number aberrations were observed most prominently in gastrointestinal stromal 
tumors (GIST) where 48.8% of tumors analyzed indicated deletions. This was 
further addressed by immunohistochemistry of 53 GIST patient samples, and 
independent of cancer origin, no positive staining for FAM96A could be observed. A 
second patient cohort of GISTs of distinct grading was analyzed for FAM96A mRNA 
expression, which was reduced in 29 out of 31 samples. Upon re-introduction of 
FAM96A in established GIST cell lines, susceptibility towards apoptotic treatment 
with the state-of-the-art tyrosine kinase inhibitor Imatinib Mesylate and, in the case 
of imatinib-resistant GIST, staurosporine was increased compared to controls. 
Tumorigenicity of GIST882 cells re-expressing FAM96A was significantly reduced in 
a tumor xenograft experiment, and the engraftment potential was diminished. 
Quantitative real time PCR analysis on the time point of FAM96A loss in the course 
of tumorigenesis indicate that reduction of FAM96A mRNA levels may occur as an 
oncogenic event during malignant transformation of interstitial cells of Cajal, the 
suspected cell of origin of GIST. FAM96A therefore represents a marker for GIST 
and a novel tumor suppressor protein in this cancer entity. Nonetheless, FAM96A 
exhibits its tumor-suppressive potential not only in GIST, but also in further tumor 
entities as suggested by multi-tumor tissue arrays. Protein levels were reduced in 
renal and transitional cell carcinoma compared to normal kidney and bladder tissue.  
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The physiological function of the protein was further investigated by the 
establishment and preliminary analysis of a conditional FAM96A knockout mouse 
model. Here, FAM96A/lacZ reporter mice were generated in which Exon 3 of the 
FAM96A gene was deleted following breeding of mice with CMV-Cre mice. Strong 
endogenous FAM96A promoter activity was observed in tissues of the immune 
system such as spleen and thymus, and in the gastrointestinal tract of the FAM96A-/- 
mice. Surprisingly, and in contrast to observations from yeast, drosophila and 
zebrafish model systems, where knockout of the gene was lethal, FAM96A-/- mice 
were born and vital and displayed no obvious phenotype under non-stressed 
conditions.  
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Zusammenfassung 
Apoptose als eine Sonderform des programmierten Zelltods ist ein konservierter, 
entwicklungsphysiologisch relevanter Prozess, der zur Gewährleistung der  
Gewebshomöostase wesentlich beiträgt. Eine Fehlregulation des apoptotischen 
Zelltods hat schwerwiegende pathologische Implikationen und ist zum Beispiel 
wesentlich für die Krebsentstehung und neurodegenerative Erkrankungen mit 
verantwortlich. Sowohl inaktivierende Mutationen in pro-apoptotischen Genen als 
auch die Aktivierung  anti-apoptotischer Onkogene tragen zur Ausbildung von 
Neoplasien bei. In nicht-kanzerogenen Zellen regulieren Sensorproteine, 
sogenannte Tumorsuppressoren, physiologische Abläufe wie den Zellzyklus, die 
Apoptose oder sind für die Zelldifferenzierung verantwortlich. Die Identifizierung und 
Charakterisierung neuer, potentieller Tumorsuppressorgene (TSG) stellt darum 
einen wichtigen Inhalt der aktuellen Krebsforschung dar.  
In dieser Arbeit wurde das in einem Hefe-2-Hybridsystem isolierte APAF-1-bindende 
Protein FAM96A als Tumorsuppressor charakterisiert und seine pro-apoptotische 
Rolle im intrinsischen Apoptoseweg näher definiert. Zunächst wurde die Interaktion 
der im Hefe-2-Hybridsystem isolierten Partner APAF-1 und FAM96A mit den 
endogenen Bindungspartnern in HEK293T Zellen verifiziert. Preliminäre Daten von 
transienten Überexpressionsexperimenten und zur APAF-1-Interaktion des Proteins 
lieferten einen Hinweis auf eine pro-apoptotische Funktion und sollten bestätigt 
werden. Um eine weitere, funktionelle Charakterisierung des Proteins zu 
ermöglichen, wurden stabile Zelllinien zur FAM96A-Überexpression generiert und 
auf ihr Apoptoseverhalten hin mit Kontrollvektor-transduzierten Zellen verglichen. 
Diese Überexpressionsstudien wurden sowohl in humanen Kolonkarzinomzellen 
(RKO) als auch in einer murinen Nierenkrebszelllinie (Renca-lacZ) durchgeführt, 
und der intrinsische Zelltod wurde mit Hilfe von Chemotherapeutika wie Mitomycin C 
oder Oxaliplatin induziert. Hierbei konnte die pro-apoptotische Funktion des Proteins 
bestätigt werden. Dieser stimulatorische Einfluss des Proteins auf den 
mitochondrialen Apoptoseweg  wurde durch FAM96A-Deletionsanalysen mit Hilfe 
von „short hairpin“ RNAs in murinen Fibroblasten und RKO-Zellen verifiziert. Ein 
signifikanter Desensitisierungseffekt gegenüber UV-induzierter Apoptose als 
Resultat der verringerten FAM96A-Proteinexpression konnte hier im Vergleich zu 
Kontrollvektor-transduzierten Zellen festgestellt werden.  
Mit Hilfe subkutaner Tumorxenograftexperimente in immunkompromittierten 
NOD/SCID Mäusen wurde die in vivo Relevanz dieser Beobachtungen näher 
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eruiert. Ein stark verringertes Tumorwachstum gegenüber der Kontrollgruppe konnte 
in den Gruppen mit gesteigerter FAM96A-Expression nachgewiesen werden. 
Desweitern ließ sich ein signifikant inhibitorischer Einfluss der Überexpression auf 
das Anwachsen der RKO-Tumoren feststellen. Insgesamt konnte eine suppressive 
Rolle von FAM96A auf das Wachstum und Anwachsen von Tumoren im Tiermodell 
nachgewiesen werden. Ein Einfluss der Überexpression von FAM96A auf die 
Zellzyklusverteilung von Renca-lacZ Zellen konnte nicht beobachtet werden. Um die 
potentielle Tumorsuppressorfunktion des pro-apoptotischen Zelltodregulators 
FAM96A näher zu charakterisieren wurde in silico in einer CGH (comparative 
genomic hybridization) Datenbank nach chromosomalen Aberrationen des Genlokus 
in einer Vielzahl von Tumorentitäten recherchiert. Deletionen im FAM96A Lokus 
konnten in 48,8% der Fälle für gastrointestinale Stromatumoren (GIST) 
nachgewiesen werden. Diese Beobachtung wurde mit Biopsien von zwei 
unabhängigen Patientenkohorten bestätigt. Zunächst wurden 31 Tumorproben mit 
Hilfe quantitativer real time PCR auf ihre FAM96A mRNA-Mengen analysiert, und in 
29 von 31 untersuchten Tumoren konnte ein verringertes FAM96A-
Expressionsniveau im Vergleich zu normalem Ileum beobachtet werden. Die 
deutlich reduzierte FAM96A-Expression verhielt sich unabhängig von der 
Tumorklassifizierung (Grading). In einer zweiten Patientenanalyse wurden 53 GIST-
Proben immunhistochemisch auf ihre FAM96A-Proteinexpression hin untersucht. 
Hier ließ sich für keine der 53 Proben aus verschiedenen Regionen des humanen 
Verdauungsapparates eine positive FAM96A-Färbung im Vergleich zur 
Positivkontrolle Lebergewebe nachweisen. Der Verlust der FAM96A-Expression im 
Laufe der Entstehung von GIST aus Cajalzellen stellt somit einen molekularen 
Marker für diese Tumorentität dar. Möglicherweise wird die Reduktion der FAM96A 
mRNA-Expression bereits während der malignen Transformation im Laufe der GIST 
Onkongenese initiiert. Mittels real time PCR-Analysen wurde in transformierten 
GIST-Vorläuferzellen ein geringeres FAM96A-Level als bei wildtyp-Cajalzellen 
festgestellt. Desweiteren wurde der Einfluss einer FAM96A Re-expression in 
etablierten GIST-Zelllinien untersucht. Hierfür wurden sowohl Imatinib-resistente 
GIST48, als auch Imatinib-sensitive GIST882 Zellen lentiviral transduziert und der 
Einfluss von Kinaseinhibitor-vermittelter Apoptose in FAM96A re-exprimierenden 
Zellen ermittelt. Eine erhöhte  FAM96A-Expression in beiden Zelllinien führte zu 
einer gesteigerten Suszeptibilität gegenüber der Kinaseinhibition durch Imatinib. 
Auch im Tumorxenograftmodell konnte in GIST sowohl ein statistisch signifikant 
reduziertes Tumorwachstum als auch eine verringerte Anzahl angewachsener 
Tumoren nach FAM96A Re-expression beobachtet werden. 
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Tumorsuppressor Funktion des pro-apoptotischen Proteins konnte somit in GIST 
bestätigt werden. FAM96A wirkt aller Wahrscheinlichkeit nach nicht nur in GIST als 
Tumorsuppressor, denn es konnte ein signifikant verringertes 
Proteinexpressionslevel immunhistochemisch in Nierenzellkarzinomen und Urothel-
zellkarzinomen nachgewiesen werden. Die Charakterisierung der tumor-
suppressiven Funktion von FAM96A in diesen Entitäten stellt einen Fokus aktueller 
Untersuchungen dar.  
Desweiteren wird eine Funktion des Proteins bei der Eisen-Schwefelcluster-
biosynthese angenommen, die durch die beschriebene Interaktion von FAM96A mit 
Ciao1 nahegelegt wird. Ciao1 wiederum stellt einen essentiellen Regulator der 
zytosolischen Eisen-Schwefelclusterbiosynthese (CIA) dar und ist für die Beladung 
von Fe-S-Apoproteinen maßgeblich verantwortlich. Zunächst wurde die Interaktion 
von überexprimiertem FAM96A mit endogenem Ciao1 in HEK293T Zellen verifiziert 
und ein potentieller gemeinsamer Einfluss der beiden Interaktionspartner auf die 
Apoptoseregulation untersucht. Nach Überexpressions- und Deletionsanalysen von 
Ciao1 konnte ein antagonistischer, anti-apoptotischer Effekt des CIA-Proteins 
nachgewiesen werden. Dieser ist voraussichtlich auf die Beteiligung des Proteins 
bei der Fe-S-Biosynthese zurückzuführen. Viele Fe-S-Proteine sind in wichtige 
Stoffwechselprozesse und DNA-Reparaturmechanismen involviert. So wirkt sich ein 
gesteigertes Ciao1-Expressionslevel vermutlich positiv auf die Beladung 
zytosolischer Fe-S-Apoproteine mit ihrer prosthetischen Gruppe aus. 
Eine weitere interessante und publizierte Funktion von Ciao1 ist die Regulation der 
Transkriptionsfaktoraktivität von WT1. Die beschriebene inhibitorische Wirkung von 
Ciao1 auf die Aktivität von WT1 wurde in Luciferase-Reporteranalysen in der AG 
Zörnig nicht bestätigt. Ciao1 trug zu einer signifikanten Steigerung der 
Fireflyluciferase-Expression durch WT1-vermittelte Aktivität des Amphiregulin-
promoters bei. Daraufhin sollte der gemeinsame Einfluss von Ciao1 und FAM96A 
auf WT1-Zielgene analysiert werden. Da das WT1-Protein seine eigene 
Promoteraktivität reguliert, wurde die WT1 mRNA-Expression mit Hilfe von 
quantitativer real time PCR nach Transfektion von Ciao1 und FAM96A untersucht. 
Hier konnte eine deutliche Reduktion der WT1 mRNA nach simultaner 
Überexpression von Ciao1 nachgewiesen werden. Die Rolle von FAM96A bei der 
Regulation der WT1-mRNA-Expression kann, den durchgeführten Experimenten 
zufolge, als vernachlässigbar eingestuft werden. Ciao1 fungiert möglicherweise zur 
Feinjustierung der WT1-Aktivität, indem es den Transkriptionsfaktor bindet und 
dieser seine autosuppressive Funktion am eigenen Promoter nicht mehr effizient 
ausüben kann und somit die Aktivität von WT1 über Ciao1 gesteigert wird.  
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Zur weiteren Analyse der physiologischen Funktion von FAM96A wurde in dieser 
Arbeit ein konditionales FAM96A Knockout-Mausmodell etabliert und preliminär 
analysiert. Durch Cre-vermittelte Rekombination wurde Exon 3 des FAM96A Gens 
deletiert. Das verbleibende Transkript unterliegt der Genfallenmutagenese und wird 
durch das Vorkommen eines Splice-Akzeptors in der Selektionskassette hinter Exon 
2 posttranskriptional trunkiert. Die inserierte Genkassette enthält neben einem 
Polyadenylierungssignal am 3´ Ende ein lacZ-Reporterelement. Die lacZ-Expression 
spiegelt die Promoteraktivität des FAM96A Promoters wider und kann durch X-Gal-
Färbung in murinen Organen nachgewiesen werden. Eine starke Aktivität des 
FAM96A Promoters konnte in Organen des Immunsystems wie etwa Thymus und 
Milz beobachtet werden. Weiterhin war eine signifikante Färbung im Ileum der 
homozygoten FAM96A-/--Tiere nachzuweisen. In vorangehenden Analysen wirkte 
sich das Ausschalten von FAM96A im Zebrafisch, der Fruchtfliege und der Hefe 
embryonal lethal auf die Organismen aus. Überraschenderweise scheint die 
Deletion von FAM96A in der Maus jedoch nicht zu einem embryonal-lethalen 
Phänotyp zu führen und die Tiere zeigen kein auffälliges Erscheinungsbild im 
ungestressten Zustand. Dies könnte auf eine mögliche funktionelle Redundanz 
zwischen FAM96A und seinem Homolog FAM96B hinweisen. 
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1. Introduction 
1.1 Mechanisms of cell death 
Cell death is initiated in a genetically controlled or uncontrolled fashion and plays a 
major role in organismal development, homeostasis and pathology. Two major 
classes of cell death exist. While necrosis was initially described as a non-
programmed alternative, apoptosis is an evolutionary conserved mechanism of 
programmed cell death (PCD) that was first described in 1842 by Carl Vogt (Vogt, 
1842). During apoptosis cells shrink, chromatin condenses, nuclear DNA is 
fragmented, phosphatidylserine is translocated from the inner to the outer 
membrane leaflet and plasma-membrane blebs containing cytosolic material form. 
The generation of apoptotic bodies which are engulfed by phagocytes (Kerr et al., 
1972) is a major feature of this cell death mechanism. Apoptosis can be induced via 
two intensively studied signaling pathways: the intrinsic and the extrinsic pathway. 
While the intrinsic pathway is triggered by DNA damage, nutrient depletion, 
oxidative stress or chemotherapeutic treatment, extrinsic cell death is induced by 
extracellular ligands that interact with so-called death receptor molecules. Both 
apoptosis pathways are mediated by sequential activation of cysteine aspartases 
(caspases) that reside as inactive zymogens in the cytosol. Caspases that are 
involved in the regulation of apoptosis can be divided into two major classes: initiator 
or apical caspases (Caspase-2,-8,-9 and -10) and effector or executioner caspases 
(Caspase-3, -6 and -7) (Olsson and Zhivotovsky, 2011; Shi, 2002). Two initiator 
caspase molecules autoactivate each other due to their close proximity following 
their recruitment to protein platform complexes, and they activate effector caspases 
by proteolytic cleavage (Salvesen and Dixit, 1999; Shi, 2004).  
Deregulated apoptosis has many clinical implications such as cancer, autoimmune 
diseases, neuronal disorders, hepatitis, cardiovascular diseases and sepsis 
(Hotchkiss et al, 2009).   
Necrosis was initially described as an unregulated mechanism of death resulting 
from injury of a cell. The characteristic morphological features of necrosis are 
distinct from apoptosis. Among them are swelling of the cell, rapid mitochondrial 
dysfunction and plasma membrane rupture (Degterev and Yuan, 2008). More and 
more evidence for a structured regulation of necrosis emerged within the last 
decade, and the term “necroptosis” for one particular type of programmed necrosis 
attained acceptance (Galluzzi and Kroemer, 2008; Proskuryakov et al., 2003).  
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In contrast to apoptosis, necrosis is attributed with an inflammatory immune reaction 
that plays a role in acute hypoxic or ischemic injury (Hotchkiss et al., 2009). A tight 
regulation of both major cell death pathways and their interconnection is important in 
many evolutionary and pathological processes of a cell (Hotchkiss et al., 2009). 
Several other genetically controlled, but non-apoptotic cell death pathways exist of 
which type II or autophagic cell death, mitotic catastrophe and poly (-ADP-ribose) 
polymerase-1 (PARP-1)-mediated necrotic killing, also termed Parthanatos, are only 
three examples (Degterev and Yuan, 2008; Galluzzi et al., 2012). The mitochondrial 
inner-membrane protein AIF (apoptosis inducing factor) or the endonuclease EndoG 
can, in a Cytochrome c-like manner, once released into the cytosol also trigger 
caspase-independent cell death. AIF as well as EndoG, can translocate to the 
nucleus and are responsible for chromatin condensation and DNA fragmentation 
(Broker et al., 2005; Li et al., 2001). A more functional and biochemical 
characterization of cell death subroutines is emerging, in contrast to the former 
morphological definitions and is subject to current controversial discussions 
(Galluzzi et al., 2012).  
 
1.1.1 The intrinsic apoptosis pathway 
Mitochondrial apoptosis is triggered by cellular stress signals such as growth factor 
deprivation, ER (endoplasmatic reticulum) stress, hypoxia, viral infections or DNA 
damage induced by irradiation or chemotherapy. Upon receipt of such a signal, p53 
is activated and can initiate transcription of its pro-apoptotic target genes Puma, 
Noxa and BAX (Nakano and Vousden, 2001; Oda et al., 2000; Thornborrow et al., 
2002; Yu et al., 2003). Puma and Noxa are members of the BH3-only subset of 
BCL-2-family proteins that can induce oligomerization of mitochondrial membrane 
proteins of the BCL-2 protein family: the pro-apoptotic members BAX, BAK or, in 
reproductive tissues, BOK (Kirkin et al., 2004; Portt et al., 2011). These proteins 
regulate the mitochondrial membrane potential and can form pores within the 
mitochondrial outer membrane, enabling Cytochrome c to escape from the inner 
membrane space. Mitochondrial membrane integrity is normally preserved by 
inhibition of BAX and BAK due to their interaction with anti-apoptotic members of the 
BCL-2 family (BCL-2, BCL-W, A1, MCL1 or BCL-xL) (Borner, 2003; Kirkin et al., 
2004; Skulachev, 1998). Anti-apoptotic BCL-2 family members can be antagonized 
by BH3-only proteins. In the cytosol, Cytochrome c can bind, together with dATP, to 
the WD40 repeat region of the key adaptor protein of intrinsic apoptosis: apoptotic 
peptidase activating factor-1 (APAF-1) (Li et al., 1997; Zou et al., 1997). APAF-1 
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then unfolds from its autoinhibited conformation and can oligomerize and form a 
heptameric multi-protein complex that serves as a platform for pro-Caspase-9 
recruitment and activation (Cain et al., 1999; Yuan et al., 2010). Caspase-9, as an 
initiator caspase, cleaves and activates downstream effector caspases such as 
Caspase-3, -6 or -7 that promote apoptosis of the affected cell. Caspases are, in 
addition, regulated by members of the inhibitor of apoptosis (IAP) family (XIAP, 
cIAP1/2, Survivin, NIAP, ML-IAP and BRUCE) that are themselves inactivated by 
the mitochondrial proteins Smac/DIABLO (Second mitochondria-derived activator of 
caspases/Direct IAP-binding protein with Low Pi) and Omi/HtrA2. IAPs are 
characterized by their baculoviral IAP repeat (BIR) domain responsible for inhibitory 
protein-interactions with already activated Caspase-3, -7 or -9 (Gyrd-Hansen and 
Meier, 2010). Upon activation of effector caspases, a wide variety of target proteins 
involved in many physiological processes such as macromolecular synthesis or 
signal transduction are cleaved, ultimately leading to cell death (Fischer et al., 
2003).  
 
1.1.2 The extrinsic pathway of cell death 
The extrinsic pathway of apoptosis is triggered by extracellular ligands that bind to 
death receptors such as tumor necrosis factor receptor 1 (TNFR1), TNF-related 
apoptosis-inducing ligand receptor 1/2 (TRAILR1/2), CD95/FAS/APO1, Death 
receptor (DR) 3, DR6, ectodysplasin A receptor and nerve growth factor receptor 
(NGFR) (Lavrik et al., 2005; Wajant, 2003). Death receptors belong to the TNF 
receptor superfamily and are characterized by their cytoplasmatic death domain 
(DD). A so-called death inducing signaling complex (DISC) is generated by CD95 
and TRAILR1/2 following recruitment of FADD (Fas associated protein with death 
domain), a cytosolic protein that interacts with the death domains of the receptors 
via its own DD. FADD can itself recruit death effector domain (DED)-containing 
proteins such as pro-Caspase-8 or-10 to the DISC. When two molecules of pro-
Caspase-8 are translocated to the DISC, induction is achieved via autocatalytic 
cleavage and the fully active initiator caspase can further activate downstream 
caspases like Caspase-3 (Dickens et al., 2012).   
A cross-talk between the extrinsic and the intrinsic pathway of apoptosis in type II 
cells is mediated by the pro-apoptotic BCL-2 familiy member BID. Active Caspase-8 
can cleave and activate BID, and the truncated tBID form then translocates to 
mitochondria and initiates Cytochrome c release upon binding to BAK or BAX 
(Korsmeyer et al., 2000; Scaffidi et al., 1998; Wei et al., 2000). The intrinsic pathway 
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in these cells serves as an additional amplification loop, which is needed due to the 
low levels of CD95 DISC formation and Caspase-8 activation in type II cells upon 
death receptor activation (Scaffidi, 1998). Type I cells, on the other hand, strongly 
activate Caspase-3 directly via the death receptor pathway. A detailed overview of 
the two pathways mediating apoptotic cell death is presented by Figure 1.1. 
 
Figure 1.1: Schematic overview of apoptotic pathways 
Apoptosis is mediated via two different pathways, the intrinsic and the extrinsic 
pathway. The two signaling pathways are crosslinked in type II cells through 
truncation of BID as an amplification loop of the extrinsic pathway due to low levels 
of Caspase-8 activation. Adapted from Favaloro et al., 2012. 
 
1.1.3 The apoptosome as a key complex formed during intrinsic apoptosis 
The apoptosome is a huge complex between 700 kDa and 1 MDa whose assembly 
can be induced in vitro by the addition of Cytochrome c and dATP to cytosolic 
fractions of cells (Lauber et al., 2001; Twiddy et al., 2006). Its molecular weight and 
stoichiometry is until now a matter of debate. APAF-1 represents a key component 
within the complex, generating a platform for protein interactions (Yuan et al., 2010). 
The large cytosolic molecule of 130 kDa resides within the cytosol in an 
autoinhibited conformation and can unfold and oligomerize upon Cytochrome c 
binding and ADP exchange (Reubold et al., 2009; Reubold et al., 2011; Riedl et al., 
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2005; Yu et al., 2005; Yuan et al., 2010). APAF-1 contains 3 major sequence motifs: 
at the N-terminus, a caspase activation and recruitment domain (CARD), followed 
by a nucleotide binding and oligomerization domain (NOD), and a C-terminal series 
of 12-13 WD40 repeats. The interaction with pro-Caspase-9 is mediated by the 
CARD domains of both proteins (Qin et al., 1999; Reubold et al., 2011), while the 
interaction with Cytochrome c occurs within the regulatory WD40 region (Fig. 1.2). A 
platform for caspase activation is formed by 7 oligomerized APAF-1 molecules, and 
the loosely tethered CARD domain forms a tilted disk-like structure above the 
activation hub where pro-Caspase-9 molecules can dock and become activated 
(Yuan et al., 2011; Yuan et al., 2010). A model for the activation of pro-Caspases-9 
and -3 is depicted in Figure 1.2 C. APAF-1 exists in 5 major isoforms generated by 
alternative splicing that differ in size and amino acid composition (Benedict et al., 
2000). APAF-1S is the smallest protein isoform that was originally described by Zou 
et al. (Zou et al., 1997). Whether this isoform is able to bind Cytochrome c or 
activate pro-Caspase-9 is discussed controversially (Benedict et al., 2000; Zou et 
al., 1997). APAF-1XL is the most abundant and physiologically relevant isoform, 
consisting of an additional N-terminal 11 amino acid insert and an extra WD40 
repeat, designating it as the longest APAF-1 protein isoform. APAF-1LN contains 
only the N-terminal insert but lacks the additional WD40 repeat. APAF-1LC contains 
the extra WD40 repeat, while the 11 amino acids at the N-terminus are missing. 
APAF-1-ALT is a fifth isoform devoid of WD40 repeats and represents an inhibitory 
opponent of APAF-1XL (Ogawa et al., 2003). Many models of caspase activation 
have been proposed, but the exact stoichiometry of molecules within the 
apoptosome complex still remains unresolved. Proteins observed within the 
apoptosome complex are: XIAP, Caspase-3, pro-Caspase-9, Cytochrome c, 
Smac/DIABLO and Omi/HtrA2 (Twiddy et al., 2006) . 
Active Caspase-3 is suggested to share the same binding site within the activation 
hub as pro-Caspase-9 and therewith serve as an inhibitor for initiator caspase 
induction (Yuan et al., 2011). Another level of intrinsic apoptosome regulation is 
based on the intracellular pro-Caspase-9 concentration, which regulates the 
duration of the molecular timer for Caspase-3 activation. Caspase-9 activation is 
suggested to follow a CARD-displacement mechanism where one molecule of 
activated caspase is subsequently replaced by pro-Caspase-9 due to its higher 
affinity for APAF-1 (Malladi et al., 2009) 
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Figure 1.2: APAF-1XL structure and the formation of the apoptosome complex  
During apoptosome formation, APAF-1 serves as a platform for caspase binding 
and activation. The domain structure of the full length APAF-1 protein and the 
structure lacking the CARD domain are presented by A and B (color code for 
different domains based on A). A model for APAF-1 activation that occurs upon 
Cytochrome c binding, replacement of the bound nucleotide and opening of the 
molecule is depicted by C. The structure of the apoptosome complex with its central 
hub and tilted disc formed by the CARD domains of Caspase-9 (pc-9: proCaspase-
9) and APAF-1 is represented in D. Figure adapted from Reubold, Yuan et al., 2012. 
 
Apoptosome formation is regulated by a further multitude of events and involved 
signaling proteins (Fig. 1.3). Intracellular nucleotide, calcium or potassium ion 
concentrations can serve as potential pro-survival factors by direct binding to 
Cytochrome c, preventing nucleotide exchange or APAF-1 oligomerization (Bao et 
al., 2007; Cain et al., 2001; Chandra et al., 2006). The oncoprotein Prothymosin-α 
(ProT) can also prevent apoptosome formation by binding to APAF-1 (Qi et al., 
2010).  
Heat shock proteins -27, -70 and -90 also serve to rescue the cell from apoptosis 
induction at several levels of apoptosome formation, whereas Hsp70 can also 
promote apoptosome formation together with cellular apoptosis susceptibility protein 
(CAS) and putative HLA (human leukocyte antigen)-DR associated protein I 
(PHAPI) (Kim et al., 2008). These proteins serve to facilitate nucleotide exchange on 
APAF-1 or assist heptamerization. Hepatocellular carcinoma antigen HCA66 is a 
positive regulator of apoptosome formation and influences Caspase-9 recruitment 
(Piddubnyak et al., 2007). The different published stages of apoptosome regulation 
are displayed by Figure 1.3.  
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Figure 1.3: Regulation of apoptosome formation and apoptosis induction 
Formation of the apoptosome and apoptosis are inhibited and positively regulated at 
various checkpoints, where the concentration and abundance of physiological 
factors defines whether signaling is blocked or cell death proceeds. Adapted from 
Fadeel et al., 2007.  
 
1.1.4 Deregulation of apoptosis in cancer and recent therapeutic interventions 
An important hallmark of cancer is the evasion of tumor cells from the apoptotic 
program. This process confers resistance to chemotherapy or other therapeutic 
interventions, enables metastasis formation and limits overall patient survival. 
Apoptosis resistance is enabled in 50% of cancers due to mutations in the p53 
tumor suppressor protein, the “guardian of the genome” (Hanahan and Weinberg, 
2000; Hanahan and Weinberg, 2011). A lot of p53-based therapy trials for cancer 
treatment are ongoing, including gene, drug and immunotherapy (Lane et al., 2010).  
As p53 is responsible for the upregulation of BAX, apoptosis is inhibited when p53 
wildtype activity is lost (Zornig et al., 2001). Diminishing p53 function implicates 
deregulation of BCL-2 and BCL-xL, anti-apoptotic BCL-2 family members that are 
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subjected to downregulation by the transcription factor p53 in normal cells 
(Miyashita et al., 1994). Consequently, BCL-2 and BCL-xL are described to be 
overexpressed in a wide range of human cancers (Kirkin et al., 2004). The disrupted 
homeostasis of BCL-2 family proteins largely contributes to dysregulated apoptosis 
in cancer and is targeted by several approaches. Upregulation of BCL-2 in cancer 
can be antagonized by the BCL-2 antisense oligonucleotide oblimersen, or BCL-2 
family members can be targeted by BH3-mimetic small molecule inhibitors such as 
ABT-737 or ABT-263, HA-14-1, gossypol, epigallocatechin-3-gallate or obatoclax 
(Flack et al., 1993; Kessel and Reiners, 2007; Lock et al., 2008; O'Brien et al., 2009; 
Oltersdorf et al., 2005; Qin et al., 2007). Pro-apoptotic family members of the BCL-2 
family normally function as tumor suppressors, and loss-of-function mutations of 
BAX and BAK have been reported in several tumor entities (Kondo et al., 2000; 
Rampino et al., 1997). APAF-1 also resembles a direct target of p53, and its 
expression has been reported to be frequently reduced or inactivated in cancer 
(Soengas et al., 2001). Due to alternative gene use, closely-related oncogenic 
members of the same gene family are expressed, while expression of the tumor 
suppressor gene PHAP is eliminated in prostate adenocarcinoma (Bai et al., 2001). 
Overexpression of HSPs, ProT and the kinase AKT, which is known to inhibit 
Cytochrome c release, upregulate XIAP and Survivin, or phosphorylate the pro-
apoptotic BH3-only protein BAD and Caspase-9, have been reported in correlation 
with several malignancies and poorer clinical outcomes (Cardone et al., 1998; Datta 
et al., 1997; Kennedy et al., 1999; Qi et al., 2010; Tran et al., 1999). Increased 
expression of IAP proteins (XIAP, Survivin) has been reported in a variety of cancer 
entities, while nonmalignant tissue expressed normal levels of IAPs. Upregulation of 
IAPs is common in cancer, making them attractive targets for chemotherapy. 
Several antisense oligonucleotides and small molecule inhibitors (Smac mimetics) 
for IAPs -in monotherapy and in combinatorial treatments- have been tested in 
Phase I/II clinical trials (http://www.clinicaltrials.gov/; (D'Amelio et al., 2008; Fischer 
and Schulze-Osthoff, 2005; Fulda et al., 2002). A reduction of caspase expression is 
common in many cancer entities and therefore, molecules that re-establish 
increased caspase-activation such as RGD-peptides or derivatives of the small 
molecule MX-2060 (Buckley et al., 1999; Fischer and Schulze-Osthoff, 2005; Zhang 
et al., 2004) are under therapeutic investigation. Direct Caspase-3 introduction into 
cancer cells is another approach followed by fusion to a Her-2-antibody or 
adenoviral infection (D'Amelio et al., 2008). 
The cell death response induced via the extrinsic apoptosis pathway is also within 
the focus of current therapeutic investigations. TRAILR1 and 2 signaling is activated 
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by agonistic human monoclonal antibodies such as conatumumab, tigatuzumab, 
lexatumumab, mapazumumab and drotizumumab. Dulanermin is a recombinant 
TRAIL-ligand agonist that triggers death receptor signaling and is currently in clinical 
trials (Ocker and Hopfner, 2012). Proteasome inhibitors, heat shock protein 
inhibitors and histone deacetylase inhibitors can activate ER stress-mediated cell 
death and restore APAF-1 and Caspase-9 levels (Ocker and Hopfner, 2012). 
 
1.2 Tumor suppressor genes and their downregulation in cancer 
Apart from the most commonly mutated tumor suppressor gene (TSG) described, 
p53, many other genes can act as tumor suppressors. Most often, these genes are 
associated with cell cycle regulation (RB) or are involved in differentiation, apoptosis 
and proliferation (WT1, NF1, PTEN) (Vogelstein and Kinzler, 2004). Normal cells 
tightly control these processes by a balanced homeostastis between proto-
oncogenes and TSGs (Evans and Prosser, 1992; Lai et al., 2012). In tumorigenesis, 
loss of heterozygosity (LOH) of a TSG is involved in the spontaneous formation of 
neoplasms. Point mutations within the remaining functional allele often lead to LOH 
and tumor formation as a consequence of inherited predisposition. Hereditary as 
well as non-hereditary cancers are thought to derive from at least four or more 
mutation events in important cellular signaling pathways (Berger et al., 2011). 
Haploinsufficiency occurs when a diploid cell has only one functional copy of one 
allele that is incapable of retaining the wild type condition. Haploinsufficiency and 
dose- and activity-dependency have been controversially discussed, but are 
common for important TSGs such as p53 or PTEN in many tumors. Obligate 
haploinsufficiency of a TSG is explained by an essential function of the TSG in 
cellular processes, so that its homozygous deletion would trigger cell death or 
senescence (Berger et al., 2011). Therefore, the expression or activity of such a 
tumor suppressor is only lowered, but not entirely lost in tumors.  
The discovery of novel tumor suppressor genes that are affected by mutational 
events triggering oncogenesis is highly important for the interference with initiation 
and progression of malignant disease. High-throughput screenings for genome-wide 
genetic aberrations or copy number profiling serve to identify mutated or deleted 
regions in tumors.   
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1.3 FAM96A 
FAM96A was discovered in a yeast two-hybrid screen of a mouse thymoma cDNA 
library with the C. elegans homologue of APAF-1: CED-4, as well as several APAF-
1S deletion constructs as baits (K. Völp, unpublished). The human FAM96A gene 
locus is located on chromosome 15 (q22.31), is 21.4 kb long and consists of 5 
exons. The mRNA is processed into two alternative splice isoforms (NM_032221.4 = 
isoform A, NM_001014812.1= isoform B) of which isoform A is the predicted 
“canonical” sequence (http://www.expasy.org/). While isoform A (FAM96A for further 
reading) codes for 160 amino acids with a predicted molecular weight of 18.355 
kDa, isoform B is smaller with a size of 102 amino acids and 11.634 kDa. The small 
protein appears with a molecular weight of around 20 kDa in Western Blot analysis 
and contains a DUF59 domain (domain of unknown function, aa 39-156) shared by 
a family of ATPases (Lezhneva et al., 2004) as well as iron-sulfur cluster proteins 
(Almeida et al., 2005; Lezhneva et al., 2004). Only two proteins exist in mammals 
that contain this sequence motif: FAM96A and its homolog FAM96B/MIP18. Both 
proteins share a 50% sequence similarity and bind to the cytosolic iron sulfur cluster 
protein Ciao1 (Chen et al., 2012). Interestingly, FAM96B is suggested to be involved 
in chromosome segregation as a member of the MMXD protein complex (Ito et al., 
2010). In contrast to the observed contribution of FAM96B to DNA maintenance 
processes, Stehling et al. rather suggest this to be related to Fe-S protein 
biogenesis (described in 1.5.1) (Stehling et al., 2012). A further function for FAM96B 
was published recently by Yang et al. The protein, and especially the DUF59 
domain, were observed to be involved in regulating the expression of the 
transcription factor E2-2 and therewith proliferation and migration of endothelial cells 
(Yang et al., 2011).  
In silico predictions suggest ER-targeting of the longer isoform due to an N-terminal 
27 amino acid signal sequence with a cleavage site between aa 27 and 28 (SignalP 
4.1 Server (www.cbs.dtu.dk/services/SignalP), Fig. 1.4 A, yellow). Investigations on 
the subcellular localization of the protein, however, revealed FAM96A to occur within 
the cytoplasmic and partly within the nuclear compartment. In spite of the in silico 
predicted N-terminal signal peptide, no targeting to the lumenal compartment could 
be observed (Chen et al., 2012; Jung, 2012; Pick, 2006).  
Chen et al. reported recombinant, bacterially expressed FAM96A (aa 39-156), 
lacking the signal peptide, to form stable monomers and two different domain 
swapped dimers that are controlled by two hinge loop regions within the molecule 
(84-TPTVPH-89 and 121-GTHSTEE-127). The two DUF59-dimers are suggested to 
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have distinct functions in vivo (Chen et al., 2012). Furthermore, FAM96A was 
observed to dimerize when Flag-tagged, overexpressed proteins extracted from 
cellular lysates were separated under non-reducing conditions via SDS-PAGE (Pick, 
2006). Dimerization is suspected to be achieved by one of the 5 cysteine residues 
(Pick, 2006) located within the DUF59 domain of which at least one was in silico 
predicted to be highly reactive (J. Heering, Frankfurt University, unpublished). The 
domain structure and structures of the crystallized monomer and the two distinct 
domain-swapped dimers are presented in Figure 1.4.  
 
Figure 1.4: Domain and dimeric structure of FAM96A and its involvement in 
the Ciao1-interaction network  
From an alternative translation initiation site, two separate FAM96A proteins are 
generated, of which the longer isoform contains an N-terminal signal sequence in 
addition to the C-terminal DUF59 (domain of unknown function). The 5 cysteine 
residues in FAM96A and the smaller isoform ΔN-FAM96A are highlighted in red (A). 
FAM96A forms stable monomeric and dimeric structures in vitro (taken from Chen et 
al., 2012) (B). FAM96A binds to Ciao1 and is included in the Ciao1-interaction 
network (http://string-db.org/) (C).  Blue lines indicate published, experimentally 
verified binding of proteins. 
  
The protein is highly conserved among species (Pick, 2006) and ubiquitously 
expressed in murine and human tissues and cell lines (AG Zörnig, unpublished 
data). FAM96A mRNA can be detected in the interdigital web of developing mouse 
limbs during embryogenesis (AG Zörnig, unpublished data). The integration of 
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FAM96A within the Ciao1-interaction network according to the string database is 
depicted in Figure 1C (verified interactions are indicated by blue lines). Preliminary 
data from transient FAM96A upregulation revealed the protein to sensitize cells to 
apoptotic stimuli employing the mitochondrial pathway (Pick, 2006). Due to an 
alternative start codon 32 amino acids downstream of the first ATG, a smaller 
isoform of around 17 kDa, ΔN-FAM96A, is generated (Pick, 2006). This isoform is 
assumed to play an antagonistic role, referring to earlier investigations (AG Zörnig, 
unpublished), functionally comparable to the smaller isoform of BCL-XL, BCL-XS.  
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1.4 Gastrointestinal stromal tumors 
Gastrointestinal stromal tumors (GIST) are of mesenchymal origin and derive from 
malignant transformation of the interstitial cells of Cajal (ICC). These cells are 
pacemaker cells of the intestine that are responsible for contractile activity 
(peristalsis) of smooth muscle cells (Bardsley et al., 2010; Sanders, 1996; Sanders 
et al., 1999). An important therapeutic and prognostic marker of GIST is the 
expression of the KIT tyrosine kinase receptor at the tumor cell surface. In normal 
cells, survival and proliferation are induced via the type III receptor tyrosine kinases 
such as KIT- or platelet-derived growth factor receptor alpha (PDGFRA/B) 
pathways. Ligand binding of stem cell factor (SCF or PDGF) induces activation of 
the MAPK- (mitogen-activated protein kinase) and the PI3K/AKT-pathways, which 
are continuously triggered without ligand stimulation in transformed cells. 70-80% of 
GISTs are described to harbor c-kit mutations. The most common primary 
oncogenic c-kit mutations have been reported for the juxtamembrane domain of the 
receptor that is encoded by Exon 11. The extracellular domain of the KIT protein, 
encoded by Exon 9 is less frequently mutated than the juxtamembrane domain and 
mutations in the activation loop, encoded by Exon 17 and the ATP-binding domain 
(Exon 13) are uncommon (Corless et al., 2011). GISTs are usually heterozygous for 
the receptor tyrosine kinase (RTK) mutations, however, in approximately 15% of 
tumors, the second allele is lost as a result of non-disjunction and only the mutant 
allele is expressed (Chen et al., 2008). Another RTK that can be mutated in GIST is 
PDGFRA. Mutations can occur in the juxtamembrane (Exon 12), the ATP-binding 
(Exon 14) or the activation loop (Exon 18) and the same downstream signaling 
pathways as of KIT are constitutively activated (Corless et al., 2011). Mutant KIT 
and PDFRA can both be stabilized by HSP90 (Bauer et al., 2006; Matei et al., 
2007), however, PDGFRA-activated GIST show distinct expression profiles and 
lower malignancy compared to KIT-mutated tumors. Other driver mutations in genes 
such as BRAF, HRAS, NRAS can lead to activation of the MAPK signaling and 
oncogenic growth independent of KIT or PDGFRA mutations. These malignancies 
resemble so-called “wild-type” GISTs, in which defects in SDH (succinate 
dehydrogenase) or mutations in NF1 (neurofibromin1) have also been reported. 
Apart from the constitutively activating RTK mutations, tumor suppressor genes 
such as CDKNA, p27 and TP53 are commonly downregulated in malignant GIST 
(Corless et al., 2011).  
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Since 2000, the kinase inhibitor Imatinib Mesylate (IM) that was originally developed 
for therapeutic intervention in chronic myelogenous leukemia (CML) is also used for 
treatment of gastrointestinal stromal tumors (Heinrich et al., 2000). Imatinib can 
directly bind to the ATP-binding site of KIT and thereby stabilize the kinase in its 
inactive conformation and inhibit substrate phosphorylation and activation. Imatinib 
treatment is an important option for the chemo- and radiotherapy resistant GIST, 
achieving a median survival of 5 years in 70-85% of patients with advanced disease. 
While overall patient survival is increased, TKI therapy using IM has some 
drawbacks of which the most important ones are disease persistence and resistance 
towards treatment. Most of the wild-type and PDGFRA mutant GISTs are resistant 
to IM treatment, and only few patients (3-5%) suffering from c-kit mutated, IM-
sensitive cancers are effectively cured (Corless et al., 2011). This is due to 
persistence and survival of transformed ICC stem cells (ICC-SC), the precursor cells 
of ICC and GIST. These cells are characterized by the expression of CD44, CD34 
and receptors for insulin (Insr) and insulin-like growth factor (Igfr) on their surface. 
Most importantly, they are independent of SCF/KIT- signaling for survival, as they 
express only minor amounts of KIT (KITlowCD44+CD34+Insr+ Igf1r+), rendering them 
resistant towards IM therapy. To overcome this problem of IM resistance, 
combinatorial treatments for selective targeting of KITlow cancer stem cells need to 
be established (Bardsley et al., 2010).  
Primary and secondary resistance towards imatinib treatment resembles the second 
major drawback of GIST therapy and is addressed by a variety of next-generation 
tyrosine kinase inhibitors such as sunitinib, nilotinib, sorafenib, dasatinib etc 
(Demetri, 2011). Secondary resistance most often occurs in the same gene and 
allele as the initial, primary driver mutation and confers resistance to imatinib 
treatment. These mutations are predominantly located within the ATP-binding 
pocket (Exon 13 or 14) and directly interfere with IM interaction. The second most 
common secondary mutations are within the activation loop (Exon 17 or 18) of the 
KIT kinase and stabilize the protein in its active conformation (Corless et al., 2011). 
Additionally, there is heterogeneity of resistance among multiple GIST lesions, 
resulting in up to seven independent secondary mutations within one patient (Liegl 
et al., 2008). Future approaches for GIST therapy would combine small molecules 
(such as RTK inhibitors) for suppression of tumor growth and apoptosis induction of 
all GIST cell subsets in order to eradicate the entire malignant tissue and truly cure 
the disease (Corless et al., 2011). The PI3K/AKT-pathway, for example, is important 
for GIST survival, and consequently, AKT presents a relevant therapeutic target in 
imatinib-resistant tumors (Bauer et al., 2007). Targeting of Hsp90 in cell culture 
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experiments by 17-AAG revealed promising results in imatinib-resistant GIST (Bauer 
et al., 2006). Furthermore, when the BCL-2 inhibitor ABT-737 was used on imatinib-
resistant GIST cell lines, significant pro-apoptotic effects could be observed, 
providing another rationale for combinatorial targeting of RTK and other independent 
but complementary mechanisms (Reynoso et al., 2011).  
 
1.5 Iron sulfur cluster biosynthesis 
Iron sulfur clusters are evolutionarily highly conserved. Their participation in the 
origin of life is widely discussed, and they were discovered in the 1960s in 
mitochondrial membranes and ferredoxin (Mortenson et al., 1962; Sieker et al., 
1972; Wachtershauser, 1988). They are essential for enzymatic reactions involved 
in fundamental biological processes such as respiration, photosynthesis or DNA 
repair. Two proteins of the citric acid cycle, aconitase and succinate dehydrogenase, 
as well as respiratory chain complexes I-III, carry Fe-S clusters. Fe-S clusters are 
co-factors that organize as [2Fe-2S] or [4Fe-4S] in eukaryotes and serve to transfer 
electrons from one protein to another, thereby catalyzing and regulating enzymatic 
reactions. The process of iron sulfur cluster biogenesis is therefore highly conserved 
from bacteria to humans, and so are the proteins involved (Rouault, 2012). Human 
mitochondrial Fe-S cluster biogenesis is initiated by complex formation of the 
dimeric cysteine desulfurase NFS1 to which two ISCU molecules bind and, together 
with the scaffold protein ISD11, this core complex provides an interaction platform 
for Frataxin. Upon Frataxin binding, the Fe-S cluster is assembled and can be 
transported to the recipient proteins. Together with two chaperone proteins of the 
heat shock protein family (HSC20 and most likely HSC70) that bind to ISCU, 
conformational changes in ISCU are induced that facilitate transfer of the Fe-S 
cluster onto target apoproteins or secondary scaffold proteins. The assembled Fe-S 
cluster can be transported across the mitochondrial membrane, a procedure 
assisted by the integral membrane protein ABCB7, and can then be loaded onto 
cytosolic apoproteins. De novo iron sulfur cluster assembly within the cytosolic and 
nuclear compartments has been reported (Tong et al., 2003; Tong and Rouault, 
2006). While still under debate whether this is also the case in yeast, cytosolic iron-
sulfur cluster assembly (CIA) is important for a wide variety of processes in humans. 
The first protein discovered to be involved in CIA was Cfd1/NUBP2 (cytosolic Fe-S 
cluster-deficient1) that forms a scaffold complex for Fe-S clusters with 
NBP35/NUBP1. Together with Ciao1 and IOP1/NARFL, clusters are then 
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transferred to apoproteins. Proteins that are involved in mammalian CIA and 
mitochondrial iron sulfur cluster assembly are depicted in Figure 1.5.  
Several human pathologies such as Friedreich´s ataxia, mitochondrial 
encephalomyopathy, ISCU myopathy, sideroblastic anaemia and multiple 
mitochondrial dysfunction syndrome have recently been associated with defects in 
iron-sulfur cluster biogenesis (Rouault, 2012).  
 
Figure 1.5: Mammalian iron sulfur cluster assembly 
In humans, the assembly of Fe-S is not exclusively restricted to mitochondria, but 
can occur de novo within the cytoplasm (CIA). Alternatively, Fe-S clusters are 
generated in the mitochondria and transported into the cytoplasm where target 
apoproteins are loaded. A potential regulatory signal is transmitted to the nucleus to 
secure mitochondrial iron homeostasis. The Figure was adapted from Rouault et al., 
2012.   
 
1.5.1 Physiological functions of Ciao1 
Ciao1 is an essential, highly conserved protein (Johnstone et al., 1999) of human 
cytosolic iron sulfur cluster assembly, and its depletion is lethal in yeast and 
Drosophila melanogaster. Yeast Cia1 can be functionally replaced by its human 
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homologue, indicating the importance of CIA conservation in eukaryotes. The 
doughnut-shaped structure of the S. cerevisiae Cia1 is defined by a central axis 
around which 7 blades (WD40 repeats) of a β-sheet propeller fold (Srinivasan et al., 
2007). Ciao1 also contains seven WD40 domains and, as many other WD40 repeat-
containing proteins, it is suggested to coordinate multi-protein complex assemblies 
(Li and Roberts, 2001). The 38 kDa protein is located in the nuclear and cytosolic 
compartment (Johnstone et al., 1998) and is described to play a role in DNA 
maintenance as an integral protein of the MMXD complex together with MMS19, 
MIP18 (MMS19-interacting protein; FAM96B), XPD and adenine nucleotide 
translocase ANT2 (Ito et al., 2010). The complex is assumed to play a role in 
chromosome segregation, whereas other groups suggested that the effects on DNA 
repair of MMS19-depleted cells result from impaired Fe-S protein biogenesis, and 
that MMS19 links CIA to DNA metabolism via maturation of Fe-S apoproteins. The 
described late-acting CIA targeting complex contains MMS19, Ciao1, ANT2, and 
FAM96B, and can load various target proteins. The complex is suggested to be 
involved in Fe-S loading of many nuclear genome stability factors apart from XPD: 
RTEL1, FANCJ, DNA Pol delta, DNA primase (Pri2) and DNA2 (Gari et al., 2012; 
Stehling et al., 2012; van Wietmarschen et al., 2012). 
Ciao1 has been found in a YTH screen to interact with the transcription factor WT1. 
The interaction of FAM96A with Ciao1 was first observed in a YTH screen for 
disease-associated genes (Rual et al., 2005) and confirmed by Chen et al. (Chen et 
al., 2012).  
Apart from its essential function which is conserved from lower to higher eukaryotes, 
mammalian Ciao1 seems to be involved in transcriptional regulation of the zinc-
finger transcription factor Wilms Tumor 1 (WT1) (Johnstone et al., 1998).   
 
1.6 The transcription factor WT1 
The human WT1 gene is located on chromosome 11p13 and is functionally 
inactivated by mutations in approximately 20% of Wilms’ tumors, a childhood 
nephroblastoma. Other known genetic alterations in this cancer entity include 
inactivation of the tumor suppressors WTX (Wilms tumor gene on the X 
chromosome) and TP53, and stabilizing mutations of the oncogene CTNNB1 (β-
catenin). In leukemia, however, and in some types of solid tumors, WT1 has been 
described as an oncogene. In undifferentiated hematopoietic cells, WT1 is important 
for viability, whereas in committed cells WT1 is essential for differentiation. Due to 
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this functional dependence on the cellular developmental status, WT1 cannot 
ambiguously be classified to function as a TSG or an oncogene (Huff, 2011).  
The human WT1 gene contains 10 Exons, which encode a transcription factor with 
four zinc-finger motives at the carboxy- and a proline glutamine rich protein 
interaction domain at the amino-terminus. Two different alternative splice sites in 
Exons 5 and 9 give rise to 4 major protein isoforms: WT1 A (-/-, lacking Exon 5 and 
9), B (+/-, containing Exon 5, lacking Exon 9), C (-/+) and D (+/+). Together with 
alternative translational start sites and RNA editing, in total 24 different isoforms are 
generated in humans that give rise to the four predominant WT1 proteins. The 
isoforms that differ in alternative splicing of Exon 9 are functionally distinct from 
each other (Hastie, 2001; Yang et al., 2007). Here, the omission or insertion of three 
amino acids (lysine, threonine and serine (KTS)) determines if the protein is involved 
in transcriptional regulation (-KTS) or RNA processing (+KTS) (Hastie, 2001). The 
four zinc-finger motifs mediate binding to GC-rich consensus Egr1 binding sites (5’-
GNGNGGGNG-3’), WTE (WT1 binding site) sites (5’-GCGTGGGAGT-3’) or (TCC)n 
regions (Han et al., 2004). 
WT1 expression is tissue-specific and the 52-54 kDa protein is predominantly 
localized in the nuclear compartment but can shuttle between the cytoplasma and 
nucleus (Niksic et al., 2004). The transcription factor was described to regulate a 
wide range of supposed target genes which include growth factor genes 
(Amphiregulin, IGF-II, PDGF-A, CSF-1, TGF-β1); growth factor receptors (insulin 
receptor, IGF-1R, EGFR) and other genes associated with proliferation or apoptosis 
(N-myc, c-myc, BCL-2, BAK, Bag3, WID, PAX2, Cyclin E, E-cadherin, CSF-1) 
(Cesaro et al., 2010; Han et al., 2004; Morrison et al., 2005). Furthermore, human 
and murine WT1 proteins inhibit the transcription of their own promoter upon 
overexpression, establishing a negative feedback-loop for autoinhibition (Malik et al., 
1994; Rupprecht et al., 1994). These findings are in line with the transient 
expression pattern of WT1 during kidney development. WT1-/- mice display severe 
developmental defects in the genitourinary system and heart and die in utero at day 
E 13.5 (Moore et al., 1999). 
Ciao1 has been reported to bind to the zinc-finger domains of all 4 WT1 protein 
isoforms, and can decrease transcriptional activity of WT1 (Johnstone et al., 1998).  
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1.7 Aims of the study 
Decreased or lost expression of pro-apoptotic TSGs, together with an increased 
expression of proto-oncogenes induces malignant outgrowth, and re-establishment 
of these natural anti-cancer genes is important in tumor therapy. Because there are 
various, yet unknown mutational events contributing to malignant transformation, the 
identification and characterization of novel TSGs is an important topic in current 
cancer research. As an interaction partner of APAF-1 and a potential regulator of the 
intrinsic apoptosis pathway, FAM96A represents a putative new tumor-suppressor. 
Objectives addressed in this study were the following:  
(I) A profound functional characterization of FAM96A was one major focus of this 
study. Importantly, the endogenous interaction of FAM96A and APAF-1 was 
confirmed. Next, a detailed functional analysis of the cytosolic protein and the 
elucidation of its potential tumor-suppressor activity in vitro and in vivo was 
addressed by modulation of gene expression in normal and cancer cell lines and 
tumor xenograft experiments.  
 (II) As the FAM96A gene encodes a putative TSG, its differential expression pattern 
in several primary tumor tissues and the correlation of FAM96A expression with 
malignancy in certain cancer entities was investigated. Gastrointestinal stromal 
tumors are the most common mesenchymal tumor of the gastrointestinal (GI) tract 
and harbor deletions of the FAM96A locus with a high incidence, as revealed by 
CGH analyses. The deletion of the FAM96A gene in GISTs might contribute to 
recurrence of the tumor after resection and imatinib therapy, and re-establishment of 
FAM96A protein expression in GIST tumor cell lines was one focus of this work. 
Furthermore, this study aimed to identify other tumor entities that display decreased 
or lost protein levels of FAM96A. 
(III) Apart from its potential contribution to the regulation of the intrinsic apoptosis 
pathway, FAM96A can bind to a mediator of cytosolic iron sulfur cluster assembly, 
Ciao1. The interaction with Ciao1 and a potential interplay of the two interaction 
partners in the regulation of intrinsic apoptosis and the activity of the transcription 
factor WT1 was analyzed in the course of this work.  
(IV) Another aim of this study was to investigate the physiological function of 
FAM96A, and therefore, a conditional knockout mouse model was established and 
preliminarily analyzed.  
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2 Materials and Methods 
2.1 Materials 
2.1.1 Laboratory equipment                                                   
Autoclave Tuttnauer Systec 2540 EL         Systec, Wettenberg 
BioRad Power PAC 300           BIO-RAD Laboratories, Munich 
Branson Sonifier 250            Heinemann, Schwäbisch Gmünd 
CASY® Cell Counter            Schärfe Systems, Reutlingen 
Centrifuge Megafuge 1.0R           Heraeus, Hanau 
Centrifuge Micro 220R           Hettich Zentrifugen, Tuttlingen 
Centrifuge Minifuge GL           Heraeus, Hanau 
DNA sub cellTM, for agarose gels         BIO-RAD Laboratories, Munich 
Electrophoresis power supply EPS 301         GE Healthcare, Freiburg 
FACSCalibur             Becton Dickinson, Heidelberg 
FACScan              Becton Dickinson, Heidelberg 
Fluorescence stereomicroscope MZ16FA        Leica Microsystems, Wetzlar 
Fluorescence microscope Eclipse TE300        Nikon Instruments, Düsseldorf 
Freezer CFC free (-80°C)           Sanyo, Wiesloch 
Freezing container Cryo1°C  “Mr. Frosty”       Nalgene, Roskilde, Denmark 
Fridge (4°C) and freezer (-20°C)          Liebherr Int., Ochsenhausen 
Hypercassettte TM           GE Healthcare, Freiburg 
Gene Amp PCR System 9700         Applied Biosystems, Darmstadt 
Incubator IR-sensor (37°C, 5% CO 2)         Sanyo, Wiesbaden 
Laminar air flow cabinet           Clean Air, Woerden 
LightCycler® 480             Roche, Mannheim 
Microwave oven             Baxter Scientific,Unterschleißheim 
Optimax Typ TR film developer          MS Laborgeräte, Wiesloch 
pH meter FE20 Five Easy           Mettler Toledo, Schwerzenbach 
Pipettes              Brand, Wertheim 
Pipetus-accu             Hirschmann, Neckartenlingen 
Roller RM5 Assistant 348           Karl Hecht GmbH, Sondenheim 
Sequencer AB1377            Perkin Elmer, Rodgau 
SemiPhor, Semi dry blotting device         Pharmacia, Freiburg 
Shaker Rocky NG            Frögel Labortechnik, Lindau 
SmartSpecTM3000 Spectrophotometer         BIO-RAD Laboratories, Munich 
Table top centrifuge, Biofuge pico          Heraeus, Hanau 
Thermocylcer GeneAmp PCR 9700         Applied Biosystems, Darmstadt 
Thermomixer compact, heating block         Eppendorf, Hamburg 
Ultracentrifuge L8M (swinging buckets)         Beckmann Coulter, Krefeld 
UV-table GelDoc 2000           BIO-RAD Laboratories, Munich 
UV-Stratalinker 1800            Stratagene, Heidelberg 
Ultra-Turrax Homogenizer          IKA, Staufen 
Vortex Genie2             Bender & Hobein, Zurich 
Water bath             GFL, Burgwedel 
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2.1.2 Consumables 
Cell culture well plates                                           Corning, Amsterdam, Netherlands 
Cell culture dishes (10mm, 145mm)            Greiner, Frickenhausen  
Cell culture flasks               Sarstedt, Nümbrecht 
Cell strainer (100 µm pores)              Becton Dickinson, Heidelberg 
Cryo tubes                Nunc, Denmark 
Cuevettes                Sarstedt, Nümbrecht 
FACS Tubes                Greiner, Frickenhausen 
Fujifilm Medical XRAY Film Super RX            Fujifilm, Düsseldorf 
Gloves                Rösner-Mautby, Kiefersfelden 
Nitrocellulose membrane 45µm             Whatman, Dassel 
Parafilm                Pechiney Plastic Packaging,USA 
PCR plates (96-well)               Abgene, Schwerte 
Pipette tips                Sarstedt, Nümbrecht 
Pipette tips with filters              BioZym, Oldendorf 
Polyallomer tubes (open-top thinwall)            Beckman Coulter, Krefeld 
Polystyrene tubes               Becton Dickinson, Heidelberg 
QIAshredder columns              Qiagen, Hilden 
Reaction tubes (0.2 ml - 2 ml)             Eppendorf, Hamburg 
Reagent reservoirs            Corning, Amsterdam, NL 
Scalpel (diposable)            Servoprax, Wesel 
Sterile filter units (0.45 µm, 0.22 µm)         Corning, Amsterdam, NL 
Syringe, 0.5 ml             Becton Dickinson, Heidelberg 
Syringe (2ml, 5ml, 10 ml)           Codan Medical, Rodby,Denmark 
Ultra-Turrax Tubes (12,0/75mm)         Greiner, Frickenhausen 
µMacs columns            Miltenyi Biotec,Bergisch Gladbach 
Whatman Chromatography paper 3MM         Whatman, Dassel 
 
2.1.3 Reagents 
Agarose Ultra PureTM Invitrogen, Darmstadt 
Ampicillin AppliChem GmbH, Darmstadt 
ANNEXIN V-FITC Beckton Dickinson, Heidelberg 
Aprotinin Sigma-Aldrich, Steinheim 
APS (Ammonium Persulfate)  Sigma-Aldrich, Steinheim 
BenchmarkTM Prestained Protein ladder Invitrogen, Darmstadt 
Bovine Pituitary Extract (BPE) Beckton Dickinson, Heidelberg 
Bovine Serum Albumin Thermo Fisher Scientific, 
Dreieich  
Bradford Reagent (Roti®-Quant) Carl Roth, Karlsruhe 
Bromophenol Blue Carl Roth, Karlsruhe 
BSA (Bovine Serum Albumin) PAA Laboratories, Pasching 
CHAPS (3- ((3-cholamidopropyl) 
dimethylammonio)-1-propanesulfonic acid) 
Sigma-Aldrich, Steinheim 
Complete Mini Protease Inhibitor Cocktail Roche, Mannheim 
Cytochrome C from Bovine heart Sigma-Aldrich, Steinheim 
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dATP Sigma-Aldrich, Steinheim 
Deoxy nucleotide triphosphate Ge Healthcare, Munich 
Digitonin Sigma-Aldrich, Steinheim 
DMSO (dimethyl sulfoxide) Merck, Darmstadt 
DTT (Dithiothreitol) Sigma-Aldrich, Steinheim 
Dulbeccos Phosphate Buffered Saline PAA Laboratories, Pasching 
ECL detection kit GE Healthcare, Munich 
EDTA (Ethylene Diamine Tetra Acetate) Sigma-Aldrich, Steinheim 
EGTA (Ethylene Glycol Tetraacetic Acid) Sigma-Aldrich, Steinheim 
Ethanol Carl Roth, Karlsruhe 
Ethidiumbromide Carl Roth, Karlsruhe 
Fetal Bovine Serum (FBS) PAA Laboratories, Pasching 
Forene® Isofluran  Abbott GmbH, Wiesbaden 
Formaldehyde [37%]  Carl Roth, Karlsruhe 
GeneRulerTM 1kb, 100bp Plus DNA ladder Fermentas, St. Leon-Rot 
Glycerol Carl Roth, Karlsruhe 
Glycin Carl Roth, Karlsruhe 
Hepes (N-2-hydroxyethylpiperazine-N’-2-
ethanesulfonic acid) 
Carl Roth, Karlsruhe 
Imatinib Mesylate Novartis, Basel, Switzerland 
Isopropanol (2-Propanol) Carl Roth, Karlsruhe 
Kanamycin A Monosulfat Sigma-Aldrich, Steinheim 
KCl (Potassium Chloride) Carl Roth, Karlsruhe 
LB-Agar Carl Roth, Karlsruhe 
Leupeptin Sigma-Aldrich, Steinheim 
L-glutamine  PAA Laboratories, Pasching 
LipofectamineTM2000 Invitrogen, Darmstadt 
LipofectamineTMLTX Invitrogen, Darmstadt 
Matrigel Beckton Dickinson, Heidelberg 
Methanol Carl Roth, Karlsruhe 
MgCl2 (Magnesium Chloride) Sigma-Aldrich, Steinheim 
Milk powder (low fat) AppliChem, Darmstadt 
Mitomycin C Sigma-Aldrich, Steinheim 
Mito Serum Extender  Beckton Dickinson, Heidelberg 
NaAc (Sodium Acetate) Carl Roth, Karlsruhe 
NaCl (Sodium Chloride) Carl Roth, Karlsruhe 
NaOH (Sodium Hydroxide) AppliChem, Darmstadt 
Oxaliplatin GRY-Pharma, Kirchzarten 
PEI, Polyethyleneimine Sigma-Aldrich, Steinheim 
Penicillin/Streptomycin PAA Laboratories, Pasching 
Pfx DNA-Polymerase (5u/µl) Roche, Mannheim 
PI (propidium iodide) Sigma-Aldrich, Steinheim 
PMSF (Phenylmethylsulfonylfluoride) Carl Roth, Karlsruhe 
Polybrene (hexadimethrine bromide) Sigma-Aldrich, Steinheim 
Polyethylenimine Polysciences, Inc., Eppelheim 
PonceauS solution Sigma-Aldrich, Steinheim 
Protease inhibitor cocktail Roche, Mannheim 
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Protein A/G PLUS Agarose beads Santa Cruz, Heidelberg 
Protein G MicroBeads Miltenyi, Bergisch Gladbach 
Puromycin  Calbiochem, Darmstadt 
REDTaq® Polymerase (1u/µl) Sigma Aldrich, Taufkirch 
RiboLock RNase Inhibitor  Fermentas, St. Leon-Rot 
RNAlater  Qiagen, Hilden 
Roti® Histofix Carl Roth, Karlsruhe 
Rotiphorese-Gel 30 (30% acrylamide/0.8% 
bisacrylamide)  
Carl Roth, Karlsruhe 
Sodium Citrate (NaCi) Carl Roth, Karlsruhe 
SDS (Sodium Dodecyl Sulfate) Carl Roth, Karlsruhe 
Staurosporine  Calbiochem, Darmstadt 
SYBR Green PCR master mix  Fermentas, St. Leon-Rot 
TEMED (N,N,N’,N’-Tetramethylethane-1,2-
Diamine) 
Carl Roth, Karlsruhe 
Tris (hydroxymethyl)-aminomethan  Carl Roth, Karlsruhe 
Triton X-100 Fluka, Buchs, Switzerland 
Trypan blue  Sigma-Aldirch, Taufkirch 
Tween-20 Carl Roth, Karlsruhe 
β-Mercaptoethanol  Carl Roth, Karlsruhe 
7-Aminoactinomycin D (7-AAD) Invitrogen, Darmstadt 
 
2.1.4 Enzymes 
Calf alkaline phosphatase (CIP)     Roche Diagnostics, Mannheim 
DNase I         Fermentas, St. Leon-Rot 
Platinum® Pfx DNA Polymerase      Invitrogen, Karlsruhe 
Restriction enzymes        New England Biolabs, Frankfurt 
RNase A        Roche Diagnostics, Mannheim 
Taq-Polymerase        New England Biolabs, Frankfurt 
T4-DNA-Ligase        New England Biolabs, Frankfurt 
 
2.1.5 Kits 
DNeasy Blood and Tissue kit     Qiagen, Hilden 
Omniscript® RT kit        Qiagen, Hilden 
QIAGEN Plasmid Maxi kit       Qiagen, Hilden 
QIAquick Gel-Extraction kit       Qiagen, Hilden 
RNase-free DNase set       Qiagen, Hilden 
RNeasy® Mini kit        Qiagen, Hilden 
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2.1.6 Cell lines 
Cell line Origin/ATCC number Description 
HEK293T CRL-11268™ Human embryonal kidney cells 
RKO CRL-2577™ Human epithelial colon carcinoma 
cells 
GIST48 J. Fletcher, Boston, 
USA 
Gastrointestinal stromal tumor cells 
GIST882 J. Fletcher, Boston, 
USA 
Gastrointestinal stromal tumor cells 
Renca-lacZ AG Wels, GSH Murine renal carcinoma cells 
NIH/3T3 CRL-1658™  Murine fibroblast cells 
 
2.1.7 Buffers and Media 
2.1.7.1 Cell culture 
Dulbecco´s modified eagles medium (DMEM)   Invitrogen, Karlsruhe 
Ham´s F-10 Nutrient Mix     Gibco®, Darmstadt 
Luria Bertani (LB) agar, broth     Invitrogen, Karlsruhe 
Opti-MEM®        Invitrogen, Karlsruhe 
Roswell Park Memorial Institute (RPMI) medium   Invitrogen, Karlsruhe 
 
FACS buffer (3% FCS in DPBS) 
2.1.7.2 Molecular biology 
Tris borate EDTA (TBE 10x)  
 108 g Tris 
 55 g boric acid 
 40 ml [0.5M] EDTA pH 8.0 
 ad 1 l H2O 
 
DNA loading dye (10x)  
 20% (w/v) glycerol 
 100mM EDTA 
 1% SDS 
 0.25% (w/v) bromphenol blue or 
0.25% (w/v) xylenecyanol 
 
GTE solution  
 50mM Glucose 
 25mM Tris/HCl pH 8.0 
 10mM EDTA 
  
NaOH-SDS buffer  
 0.2 N NaOH 
 1% SDS 
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2.1.7.3 Protein biochemistry 
µMacs lysis buffer  
 50 mM Tris-HCl pH 8 
 150 mM NaCl 
 1% Triton X 100 
 1 tablet Complete Mini Protease 
Inhibitor cocktail 
 
Cell lysis buffer (Stock solution)  
 10mM KCl 
 1.5mM MgCl2 
 10mM Tris-HCl pH 7.4 
 
Cell lysis buffer (working solution) 
 
 
 
 
9.5 ml stock solution 
495 µl 10% SDS 
132 µl 100mM PMSF 
1 tablet Complete Mini Protease 
Inhibitor cocktail 
 
5x SDS PAGE sample buffer   
 62.5mM Tris HCl pH 6.8 
 20% glycerine 
 2% SDS 
 0.01% bromphenol blue 
 50mM DTT (added before use) 
 
CEB buffer  
 20 mM HEPES-KOH pH 7.5 
 10 mM KCl 
 1.5 mM MgCl2 
 1 mM EGTA 
 1 mM EDTA 
 1 µM DTT 
 250 µM PMSF 
 1 µg/ml Leupeptin 
 2 µg/ml Aprotinin 
 
Apoptosome lysis buffer  
 20 mM HEPES-KOH pH 7.5 
 50 mM NaCl 
 10 mM KCl 
 1.5 mM MgCl2 
 1 mM EGTA 
 1 mM EDTA 
 1 µM DTT 
 250 µM PMSF 
 1 µg/ml Leupeptin 
 2 µg/ml Aprotinin 
 0,3 % CHAPS 
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10x SDS-running buffer  
 60g Tris 
 150g Glycin 
 75ml SDS (20 %) 
 ad 1 l H2O 
 
10x Transfer buffer  
 58.2 g Tris 
 29 g Glycin 
 200 ml Methanol 
 ad 1 l H2O 
 
Blocking buffer  
 TBS (0.1% Tween 20) 
 5 % skim milk powder 
 
10x AnnexinV-binding buffer  
 0.1 M Hepes-KOH pH 7.4 
1.4 M NaCl 
 25mM CaCl2 
  
Ultra-Turrax lysis buffer  
 30mM Tris-HCl pH7.5 
 150mM NaCl 
 1% Triton X 100 
 10% Glycerol 
 1mM PSMSF (added before use) 
 1 tablet Complete Mini Protease 
Inhibitor cocktail added before use) 
  
X-Gal staining buffer  
 5 mM K4[Fe(CN)6] 
 5 mM K3[Fe(CN)6] 
 2mM MgCl2 
  
 
SDS-Gel pipetting scheme (for 2 gels):  
 10 % running 
gel 
12% running 
gel 
15% running 
gel 
stacking 
gel 
Acrylamide 5 ml 6 ml 7.5 ml 1.25 ml 
1.5M Tris-HCl 
(pH8.8) 
3.75 ml 3.75 ml 3.75 ml - 
0.5M Tris-HCl 
(pH6.8) 
- - - 1.825 µl 
10% SDS 75 µl 75 µl 75 µl 37.5 µl 
Aqua dest 6.25 ml 5.25 ml 3.75 ml 4.325 ml 
10% APS 100 µl 100 µl 100 µl 100 µl 
TEMED 10 µl 10 µl 10 µl 10 µl 
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2.1.8 Plasmids and Oligonucleotides 
2.1.8.1 Sequencing oligonucleotides 
Name Sequence 
SFFV 5´-CTGCTTCTCGCTTCTGTTCG-3 
T7 5‘-GAATTGTAATACGACTCACTATAG-3‘ 
pcDNA3.1 rev 5‘-TAGAAGGCACAGTCGAGGCTGATC-3‘ 
pGIPZ 5´- GCATTAAAGCAGCGTATC -3’ 
pLKO1.Puro 5´-GACTATCATATGCTTACCGT-3´ 
pEGFP-N1 5´-GTAACAACTCCGCCCCATTGA-3´ 
 
 
2.1.8.2 Oligonucleotides for cloning  
Name Sequence 
hFAM96A for BamH1 5´-AAAGGATCCATGCAGCGGTGTCCG-3 
hFAM96A rev Not1 5´-AAAGCGGCCGCTCAGTCAGGTTC-3´ 
mFAM96A for BamH1 5´-AAAGGATCCATGGAGCGAGTGTC-3 
mFAM96A rev Not1 5´- AAAGCGGCCGCTCAGTCCGGCTCG-3´ 
 
 
2.1.8.3 Oligonucleotides for quantitative real time PCR 
All primers were designed using the Sofware Primer 3 (Rozen and Skaletsky, 2000) 
Version 4.0 (http://frodo.wi.mit.edu/) 
Name Gene Sequence (5´-3´) Accession no. (nucleotides cds) 
mWT1 for WT1 ACCCAGGCTGCAATAAGAGA NM_144783 (1184-1203) 
mWT1 rev WT1 CCTGGTGTGGGTCTTCAGAT NM_144783 (1394-1413) 
hGAPDH 
for GAPDH AATGGAAATCCCATCACCATCT 
NM_001256799 
(82-103) 
hGAPDH 
rev GAPDH CGCCCCACTTGATTTTGG 
NM_001256799 
(122-139) 
hHPRT for HPRT TGACACTGGCAAAACAATGCA NM_000194 (411-431) 
hHPRT rev HPRT GGTCCTTTTCACCAGCAAGCT NM_000194 (484-504) 
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2.1.8.4 Oligonucleotides for genotyping of mouse strains 
Oligonucleotides for genotyping of the different conditional knockout strains were 
designed with the ApE software(http://biologylabs.utah.edu/jorgensen/wayned/ape/).  
Name Sequence 
FAM96A (5´arm) for 5´-TACCATGTGCCAACAGAGACC-3´ 
FAM96A (3´arm) rev 5´- ATCTGGCTGTGTAGCCCAGG-3´ 
En2 SA rev 5´- CCTGTCCCTCTCACCTTCTACC-3´ 
LacZ for 5´-CGGTCGCTACCATTACCAGTTG-3´ 
LoxP for 5´-CTAAGTCATCCCGACGGCAG-3´ 
LoxP rev  5´-TCAGGCATAATGGACGGACC-3´ 
Cre for 5´-GACCAGGTTCGTTCACTCATGG-3´ 
Cre rev 5´-AGGCTAAGTGCCTTCTCTACAC-3´ 
FLP for 5´-GAGAAGAACGGCATAGTGCGT-3´ 
FLP rev 5´-GACAAGCGTTAGTAGGCACAT-3´ 
 
2.1.8.5 Lentiviral expression constructs 
2.1.8.5.1 pLKO.1-puro shRNA vectors  
shRNA constructs cloned into pLKO.1-puro were purchased from Sigma Aldrich 
(Steinheim, Germany). Human FAM96A (NM_032231) shRNAs were cloned into in 
the TRC2 backbone, and murine shRNAs targeting mFAM96A into the TRC1 vector 
backbone.  
Construct  Mature antisense (5´-3´) Targeted mRNA-region  
hFAM96A sh1 CAATGAGGTACTGTTGGCGT
G 
489-509 
hFAM96A sh2 CAAATTAGGTACTACCTTATA 868-888 
hFAM96A sh3 ATTTATCTCCTGAACTTCCAC 439-459 
hFAM96A sh4 TTAAATGGTAAACATCGCTGA 552-572 
hFAM96A sh5 ATTTATCTGCTTATTGATGTC 622-641 
mFAM96A sh1 TTACAAAGGATTGAAACTAGC
T 
759-779 
mFAM96A sh2 ATTTGCTCAGAAAGAATCCTC
T 
1003-1023 
mFAM96A sh3 TGGTGTGAACTTGATAATAAC
T 
471-491 
mFAM96A sh4 AATGTAGATTTCCAACTTGTG
T 
570-590 
mFAM96A sh5 CATGTTGACTAGATAGGTGAT 793-813 
TRC shctrl TGGTGCTCTTCATCTTGTTG Non-targeting 
A non-targeting control shRNA for each vector backbone was transduced.  
2.1.8.5.2 pGIPZ-shRNA vectors 
The following constructs were purchased from Open Biosystems, Lafayette, USA 
(pGIPZ shctr) or provided by Prof. Dr. S. Fulda (Institute for Experimental Cancer 
Research in Pediatrics, J.W. Goethe University Hospital, Frankfurt, Germany) for 
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lentiviral knockdown of human Ciao1 (NM_004804) and human FAM96A 
(NM_032231): 
Construct name Clone ID Mature Antisense 
Targeted 
mRNA-
region 
pGIPZ-sh1  
Ciao1 V3LHS_300519 ACACACTCAAAGTCATCCT 480-498 
pGIPZ-sh2  
Ciao1 V3LHS_300520 TCACTGTGTCATCATAGCT 710-728 
pGIPZ-sh3  
Ciao1 V3LHS_300522 TGCTTGACATCCTGTGTGT 651-669 
pGIPZ-sh4  
Ciao1 V3LHS_300524 TACACACTCAAAGTCATCC 481-499 
pGIPZ-sh5 
 Ciao1 V3LHS_300523 TCATCAACTTCCCAGACCC 594-612 
pGIPZ-sh1 
FAM96A 
V2LHS_138077 ATATCAAACAATTACAGGC 745-765 
pGIPZ-sh2 
FAM96A 
V2LHS_138078 TATAATTAAATCTCGCTTG 853-871 
pGIPZ-sh3 
FAM96A 
V3LHS_308911 TCTTCTTCATTTATCTCCT 449-458 
pGIPZ-sh4 
FAM96A 
V3LHS_308912 AAACTTCTAGCGCTTTCTC 343-361 
pGIPZ-sh5 
FAM96A 
V3LHS_308913 AACCAGATATTCTTCTTCA 459-477 
pGIPZ-sh6 
FAM96A 
V3LHS_400981 ATAATTAAATCTCGCTTGG 852-870 
pGIPZ-sh7 
FAM96A 
V3LHS_400982 TAAACATGAGTCTCTGACA 776-805 
pGIPZ-sh8 
FAM96A 
V2LHS_138081 TAAATTGAGTACATTTGGG 1032-1050 
pGIPZ-shctr verified negative control Cat No. # RHS4346 non-silencing 
 
2.1.8.5.3 LeGoiG2 
For lentivirally-mediated overexpression, murine as well as human FAM96A coding 
sequences were cloned into the LeGoiG2 vector (Weber et al., 2008) . The empty 
vector served as a control. http://www.lentigo-vectors.de/ 
 
 
LeGoiG2 vector element description:  
SIN-LTR: Self-inactivating long terminal repeat Ψ: Psi, packaging signal for DNA 
into capsid, RRE: rev response elemen; cPPT: central polypurine tract; LoxP: Cre 
recombinase recognition site; SFFV: spleen focus-forming virus promoter; IRES: 
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internal ribosomal entry site; eGFP: enhanced green fluorescent protein; wPRE: 
woodchuck posttranscriptional regulatory element 
 
2.1.8.5.4 Ectopic expression plasmids 
For transient overexpression in cell lines, the following vectors were used:  
Plasmid Description Reference 
pcDNA3.1 (+) AmpR, empty vector control Invitrogen, Darmstadt 
pcDNA 3.1 hFAM96A AmpR, expression plasmid for 
human FAM96A 
S.Bösser, AG Zörnig, 
GSH, Frankfurt 
pcDNA 3.1 ΔN-
FAM96A 
AmpR, expression plasmid for 
human ΔN-FAM96A 
S.Bösser, AG Zörnig, 
GSH, Frankfurt 
pcDNA3.1 Flag-
hFAM96A 
AmpR, expression plasmid for 
flag-tagged human FAM96A 
S.Bösser, AG Zörnig, 
GSH, Frankfurt 
pcDNA3.1 Flag-ΔN-
hFAM96A 
AmpR, expression plasmid for 
flag-tagged human ΔN-
FAM96A 
S.Bösser, AG Zörnig, 
GSH, Frankfurt 
pcDNA3.1 Flag-hAVEN AmpR, expression plasmid for 
flag-tagged human AVEN 
S.Bösser, AG Zörnig, 
GSH, Frankfurt 
pcDNA3.1 Flag-hFADD AmpR, expression plasmid for 
flag-tagged human FADD 
S.Bösser, AG Zörnig, 
GSH, Frankfurt 
pcDNA3.1 Myc-APAF1S AmpR, expression plasmid for 
myc-tagged human APAF1S 
S.Bösser, AG Zörnig, 
GSH, Frankfurt 
M289-Bcl-xL AmpR, expression plasmid for 
human Bcl-xL 
Prof. Dr. Dorothee M v. 
Laer, GSH, Frankfurt 
peGFP N1 KanR, green fluorescent 
protein expression control  
Clontech Laboratories 
Inc., USA 
pCMV Sport6 Ciao1 AmpR, expression plasmid for 
human Ciao1 
Invitrogen, Darmstadt 
mWT1 +/-KTS pCB6+ AmpR, expression plasmid for 
murine WT1 
Prof. Holger Scholz, 
Charité, Berlin 
pCB6+ empty vector AmpR, empty vector control Prof. Holger Scholz, 
Charité, Berlin 
pMD2.G (vsv-g) AmpR, vesicular stomatitis 
virus glycoprotein expression 
Addgene Inc., Cambrige, 
MA, USA 
p8.91 (gag pol) AmpR, encapsidation plasmid 
for viral integration 
(Zufferey et al., 1997) 
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2.1.8 Antibodies 
2.1.8.1 Non-conjugated antibodies 
Antibody Origin Dilution Reactivity Host  
anti-FAM96A Pineda 
1:100-
500 
human, mouse rabbit 
anti-β-ACTIN 
(C11) 
Santa Cruz Biotech. 1:2,000 human, mouse, rat goat 
anti-APAF1 BD Biosciences 1:1,000 human, mouse rabbit 
Anti-EZRIN 
(3C12) 
Invitrogen 1:1,000 human mouse 
anti-FLAG (M2) Sigma-Aldrich 1:1,000 DYKDDDDK mouse 
anti-rabbit IgG Zymed Laborat. 1µg rabbit goat 
Anti-goat IgG Zymed Laborat. 1µg goat rabbit 
Anti-Ciao1 Sigma-Aldrich 1:2,000 human, mouse rabbit 
Anti-WT1 (C-19) Santa Cruz Biotech. 1:1,000 human, mouse, rat rabbit 
Anti-p15 (K18) Santa Cruz Biotech. 1:1,000 human, mouse, rat rabbit 
 
2.1.8.2 Conjugated antibodies 
Antibody Origin Dilution Host 
anti-rabbit HRP Ge Healthcare, Munich 1:2,000 donkey 
anti-mouse HRP Ge Healthcare, Munich 1:1,000 sheep 
anti-goat HRP Ge Healthcare, Munich 1:1,000 rabbit 
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2.1.9 Mouse strains 
Name Genetic background Origin 
NOD-SCID NOD.CB17-Prkdcscid/J 
Jackson 
Laboratory 
FAM96A B6NTac;B6N-A
tm1Brd Fam96atm2a(EUCOMM)Wtsi/ 
WtsiBiat 
EUCOMM 
CMV-Cre 
GO-Tg-Deleter-Cre B6.C-Tg(CMV-
cre)1Cgn/J   
ZVTE Mainz 
FLPeR GO-Tg-Act-Flp ZVTE Mainz 
FAM96A/lacZ 
B6NTac;B6N-Atm1Brd 
Fam96atm2a(EUCOMM)Wtsi/WtsiBiat GO-Tg-
Deleter-Cre B6.C-Tg(CMV-cre)1Cgn/ 
Georg-Speyer-
Haus (AG 
Zörnig) 
FLP/FAM96A GO-Tg-Act-Flp B6NTac;B6N-A
tm1Brd 
Fam96atm2a(EUCOMM)Wtsi/WtsiBiat 
Georg-Speyer-
Haus (AG 
Zörnig) 
FLP/FAM96A/Cre 
GO-Tg-Act-Flp B6NTac;B6N-Atm1Brd 
Fam96atm2a(EUCOMM)Wtsi/WtsiBiat/ GO-Tg-
Deleter-Cre B6.C-Tg(CMV-cre)1Cgn/J  
Georg-Speyer-
Haus (AG 
Zörnig) 
C57Bl/6 C57BL/6NCrl Charles River 
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2.2 Methods 
2.2.1 Molecular biology 
2.2.1.1 Transformation of chemocompetent E.coli 
30 µl of frozen chemocompetent E.coli cells (DH5α (TaKaRa Bio, Saint-Germain-en-
Laye, France) or Top10 cells (Life Technologies, Darmstadt), stored at -80°C) were 
thawed on ice, and 1 µg plasmid DNA or 5 µl of a DNA ligation reaction were added. 
Bacteria were incubated on ice for 30 minutes, and a heat-shock was applied at 
42°C for 30 seconds. Subsequently, bacterial cells were returned on ice, and 250 µl 
of antibiotics-free LB Medium were added, followed by incubation for 1.5 h at 37°C 
while shaking (750 rpm, Thermomixer). Then 150 µl of the transformed bacterial 
suspension was plated on agar-plates and incubated overnight at 37°C.  
 
2.2.1.2 Storage of bacteria  
Bacterial suspensions were frozen in 50% sterile glycerol and stored until further 
usage at -80°C. 
 
2.2.1.3 DNA and RNA isolation and analysis 
2.2.1.3.1 Small scale plasmid DNA isolation (Mini-prep) 
The alkaline lysis method was used for small scale isolation of bacterial plasmid 
DNA (Birnboim, 1983). During the protocol, cell lysis is induced by a NaOH-SDS-
containing buffer. SDS denatures the proteins, whereas addition of NaOH leads to 
denaturation of chromosomal and plasmid DNA. Subsequent neutralization with 
potassium acetate causes precipitation of SDS and formation of complexes 
including chromosomal DNA, denatured proteins and cellular debris, which can be 
removed by centrifugation. The plasmid DNA remains in the supernatant.  
3 ml LB medium (containing 100 µg/ml of Ampicillin) were inoculated with one 
colony of transformed E. coli from an agar plate or a bacterial glycerol stock and 
incubated at 37°C overnight while shaking at 160 rpm. 1.5 ml of this overnight 
culture were centrifuged at 12,000 x g for 2 min, the supernatant was discarded and 
the cell pellet was resuspended in 100 µl of ice-cold GTE solution. After addition of 
200 µl freshly prepared NaOH-SDS buffer, the tube was inverted 5 times and 
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incubated at room temperature for 5 min. Afterwards, 150 µl of ice-cold 5M KOAc 
were added and mixed carefully by inverting the tubes, followed by incubation for 5 
min on ice. After centrifugation at 12,000 x g for 5 min, the supernatant was 
transferred to a new tube. Plasmid DNA was precipitated after addition of 1 ml 100% 
ethanol and centrifugation at 12,000 x g for 10 min at room temperature. The pellet 
was washed with 70% ethanol, and after centrifugation for 5 min at 12,000 x g, the 
DNA was air-dried and resuspended in 30 µl sterile deionized water containing 0.2 
mg/ml RNase A. The isolated plasmid DNA was stored at –20°C. 
 
2.2.1.3.2 Large scale plasmid DNA isolation (Maxi-prep) 
For a large scale plasmid isolation, 250 ml of LB supplemented with the respective 
antibiotic were inoculated with transformed bacteria and grown overnight at 37°C 
and 160 rpm. After 12 to 16 hours, cells were harvested by centrifugation at 4,500 x 
g and 4°C for 15 min. Large-scale DNA isolation was performed according to the 
manufacturer’s instructions (Plasmid Maxi Kit, Qiagen, Hilden) to isolate plasmid 
DNA, which was stored at -20°C until further usage. DNA and RNA concentrations 
were determined by photometric measurement, based on the absorption of DNA at 
260 nm, using the NanoDrop™ 1000 spectrophotometer (Peqlab, Erlangen). The 
260/280nm-ratio is used to determine the purity of the measured DNA or RNA and 
should be within a range 1.8 to 2.1. 
 
2.2.1.3.3 Polymerase chain reaction 
Specific DNA fragments can be amplified by polymerase chain reaction (PCR). A 
PCR reaction includes denaturation of the template, hybridization of specific primers 
to the target DNA and repeated elongation cycles during which the DNA fragment is 
enriched. The elongation time depends on the length of the amplified sequence. 
Here, 1 min for 1 kb was used. 
A standard PCR reaction was set up according to the following composition:  
Reagent Final concentration Volume (µl) 
10 x Platinum Pfx amplification 
buffer 
1 x 5 
50 mM MgSO4 1 mM 1 
dNTPs (100 mM) 10 µM 2 
Forward Primer 20 µM 1 
Reverse Primer 20 µM 1 
Pfx-DNA-Polymerase 1.75 units/reaction 0,75 
template-cDNA-Volume 100ng -1µg  1 
sterile, distilled water ad 50 µl 38,25 
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A standard PCR for the amplification of FAM96A was performed as follows:  
 
Amplification step Time Temperature Cycle number 
Initial denaturation 3 min  95°C 1 
Dentauring 30 sec 95°C 
Annealing 30 sec 60°C Elongation 
Extension 30 sec 68°C 
 
30 cycles 
Final Elongation 10 min 68°C 1 
Cooling ∞ 4°C  
 
Amplified fragments were visualized using UV light following intercalation of 
ethidium bromide during agarose gelelectrophoresis. The desired amplified DNA 
was extracted from the gel and purified with the QIAquick gel extraction kit (Qiagen, 
Hilden).  
 
2.2.1.3.4 Agarose gelelectrophoresis 
DNA fragments can be separated according to their size by agarose 
gelelectrophoresis. This is based on movement of the negatively charged DNA 
towards the anode in an electric field. The agarose forms a meshwork in which the 
migration velocity of DNA depends on the size of the fragments. Separated DNA 
fragments can be visualized by UV light (Helling et al., 1974). PCR products or 
plasmid DNA were separated in agarose gels containing 1% to 2% of agarose in 0.5 
x TBE buffer and 0.5 µg/ml ethidium bromide. Electrophoresis was performed in 
chambers filled with 0.5 x TBE buffer, and DNA samples were mixed with 10 x DNA 
loading buffer, loaded onto agarose gels and separated at 120 V. A 1 kb DNA ladder 
or a 100 bp DNA ladder (Fermentas, St. Leon-Rot) were used as DNA size markers. 
 
2.2.1.3.5 DNA extraction from agarose gels  
The ethidiumbromide-stained DNA of interest was cut out from an agarose gel with 
a scalpel. DNA purification was performed using the QIAquick gel extraction kit 
(Qiagen, Hilden) according to the manufacturer’s instructions.  
 
2.2.1.3.6 Ligation of DNA 
The enzyme DNA ligase catalyzes formation of phosphodiester bonds between 
5´phosphates and 3´hydroxyl groups of DNA strands, thereby coupling the ends of 
DNA fragments with complementary nucleotide overhangs. Vector and insert DNA 
were ligated in a total reaction volume of 10 µl. The ligation mix contained DNA, 1 µl 
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T4-DNA-ligase (40u/ml) and 1 µl 10 x ligase buffer. The ligation reaction was 
performed at room temperature for 1 hour, or at 16°C overnight. Afterwards, 5 µl of 
the ligation volume were used for transformation of chemocompetent E.coli. 
 
2.2.1.3.7 Restriction digest and dephosphorylation of 5´ends 
For restriction enzyme digestion of DNA, a reaction mix consisting of the restriction 
enzyme, a suitable reaction buffer (10x) and, if required, 10% BSA were used. An 
analytic restriction digest was performed with 1 µg DNA in a volume of 20 µl for at 
least 1 hour, while preparative digestions were conducted overnight with 10 µg to 20 
µg DNA in 50 µl reaction volume at 37°C. DNA fragments were analyzed by agarose 
gel electrophoresis. 
Dephosphorylation of DNA 5´ ends by incubation with Calf intestine phosphatase 
(CIP) prevents self-ligation of digested DNA. 5´ dephosphorylation of cut plasmid 
vectors increases efficiency of the ligase reaction with desired inserts. For 
5´dephosphorylation of vectors, 1 u CIP was added to the restriction digestion mix. 
 
2.2.1.3.8 Sequencing  
Sequencing of DNA was performed with the AB1377-sequencer (Perkin Elmer, 
Rodgau) using dye primer chemistry. Sequences were analyzed with the Lasergene 
software (Version 8.0, DNAStar) and NCBI Blast (http://blast.ncbi.nlm.nih.gov/). For 
sequencing, 0.5 µg DNA or 3 µl Mini-prep DNA and 1 µl sequencing primer (10 µM) 
were adjusted with sterile water to a total volume of 15 µl. 
 
2.2.1.3.9 RNA Isolation 
For isolation of total RNA, cells were harvested mechanically in DPBS and 
centrifuged (5 min, 450 x g, 4°C). Cell pellets were either resuspended in RNAlater 
stabilization reagent (Qiagen, Hilden) and frozen at - 80°C, or used immediately for 
RNA isolation via the RNeasy Mini Kit according to the manufacturer´s instructions 
(Qiagen, Hilden). Cells were lysed using QIAshredder columns (Qiagen, Hilden), 
and on-column DNAseI digestion was performed for 15 min prior to elution of total 
RNA. 
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2.2.1.3.10 cDNA synthesis 
1 µg of total RNA was transcribed enzymatically to cDNA according to the 
manufacturer´s instructions using the Omniscript® RT Kit (Qiagen, Hilden). In a 20 
µl volume, an oligo(dT) primer (Qiagen, Hilden) was used together with the 
RiboLock RNAse inhibitor (Fermentas, St. Leon-Rot). A control reaction with RNA 
lacking reverse transcriptase was performed (RT-) to exclude sample contamination 
with foreign DNA.  
 
2.2.1.3.11 Quantitative real time PCR (RT qPCR) 
The exact quantity of an mRNA transcript or DNA molecules in a sample (e.g. 
cultivated cells or tissue samples) can be determined via quantitative real time PCR. 
Isolated DNA can directly be used as a template for qPCR analysis. A reverse 
transcription reaction has to be performed prior to the analysis of isolated RNA. The 
obtained cDNA is used for the quantitative PCR reaction. The signal of an 
intercalating fluorescent dye (SYBR Green 1) is detected at the end of each 
amplification cycle and directly correlates with the amount of double stranded DNA 
in the sample. The amount of target cDNA can either be compared to a DNA of 
known concentration (absolute quantification) or normalized to expression of a 
certain housekeeping gene (relative quantification). The threshold cycle (Ct) at 
which the fluorescence signal of the sample is higher than background level is 
determined for each sample, and the ΔCt value is calculated by subtraction of the Ct 
of the housekeeping gene from the Ct of the target gene.  
To compare the relative abundance of a target cDNA in different samples, the ΔΔCt 
value is calculated as follows: ΔΔCt = ΔCt (sample 1) - ΔCt (sample 2) 
Assuming a doubling of the target sequence in each cycle (PCR efficiency of 2), the 
relative target sequence abundance can be calculated using the following equation: 
Fold difference of the target gene compared to the housekeeping gene = 2 (-ΔΔCt). 
Quantitative real time PCR analysis was performed on a LightCycler® 480 system 
(Roche, Mannheim). Specificity of the RT qPCR was further confirmed by agarose 
gel electrophoresis and sequencing of the reaction product. The crossing point 
values for each amplification curve were calculated using the LightCycler® 480 Abs 
Quant/2nd Derivative Max method (Relative Quantification Software, Roche Applied 
Science). 
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A qRT-PCR reaction was set up as follows:  
Reagent Final concentration Volume (µl) 
Forward Primer (10µM) 0,25 µM 1,25 
Reverse Primer (10µM) 0,25 µM 1,25 
Maxima SYBR Green 1 - 12,5 µl 
Template-cDNA ≤ 500 ng  
sterile, distilled water - 10 µl 
All PCR reactions were set up in triplicates, 2 µl of cDNA were added and 24 µl per 
sample were distributed among a 96 well plate. An RT- as well as a template-lacking 
control were included. 
Amplification step Time Temperature Cycle number 
Initial denaturation 15 min  95°C 1 
Dentauring 20 sec 95°C 
Annealing 30 sec 60°-62°C  Elongation 
Extension 30 sec 72°C 
 
 40 cycles 
Melting 
curves 
 10 sec 50°C  
  10 acquisitions/°C 95°C  
Cooling 10 min 37°C  
 
2.2.1.3.12 Genomic DNA isolation from mouse tails 
Total DNA was isolated from mouse tails using a DNeasy Blood and Tissue Kit 
according to the manufacturer´s instructions (Qiagen, Hilden). Tail tips of 0.3-0.5 cm 
were lysed overnight in a 56°C water bath in tissue lysis buffer supplemented with 
proteinase K. Genomic DNA was eluted in a volume of 200 µl and kept at 4°C until 
further usage. 
 
2.2.1.3.13 Genotyping of a conditional FAM96A knockout mouse  
Genetically mutated mouse strains serve as a valuable tool to investigate the 
physiological function of a gene. Constitutive and conditional knockin or knockout 
mice are generated by targeted incision or excision of a specific DNA sequence into 
and off their genome. Murine embryonic stem (ES) cells transfected with a targeting 
vector are positively screened for the correct homologous recombination construct 
and injected into a diploid blastocyst. This blastocyst is implanted into the uterus of a 
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pseudo pregnant mouse, giving rise to chimeric animals whose germline is derived 
from the donor ES cells.  
A conditional knockout of a gene can be induced by recombination achieved via 
breeding of animals together with deleter mice that express recombinases of the 
Cre/loxP- or FLP/FRT-system that cut and recombine DNA at site-specific re-
combination target sites (SSRTs: loxP- or FRT-sites). As approximately 15 % of all 
gene knockouts are developmentally lethal, a conditional knockout model provides 
the opportunity to induce a tissue-specific knockout. A conditional FAM96A knockout 
mouse on the C57Bl/6 background was generated by and received from EUCOMM 
(European Conditional Mouse Mutagenesis Program), a member of the International 
Knockout Mouse Consortium (IKMC) (Project: 26229; 
http://www.knockoutmouse.org/search_results?criteria=FAM96A). The targeting 
vector construct is shown below.  
 
 
 
FAM96A targeting vector, description of functional elements:  
FRT: recombination target site for FLP recombinase; En2SA: mouse Engrailed-2 
gene splice acceptor; IRES: internal ribosomal entry site; lacZ: reporter gene; pA: 
Polyadenylation signal; loxP: recombination target site for Cre recombinase; hBactP: 
human beta-actin promoter; neo: neomycin resistance gene 
 
The conditional knockout is achieved via the so-called “knockout first” strategy 
where a cassette is inserted into an intron of the target gene, and the knockout is 
produced at the level of mRNA processing (Testa et al., 2004). A splice acceptor in 
the cassette is responsible for mRNA-capturing and a polyadenlyation-signal serves 
as a truncation signal to interfere with mRNA transcription downstream of the 
cassette. For gene targeting of murine FAM96A, Exon 3 was floxed (flanked by loxP 
sites), and a cassette upstream of the floxed region was inserted that is flanked by 
FRT-sites. As shown above, the targeting cassette contains a splice acceptor (En2 
SA), an internal ribosomal entry site (IRES) between splice acceptor and lacZ 
reporter gene as well as a polyadenlyation signal (pA). For selection of embryonic 
stem cells, the human β-actin promoter (hBactP) was cloned in front of a neomycin 
resistance gene and another polyA signal flanked by loxP and FRT-sites. 
Genotyping of the heterozygous FAM96A mice was performed by conventional 
PCR. Here, a three-primer strategy served to discriminate between the wildtype (wt) 
allele and the allele containing the inserted cassette (red arrows). In heterozygous 
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mice, two fragments were obtained after amplification, one for the wt allele (945 bp) 
and another for the inserted cassette (408 bp). A 5´-3´-fragment that contains the 
inserted cassette is not amplified under these conditions, due to the large fragment 
size of 7.9 kb.  
 
 
Mating between heterozygous FAM96A mice and transgenic CMV-Cre animals that 
ubiquitously express the Cre recombinase under the control of the human 
cytomegalovirus promoter generates reporter mice in which the truncation of the 
FAM96A gene can be monitored in all tissues of the animal. The strategy for 
genotyping of FAM96A/lacZ mice is shown below. Three PCR reactions were 
carried out of which the first distinguished between the wt allele and insertion of the 
targeting cassette (FAM96A PCR, red arrows). In a second PCR reaction, 
occurrence of Cre recombinase DNA was determined and the third PCR served to 
confirm the deletion of Exon 3 (LacZ PCR, green arrows). A fragment of 404 bp was 
generated if Exon 3 and the selection marker were deleted after Cre-recombination.  
 
 
 
   
Cross-breedings of heterozygous FAM96A/lacZ mice gave rise to homozygous 
knockout reporter animals that were genotyped following the same strategy. 
The targeting cassette was deleted by recombination with FLP-recombinase at the 
FRT-sites. The resulting FLP/FAM96A mice were genotyped via three different PCR 
reactions. 
                       
The first PCR was performed to investigate the absence of the targeting cassette by 
primers that bind in the 5´ and 3´ arm of the vector (961 bp, red arrows). In a second 
reaction, occurrence of Flp-recombinase DNA was analyzed. In a third PCR 
reaction, wt alleles were distinguished from the targeted, floxed alleles by 
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amplification of the remaining loxP sites (269 in wt compared to 301 bp in targeted 
allele, purple arrows).  
 
To produce a null allele, heterozygous FAM96A mice were crossbred with FLPeR 
mice prior to exposition to the Cre recombinase. Heterozygous FLP/FAM96A mice 
from the first mating were bred to CMV-Cre mice to achieve a complete knockout of 
Exon 3 without the reporter cassette. The remaining transcript that consists mainly 
of Exons 1 and 2 is in silico predicted to not to be recognized by non-sense 
mediated decay (NMD). Heterozygous mice were genotyped by amplification of the 
wildtype allele (945 bp, red arrows) and in addition, a fragment of 342 bp was 
generated from the knockout allele. Only the smaller fragment was amplified in 
homozygous knockout animals. 
                                     
                                
PCR reactions using genomic DNA from mouse tails were set up as follows: 
Reagent Volume (µl) 
 FAM96A(1x) FLPer(1x) Cre(1x) LoxP(1x) LacZ(1x) 
isolated DNA 4 2 5 4 4 
dNTP-mix (2.5mM 
each) 
3 3 3 3 3 
Forward (10µM) 1.5 1.5 1.5 2 2 
Reverse (10µM) 1.5 1.5 1.5 2 2 
En2 SA rev (10µM) 1.5 / / / / 
10 x PCR buffer 2.5 2.5 2.5 2.5 2.5 
REDTaq Polymerase 1.5 1.5 1.5 1.5 1.5 
H2O 9.5 13 10 10 10 
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For genotyping of FAM96A, FAM96A/lacZ and FLP/FAM96A mice, the following 
PCR programs were used:   
Amplification step Temperature Time (min)  Cycle number 
 FAM96A LacZ LoxP    
Denaturing 95°C 95°C 95°C 3  1 
Primer hybridization 95°C 95°C 95°C 0.5   
Primer hybridization 55°C 55°C 55°C 0.5  3 
Primer hybridization 72°C 72°C 72°C 0.5   
Denaturing 95°C 95°C 95°C 0.5   
Annealing 62°C 60°C 60°C 0.5  35 
Extension 72°C 72°C 72°C 0.5   
Final Extension 72°C 72°C 72°C 4  1 
Cooling 4°C 4°C 4°C ∞   
 
PCR programs to detect FLP- and Cre recombinase transgenes are depicted below: 
Amplification step Temperature Time (min) Cycle number 
 FLP Cre FLP Cre  
Denaturing 95°C 95°C 3 3 1 
Denaturing 95°C 95°C 1 0.5  
Annealing 58°C 55°C 1 0.5 35 
Extension 72°C 72°C 1 0.5  
Final Extension 72°C 72°C 4 4 1 
Cooling 4°C 4°C ∞ ∞  
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2.2.2 Protein biochemistry 
2.2.2.1 Protein isolation from cellular lysates 
Cells were harvested and washed once with 1ml of DPBS prior to centrifugation for 
5 min at 450 x g and 4°C. Pellets were resuspended in a suitable volume of 1x 
protein lysis buffer and incubated for 10 min on ice. Lysates were then sonicated 
(Sonifier 250, Branson; Duty cycle 30%, Output 5) and centrifuged for 15 min at 
15,700 x g and 4°C. Pellets were discarded and protein concentration in the 
supernatant was determined by the Bradford assay.  
 
2.2.2.2 Protein extraction from tumor and tissue material 
A piece of tumor or murine tissue was cut from the solid mass with a scalpel and 
transferred into a tube (12,0/75mm, Greiner) filled with 1 ml of Ultra-Turrax lysis 
buffer. The tumor or tissue sample was homogenized, transferred into an eppendorf 
tube and centrifuged at 15,700 x g for 10 min at 4°C. Protein concentration of the 
supernatant was analyzed according to the Bradford protocol.  
 
2.2.2.3 Protein quantification using the Bradford protocol 
Protein concentration of cellular lysates was determined spectrophotometrically via 
the Bradford assay (Bradford, 1976). The reagent Coomassie Brilliant Blue G-250 
binds to cationic and unpolar amino acid residues, which shifts the reagent’s 
absorption maximum from 470 nm to 595 nm. The extent of absorption at 595 nm is 
proportional to the protein amount in the lysate, and using a standard curve of 
known concentrations, the total protein amount can be quantified. 400 µl of 
deionized water were supplemented with 0.5 µl of protein lysate and 100 µl of 
Bradford reagent, followed by a 5 min incubation and subsequent measurement. 
 
2.2.2.4 SDS PAGE 
Separation of proteins according to their molecular weight is achieved by 
sodiumdodecyl-sulfate polyacrylamide gel electrophoresis. Disulfide bonds are 
reduced due to addition of ß-Mercaptoethanol or DTT to the 5 x sample buffer, and 
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proteins are denatured by SDS in the running buffer and an initial denaturation of 
cellular lysates for 5 min at 95°C. Gels were run in 1 x SDS-running buffer using the 
Mini Protean II system (BioRad, Munich) at 90 V for the first 20 min (stacking gel) 
and at 130 V for the separation gel.  
 
2.2.2.5 Transfer of proteins onto nitrocellulose membranes 
Proteins separated by SDS PAGE were transferred onto 0.45 µm nitrocellulose 
membranes using a TE77X semi-dry transfer unit (Hoefer Pharmacia Biotech Inc., 
San Francisco). Whatman papers were soaked in 1 x transfer buffer. 3 layers of 
Whatman paper were placed on top of the anode of the chamber, followed by a 
nitrocellulose membrane, the SDS gel, 3 Whatman papers and the cathode of the 
blotting chamber on top. Protein transfer was performed at 0.8 mA/cm2 for 2 hours. 
After blotting, membranes were stained with PonceauS solution to confirm equal 
transfer and loading of proteins from the gel. 
 
2.2.2.6 Immunodetection of blotted proteins 
To prevent unspecific binding of antibodies, the membranes were blocked in TBS-T 
(0.1% Tween in 1xTBS) supplemented with 5% skim milk powder for 1 h at room 
temperature, before they were incubated in TBS-T plus skim milk with primary 
antibodies overnight at 4°C. The membranes were then further washed 3 x 30 min 
with blocking buffer and incubated with peroxidase-conjugated secondary IgG 
antibodies in TBS-T plus 5% skim milk for 1 h at room temperature. Protein bands 
were visualized by chemiluminescence with the ECL kit (GE Healthcare, Munich). 
 
2.2.2.7 Co-immunoprecipitation analysis via antibody-coupled beads 
2 to 4 x106 HEK293T cells were seeded in 10 cm2 or 14.5 cm2 dishes 48 h prior to 
harvesting in DPBS. 24 h afterwards, cells were either transfected with PEI or left 
untransfected. Lysates were prepared by resuspending the pellets in 500 µl to 1 ml 
of ice-cold CEB buffer, followed by incubation for 10 min on ice. After 30 strokes 
with a Dounce homogenizer (VWR, Leicestershire, UK) and centrifugation at 15,700 
x g for 15 minutes, pre-clearing of the lysates was performed by incubation with 
equilibrated protein A/G-agarose beads for at least 2 h in an overhead rotator at 
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4°C. Beads were equilibrated by washing them three times with CEB buffer and 
centrifugation steps for 3 min at 830 x g and room temperature in between the 
washing steps. Meanwhile, 1 µg of the appropriate antibody was coupled to 
equilibrated agarose beads for 4 h at 4°C in TBS/3%BSA. Coupled beads were 
washed three times with apoptosome lysis buffer, centrifuged for 3 minutes at 830 x 
g, and immune complexes were collected overnight at 4 °C. Immune complexes 
were washed three times with apoptosome lysis buffer prior to boiling in 5x SDS 
PAGE sample buffer for 5 minutes at 95°C. Precipitates were analyzed by SDS 
PAGE and visualized via immunodetection. 
 
2.2.2.8 Co-immunoprecipitation via Protein G µMacs beads 
The pelleted cells were taken up in 1 ml of µMacs lysis buffer and incubated on ice 
for 10 min. After centrifugation of the lysate at 15,700 x g for 15 minutes at 4°C, 
protein concentration of the supernatant was determined by Bradford assay. 1-3 mg 
of total protein in a cellular lysate and 1-3 µg of the corresponding antibody were 
mixed for precipitation together with 50 µl Protein G MicroBeads (Miltenyi Biotec, 
Bergisch Gladbach). Complexes were incubated for 30 min on ice and subsequently 
added to freshly equilibrated µ columns in a magnetic field. Washing and elution 
were carried out according to the manufacturer´s instructions, and the precipitated 
protein complexes were separated by SDS PAGE and visualized by Western 
blotting and immunodetection.  
 
2.2.3 Cellular assays 
2.2.3.1 Cell culture and transfections 
HEK293T, NIH/3T3 and RKO cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum, 1% L-Glutamine and 
1% Penicillin/Streptomycin. Murine Renca-lacZ renal carcinoma cells were cultured 
in Roswell Park Memorial Institute medium (RPMI) 1640 containing the same 
supplements. GIST48 (kindly provided by J. Fletcher, Boston, USA) were cultured in 
Ham´s F-10 medium supplemented with 18% FBS, 1% Pen/Strep, 1% L-Glutamine, 
7,5 mg Bovine Pituitary Extract and 1,25 mg MitoTM plus Serum Extender. GIST882 
(kindly provided by J. Fletcher, Boston, USA) were cultured in RPMI 1640 containing 
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15% of heat-inactivated FBS, 1% L-Glutamine and 1% Penicillin/Streptomycin. All 
cell lines were cultured at an atmosphere of 5% CO2 at 37 °C. 
 
2.2.3.2 Freezing and thawing of cells 
Adherent cells were washed, trypsinized and pelleted by centrifugation for 5 min and 
450 x g. Then, cells were resuspended in 1 ml of 90% FBS supplemented with 10% 
of sterile DMSO. The suspension was slowly cooled down to -80°C in a freezing 
container (Nalgene, Roskilde, Denmark).  
For gentle thawing of cells, cells were incubated in a water bath at 37°C and mixed 
with 10 ml complete growth medium. Cells were then centrifuged for 5 min at 450 x 
g and room temperature to remove DMSO and subsequently taken up in culture 
medium. 
 
2.2.3.3 Counting cell numbers (Neubauer Hematocytometer) 
Total cell numbers in a suspension were quantified by manual counting of cells in a 
hematocytometer. 10 µl of cell suspension were transferred to one chamber, and 16 
small squares (1 corner square) were counted under a microscope. The number of 
cells per ml was calculated by multiplying the counted number of cells with 104. Cell 
viability was additionally determined by trypan blue staining of cells in a ratio of 1:1. 
 
 
 
2.2.3.4 Polyethyleneimine (PEI)-mediated transfection 
Transfection via the polymer is most efficient when the ratio between positively 
charged amine nitrogens in PEI and negatively charged phosphates of the DNA 
backbone is in a range of 9-13.5 (Boussif et al., 1995). According to this, the 
transfection protocol was set up as follows: 
1 µg DNA = 3nmol phosphate; 1 µl 10mM PEI (monomer) = 10nmol amine nitrogens  
A ratio of 9 corresponds to 27nmol nitrogen amines per 1 µg DNA, therefore 2.7 µl 
of 10mM PEI working solution were used to transfect 1 µg of DNA. DNA and PEI 
were diluted in 150 µl DPBS in separate eppendorf tubes. Both solutions were 
mixed and incubated at room temperature for 20-30 min. Cells were washed and 
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FBS-free medium was added. After 4-6 hours in the incubator, the medium was 
replaced by different medium containing FBS. 
 
2.2.3.4 Lipofectamine-2000TM- and Lipofectamine LTX-mediated transfection 
Lipofectamine 2000- and Lipofectamine LTX-mediated transfection were carried out 
following the manufacturer´s instructions. Medium was replaced by other medium 
lacking antibiotics for 6 hours during the transfection of DNA. For Lipofectamine LTX 
transfections, Plus Reagent and Lipofectamine were added in a ratio of 1:1 in order 
to achieve higher transfection efficiencies.  
 
2.2.3.5 Lentiviral transduction of cells 
Lentiviral transduction was used to introduce expression constructs for shRNAs or 
cDNA into mammalian cells in order to knock down or overexpress a certain target 
gene (Sumimoto and Kawakami, 2007). Advantages to use lentiviral vectors are, 
amongst others, highly efficient DNA transfer, the possibility to achieve stable long-
term expression due to integration into the host genome, and the ability of 
lentiviruses to infect non-dividing, slowly proliferating cells. 2 x 106 HEK293T cells 
were transfected with 1.625 µg of p8.91 (gag/pol), 0.875 µg pMD2.G (env) and 2.5 
µg overexpression or shRNA constructs for the production of lentiviral particles. 48 
hours post-transfection, 2 x 105 target cells seeded in 6 well plates were infected 
with filtered virus-containing supernatant (0.45µm filter), together with polybrene at a 
concentration of 8 mg/ml, by centrifugation for 1 hour at 340 x g and 32°C (spin 
infection). 4-6 hours later, medium was changed, and the infection procedure was 
repeated the next day. 2 µg/ml of the antibiotic puromycin (0.5 mg/ml) served as the 
selective agent for infected cells. Alternatively, cells were sorted using a FACS cell 
sorter (FACSAria, BD, Pharmingen). 
 
2.2.4 Apoptosis assays  
2.2.4.1 Viability stainings 
Cell viability was determined by staining of dead cells with DNA-intercalating agents 
such as Propidium iodide (PI) or 7-Aminoactinomycin D (7-AAD). Living cells 
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exclude these dyes, whereas due to changes in membrane integrity, dying cells are 
stained. Intracellular single cell staining can be quantified by FACS analysis (Philpott 
et al., 1996).  
Cells were seeded at 1-2 x 105 cells per well in a 6 well plate 24 to 48 hours prior to 
induction of apoptosis by UV-irradiation, recombinant Fas ligand or one of several 
chemotherapeutics. Supernatant and cells were harvested in FACS tubes, filled with 
DPBS and centrifuged for 5 min at 450 x g and 4°C. Cells were harvested and 
stained for 20 min with propidium iodide (50 µg/ml) in DPBS supplemented with 3% 
FBS or 7-AAD (4 µg/ml) for 20 min in the dark. PI- or 7-AAD-positive (dead) cells 
were quantified using FACS analysis (FACS Calibur, FACS Scan). 
 
Cell line Treatment Concentration Incubation period (h) 
Renca-lacZ Mitomycin C 30 µg/ml 24 
RKO Mitomycin C 15 µg/ml, 10 µg/ml, 4µg/ml 20, 6, 12  
Renca-lacZ Oxaliplatin 100µM 24 
RKO Oxaliplatin 100µM 20 
RKO  Staurosporine 1µM 6 
RKO Fas ligand 40 ng/µl, 1µg/µl anti-Flag, 0.1 
µg/µl Cycloheximide 
6  
Renca-lacZ Rad-001 
(Everolimus) 
10nM, 50nM, 100nM, 500nM, 
1µM 
30-48  
NIH/3T3 Fas ligand  20 ng/µl, 1µg/µl anti-Flag, 0.1 
µg/µl Cycloheximide 
6  
NIH/3T3 UV-irradiation 70, 100, 120 and 150 mJ 6 
RKO UV-irradiation 70, 100, 120 and 150 mJ 6 
GIST48 Staurosporine 1µM 18  
GIST882 Imatinib 
Mesylate 
10µM 24  
 
2.2.4.2 Cell cycle profiling using the Nicoletti protocol 
During apoptosis, DNA is cleaved by Caspase activated DNAse (CAD), and 
fragments of about 200 bp and multiples of 200 bp are generated. Intercalating 
agents such as propidium iodide (PI) can bind specifically to nucleic acids and stain 
them. This intracellular staining can be analyzed cytometrically in ethanol-fixed cells. 
This method allows cell cycle profiling and quantification of the apoptotic subG1 
fraction within a population of cells (Nicoletti et al., 1991; Riccardi and Nicoletti, 
2006). Cells are stained after fixation with ethanol and after addition of RNase A. 
The DNA content of a cell is proportional to the PI intensity after RNAse digestion 
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and, due to fixation, fragmented DNA of the apoptotic cells generates a subG1 peak 
that is illustrated in a cell cycle profile.  
1 x 105 RKO cells per well were seeded in 6-well plates. For induction of cell death, 
cells were irradiated with UV or treated with chemotherapeutics (such as mitomycin 
C and oxaliplatin). After an accordant incubation time, cells were harvested, washed 
with DPBS and fixed by gentle addition of ice-cold 70% ethanol prior to incubation at 
4 °C for at least 24 h. This was followed by a washing step with 38mM sodium 
citrate (pH 7.4) and centrifugation for 5 min at 4°C and 400 x g. Cells were then 
stained for 20 min with propidium iodide (50 µg/ml) in 38mM sodium citrate plus 5 
µg/ml RNaseA at room temperature in the dark. The apoptotic subG1 fraction of 
RKO cells was quantified by FACS analysis (FACS Calibur or FACS Scan) using the 
CellQuest Pro software (BD Biosciences, Pharmingen). Fluorescence intensity in 
the FL-2A channel was quantified using the doublet discrimination module (DDM). 
20,000 events were acquired for each sample, and a gate was set on the cell 
population present in a FL2-A/FL2-W dot plot, so that the cell cycle profile could be 
visualized in a FL2-A histogram.  
 
2.2.4.3 AnnexinV staining of apoptotic cells 
During the onset of cell death, phosphatidylserine (PS) is exposed at the outer 
leaflet of the plasma membrane to mark the dying cells for phagocytosis. 
Fluorescently-labeled Annexins bind to phospholipids, preferentially PS, in a 
calcium-dependent manner and can thereby serve as a marker for early apoptotic 
cells. Together with a viability dye (PI or 7-AAD) detecting membrane disintegrity, 
early (AnnexinV-positive) and late apoptotic cells (double positive) can be 
distinguished from necrotic cells that stain only positive for PI or 7-AAD (Zhang et 
al., 1997) 
2 x 105 NIH/3T3 were seeded in 6 well plates, and after adhesion for 24 hours, 
apoptosis was induced by several stimuli of the intrinsic or extrinsic apoptosis 
pathway. Cells were incubated for 6 hours and afterwards, the supernatant as well as 
living cells were harvested and transferred to FACS tubes. Tubes were filled with 
PBS, and the samples were centrifuged for 5 min at 4°C and 450 x g. Cells were 
subsequently stained with PI (50 µg/ml) and AnnexinV-FITC (2 µl/sample) in 100 µl of 
AnnexinV-binding buffer for 20 min at room temperature in the dark. Another 400 µl of 
binding buffer were subsequently added to the stained samples, and AnnexinV- and 
PI-single-stained as well as double positive cells were quantified by FACS analysis 
(FACS Calibur) using the CellQuestPro software (BD Biosciences, Pharmingen). 
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20,000 events were acquired for each sample and visualized by quadrant stats in a 
FL1-FL2 dot plot.  
 
2.2.5 Animal work 
2.2.5.1 Mice 
Non-obese-diabetic/severe-combined immunodeficient (NOD-SCID) mice were bred 
in the animal facility of the Georg-Speyer-Haus, fed food and water ad libitum, and 
were housed in individually ventilated cages under pathogen-free-like conditions. All 
xenograft experiments were performed in compliance with the guidelines for animal 
experimentations.  
 
2.2.5.2 Tumor xenograft experiments 
Subcutaneous xenograft experiments were performed in non-obese-diabetic/severe-
combined immunodeficient (NOD/SCID) mice, and the lentivirally transduced tumor 
cells were injected into the left flank of 8- to-12-week old animals. Tumor cells were 
applied either in 100 µl of DPBS or in 100 µl of a Matrigel suspension at a ratio of 
1:1 in DPBS. Tumor growth was quantified twice to three times a week with external 
calipers for 5-8 weeks. Tumor size was calculated as follows: tumor volume [mm3] = 
length x (width)2/2. When the tumor reached a size of 70-150 µl, mice were treated 
intraperitoneally with 3mg/kg of mitomycin C once a week. 
 
 
2.2.5.3 X-Gal staining of mouse tissues 
Tissues were excised and washed once in DPBS and stored in fixative solution 
(Roti® Histofix) overnight at room temperature. Prior to staining, tissues were 
washed four times for at least 30 minutes in DPBS. Tissues were stained overnight 
to 40 hours in X-Gal staining buffer supplemented with 1mg/ml X-Gal (50mg/ml) at 
37°C and gentle shaking (30 rpm) in the dark and washed three times afterwards. 
Positive staining of tissues was documented with a digital camera (Nikon 
COOLPIX3700; Panasonic, Lumix).  
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2.2.6 In silico comparative genomic hybridization  
Chromosomal aberrations can be screened in several tumor entities, and 
comparative genomic hybridization data are pooled in certain databases of which 
the largest one currently is the Progenetix database (Baudis and Cleary, 2001; du 
Manoir et al., 1993; Kallioniemi et al., 1993) (http://www.progenetix.org/cgi-
bin/pgHome.cgi). It contains anonymized information from 29, 743 human cancer 
patients.  
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3. Results 
3.1. Interaction of FAM96A and APAF-1  
FAM96A was isolated as an interaction partner of APAF-1 in a yeast two hybrid 
screen performed with a mouse thymoma cDNA library and CED-4 or different 
APAF-1 constructs as baits. Several investigations on the protein-protein interaction 
of FAM96A and APAF-1 were performed previously in the group of Prof. Zörnig (R. 
Pick, S. Mateus-Fernandez, K. Völp, unpublished data), and further verification of 
the binding was one focus of this work. Therefore, APAF-1S (1-1194), the shortest of 
the five APAF-1 isoforms that lacks the extra WD40 repeat and the 11 aa insert at 
the N-terminus, was co-transfected together with Flag-tagged expression vectors for 
the APAF-1-binding protein AVEN, FAM96A and Fas-associated protein with Death 
Domain (FADD) as a negative control into HEK293T cells (Fig. 3.1 A). After protein 
precipitation via a specific anti-Flag-antibody, an interaction of APAF-1 could be 
confirmed with its well-known interactor AVEN as well as with FAM96A. APAF-1 
was not detected following FADD-precipitation.  
Endogenous APAF-1 was successfully co-precipitated following precipitation of 
overexpressed Flag-FAM96A (Fig. 3.1 B) and after incubation of the endogenous 
protein lysate with a purified polyclonal anti-FAM96A-antiserum (Immunogen: 
YDLIRTIRDPEKPN) (Fig. 3.1 D). Rabbit IgG (IP control) served as a negative 
control for unspecific antibody binding. A moderate co-precipitation of Flag-tagged 
FAM96A was achieved following precipitation of overexpressed, Myc-tagged APAF-
1S (Immunogen: REALEKDIKTSYIMDH) (Fig. 3.1 C). FLICE inhibitory protein 
(FLIP)-precipitation, as a negative control, confirmed specific interaction of both 
proteins.  
Binding site mapping of recombinant FAM96A on APAF-1 was performed to confirm 
previous data from immunoprecipitation of truncated APAF-1-deletion mutants that 
suggested an interaction of FAM96A with the nucleotide binding domain (NBD) of 
APAF-1. Bacterially expressed recombinant FAM96A was purchased from RiNA, 
Berlin. APAF-1ΔWD40 was spotted on a nitrocellulose membrane in linear 18mer 
peptides with an offset of 1 or 3 amino acids. Recombinant FAM96A was incubated 
on the two different membranes overnight, and 5 potential binding peptide 
candidates could be identified of which one is located in the NOD, one in the NBD, 
one in the HD1, one within the WHD and two in the HD2-domain of APAF-1 (data 
not shown). 
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Figure 3.1: Co-immunoprecipitation experiments of FAM96A and APAF-1 
The interaction of FAM96A and APAF-1 was investigated after transient over-
expression of one or both binding partners in HEK293T cells (A-C). For this 
purpose, 2 x 106 cells were co-transfected with Flag-tagged pcDNA3.1 constructs 
together with APAF-1S. 24 hours later, proteins were immunoprecipitated via their 
Flag-tag (A). Successful precipitation was achieved with the known APAF-1 
interaction partner AVEN and FAM96A. Flag-FADD served as a negative control for 
APAF-1-interaction. Endogenous APAF-1 was co-precipitated following 
overexpression of Flag-FAM96A (B) and following precipitation of endogenous 
FAM96A using a purified anti-FAM96A-antiserum (D). Rabbit IgG served as a 
negative control (IP control). Precipitation of APAF-1 was achieved via an antibody 
recognizing the C-terminus (APAF-1 K20) (C), and an anti-FLIP antibody served as 
a negative control (IP control).  
 
3.2 Functional involvement of FAM96A in the intrinsic apoptosis pathway  
3.2.1 Consequences of stable overexpression of human and murine FAM96A in 
cancer cell lines and its influence on cell death 
Transfection of human FAM96A, followed by UV-induced killing of RKO cells, 
resulted in an increase in apoptotic cell numbers compared to empty vector control- 
transfected cells (Mateus-Fernandez, data not shown). To confirm these preliminary 
data obtained by transient overexpression of FAM96A in RKO cells, lentiviral 
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constructs for stable ectopic upregulation of human and murine FAM96A were 
generated. Coding sequences of FAM96A were cloned into the LeGoiG2 vector that 
controls transgene expression by the SFFV promoter, and the inserted target 
sequence is followed by a 3´ IRES-eGFP element. The GFP-reporter gene activity 
resembles transgene expression and allows sorting of cells with homogeneous 
expression levels. Cytostatic drugs such as mitomycin C or oxaliplatin are widely 
used in chemotherapy for treatment of colon and renal cancer and were therefore 
used to treat the virus-transduced cells.  
 
3.2.1.1 Ectopic expression of FAM96A in human colon cancer cells 
A polyclonal population of FAM96A-transduced RKO cells was analyzed for a 
potential involvement of FAM96A in modulating the intrinsic apoptosis pathway. The 
lentivirus-transduced cell population was separated from non-transduced cells by 
FACS sorting (Fig. 3.2 A), and upregulation of FAM96A in the GFP-positive cells 
was analyzed over several passages by immunoblotting. Ectopic expression of 
FAM96A was stable up to passage 8 after initial sorting (Fig. 3.2 B) of the cells. The 
empty LeGoiG2 vector served as a negative control. Following overexpression of 
hFAM96A, untreated cells displayed no enhanced numbers of dead cells compared 
to controls. To investigate the influence of FAM96A on apoptosis induction, the 
intrinsic pathway was induced via treatment of cells with the cytostatic 
chemotherapeutics oxaliplatin (Fig. 3.2 C) and mitomycin C (Fig. 3.2 D). Upon 
upregulation of FAM96A, the susceptibility of the cells was significantly increased 
upon treatment with oxaliplatin, and a moderate pro-apoptotic influence of FAM96A 
could also be observed after incubation with mitomycin C.  
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Figure 3.2: Stable overexpression of human FAM96A in RKO cells 
2 x 105 RKO cells were stably transduced with viral particles containing a hFAM96A 
cDNA construct and compared to empty vector-infected cells as a control. GFP-
positive cells were sorted (A), and long-term stability of expression was investigated 
by immunoblotting over a period of 8 passages (B). Intrinsic apoptosis was induced 
via treatment of the RKO cells with 100µM oxaliplatin (C) or 15 µg/ml mitomycin C 
(D) for 20 hours and investigated using a Nicoletti-assay. C: n=6; *=p<0.05, D: n=4; 
unpaired student´s t-test; Mean ± SD. 
 
3.2.1.2 Ectopic expression of murine FAM96A in renal cancer cells 
Murine FAM96A was stably introduced into the genome of Renca-lacZ (RLZ) cells 
following lentiviral transduction. Cells were sorted and compared to empty LeGoiG2-
vector-transduced cells (Fig. 3.3 A). Protein upregulation was monitored over 
several passages and diminished during proliferation of the renal cancer cells (Fig. 
3.3 B). Apoptosis sensitivity of infected cells was therefore investigated until 
passage 7 post transduction. Elevated cell death was observed in PI-exclusion 
stainings among the untreated cell population when FAM96A was upregulated (Fig. 
3.3 C). The intrinsic pathway of apoptosis was induced by treatment of Renca-lacZ 
with mitomycin (MMC) and oxaliplatin (Fig. 3.3 C). FAM96A-overexpressing cancer 
cells displayed a significantly increased susceptibility to treatment with cytostatic 
drugs compared to controls.  
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Figure 3.3: Influence of stable ectopic expression of murine FAM96A on 
apoptosis in Renca-lacZ cells 
2 x 105 Renca-lacZ (RLZ) were transduced with mFAM96A-LeGoiG2 and compared 
to empty vector-transduced cells as a control. After sorting of the clonal population 
(A), protein expression was investigated by immunoblotting over 7 passages (B). PI-
exclusion stainings were performed after treatment of RLZ with 30 µg/ml mitomycin 
C and 100µM oxaliplatin for 24 hours. C: n=7; *=p<0.05, unpaired student´s t-test; 
data are presented as Mean ± SD. 
 
3.2.1.3 Influence of murine and human FAM96A upregulation on tumor growth 
in vivo 
After the pro-apoptotic influence of FAM96A on intrinsic apoptosis was confirmed in 
cell culture experiments, subcutaneous tumor xenograft experiments were 
performed to investigate the consequences of FAM96A expression on tumor growth 
in vivo. LeGoiG2-FAM96A and empty vector-transduced RKO and RLZ cells were 
injected into the right flank of nonobese diabetic/ severe combined immunodeficient 
(NOD/SCID) mice, and tumor growth was monitored over several weeks. 
Additionally, mice injected with FAM96A- and empty vector transduced tumor cells 
were treated with mitomycin C intraperitoneally (i.p.) once a week. Tumor growth 
was significantly reduced in both xenograft experiments comparing untreated 
FAM96A groups to LeGoiG2 control groups (Fig 3.4 A, D). At the last day of the 
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xenograft experiment, tumors were excised, and elevated FAM96A expression was 
confirmed via immunoblotting of tumor material or GFP-fluorescence under a 
stereomicroscope (Leica, Wetzlar) (Insets, Fig. 3.4 A, D).  
Mitomycin C treatment of mice that were injected with RKO cells was started at a 
tumor volume of 70 mm3 (day 0). Chemotherapeutic mitomycin C treatment once to 
twice a week displayed slight beneficial effects on tumor growth in the control 
groups (Fig. 3.4 B). However, in the groups with FAM96A-overexpressing cells, 
mice treated with mitomycin C did not benefit from treatment compared to their 
untreated controls. The relative tumor volume of treated mice was reduced upon 
upregulation of FAM96A compared to control vector-transduced tumors, as depicted 
by Figure 3.4 C. Interestingly, of the 14 injected tumors in the FAM96A group, only 5 
tumors successfully engrafted, while in the control group, 4 out of 14 tumors did not 
expand.  
Tumor growth was impaired when murine FAM96A was introduced into Renca-lacZ 
cells and compared to controls (Fig. 3.4 D). Additional chemotherapeutic treatment 
of tumor-bearing mice with mitomycin C was started when the tumors had reached a 
size of 150 mm3, but a beneficial effect from the treatment could not be observed 
(Fig. 3.4 E). Due to the high degree of ulceration of Renca-lacZ tumors, 15 of the 32 
mice had to be sacrificed at this time point. Relative tumor volumes for all mice in 
mitomycin C-treated groups are indicated in Figure 3.4 F. The relative tumor growth 
under mitomycin C treatment was not affected when FAM96A was overexpressed 
compared to control cells.   
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Figure 3.4: Influence of FAM96A upregulation on tumorigenicity of RKO and 
Renca-lacZ cells  
4 x 106 RKO/mouse stably transduced either with FAM96A or the empty LeGoiG2 
vector were supplemented with matrigel (1:1), injected subcutaneously into the flank 
of NOD/SCID mice (RKO: n=7 mice/group), and tumor growth was monitored twice 
weekly for 36 days (A, B, C). Tumor growth was significantly reduced at 20 and 36 
days post injection (p.i.) comparing non-treated mice injected with FAM96A-
overexpressing cells to mice with control vector-transduced cells (p˂0.05). Once the 
tumor volume had reached 70 mm3, two groups of mice were injected i.p. weekly 
with 3 mg/kg mitomycinC/100µl DPBS (arrows) (B). The relative tumor growth at 
days of measurement (twice a week; day 0 = first time point of mitomycin C 
injection, tumor volume 70 mm3) under mitomycin C (Time points under Mitomycin 
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C) treatment is depicted in C. Excised tumors were analyzed for FAM96A protein 
expression by immunoblotting (Inset, A). 1 x 106 transduced Renca-lacZ cells/mouse 
were injected into NOD/SCID mice (n=8 mice/group), and tumor development was 
measured for 24 days (D). Mice were treated intraperitoneally once a week with 2 
mg/kg mitomycin C/100µl DPBS starting at a tumor volume of 150 mm3 (day 0) (E). 
Highly significant (p˂0.01) differences in tumor growth were observed at days 20 
and 24 p.i. in the untreated groups and in between the treated groups at day 24 p.i. 
(p<0.05). Arrows indicate time points of mitomycin C treatment. Relative tumor 
volumes were calculated for mitomycin C-treated mice; start of treatment: day 0; 
days of monitoring twice weekly from day 0= Time points under Mitomycin C (F). 
GFP-fluorescence was investigated in isolated tumors (Inset, B). Data are presented 
as Mean ± SEM; unpaired student´s t-test.  
 
3.2.2 Consequences of shRNA-mediated silencing of endogenous murine and 
human FAM96A on intrinsic apoptosis 
To further investigate whether FAM96A is required for efficient induction of intrinsic 
apoptosis, polyclonal murine and human gene knockout cell lines were generated by 
lentiviral transduction. Transduced cells were selected with the antibiotic puromycin, 
and two separate vector systems were applied for reduction of human FAM96A in 
vitro. The pLKO.1-puro constructs (Sigma Aldrich) contain a puromycin selection 
cassette, whereas in the pGIPZ vector (Open Biosystems), an IRES element is 
inserted between a tGFP reporter and the puromycin resistance gene. A 
corresponding control vector, containing a non-targeting control shRNA, was 
transduced for both vector systems. Following infection of human and murine cells, 
sensitivity to induction of intrinsic apoptosis was analyzed.  
 
3.2.2.1 Lentiviral, short-hairpin mediated knockdown of murine FAM96A  
To induce efficient lentivirus-mediated downregulation of FAM96A protein levels, 5 
individual shRNAs were investigated for their knockdown potential in the murine 
fibroblast cell line NIH/3T3. Upon transduction of the sh4 (mFAM96A sh) construct, 
reduction in protein expression of FAM96A and ΔN-FAM96A was most efficient 
compared to the other four introduced shRNAs (Fig 3.5 A). Long-term stability of 
FAM96A depletion under constant selection pressure was investigated by 
immunoblotting of the cells in later passages (data not shown) (Inset, Fig. 3.5 B, 
passage 2 post transduction). Viability assays were performed to analyze sensitivity 
to UV irradiation of knockdown cells compared to the non-targeting control 
population. Susceptibility of untreated cells was largely reduced in the knockdown 
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cells as measured by PI-exclusion stainings. Upon UV-mediated induction of cell 
death in increasing doses, a significant desensitization towards irradiation could be 
observed comparing knockdown cells to control vector transduced NIH/3T3 (Fig 3.5 
B). Surprisingly, no dose-dependency of the UV-induced killing upon application of 
70, 100, 120 and 150 mJ was detected. As simple viability stainings do not provide 
information whether apoptotic or necrotic cell death is occurring, an additional 
AnnexinV/PI assay was performed. Early (AnnexinV positive/PI negative) and late 
apoptotic cell death (AnnexinV and AnnexinV/PI positives) was severely diminished 
in cells expressing low levels of FAM96A (Fig. 3.5 C and D). Killing via the extrinsic 
pathway of apoptosis, however, when induced by treatment of cells with 
recombinant Fas ligand, remained unaffected after reduction of FAM96A 
expression.  
 
Figure 3.5: Influence of FAM96A knockdown on apoptosis of NIH/3T3  
Endogenous murine FAM96A was reduced by short hairpin RNA delivered via 
lentiviral transduction of NIH/3T3 cells. 5 different vector constructs were analyzed 
for their knockdown efficiency and a significant reduction in protein levels of 
FAM96A was achieved by the sh4 construct (A). The sh4 construct was compared 
to non-targeting control vector-transduced NIH/3T3 in viability stainings following 
UV-irradiation of cells with four different doses. PI-staining was carried out 6 hours 
after apoptosis induction. Data from two independent transductions are represented 
as Mean ± SEM; n=4; * = p<0.05, unpaired student´s t-test (B). Apoptosis of 
NIH/3T3 was investigated in an AnnexinV/PI staining (AnnexinV-positive cells: C, 
AnnexinV- and Pi-positive cells: D). Cells were treated for 6 hours with four different 
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doses of UV or Fas ligand. Wild type cells were compared to control vector-
transduced and mFAM96A knockdown cells. n=2 (control sh: n=1); Mean ± SEM.  
 
3.2.2.2 Consequences of FAM96A downregulation in human colon cancer cells 
To demonstrate an influence of human FAM96A on intrinsic apoptosis, 5 different 
shRNA constructs (pLKO.1-puro) were investigated in two independent 
transductions for their efficiency to reduce FAM96A protein levels in the colon 
cancer cell line RKO. Of the five different constructs, the sh4 (hFAM96A sh) 
construct was most effective in transcriptional interference (Fig 3.6 A). A significant 
reduction in ΔN-FAM96A protein expression was achieved by all 5 constructs. The 
result of 6 independent cell killing assays from two separate transductions is 
depicted in Fig. 3.6 B.   Knockdown cells were compared to non-targeting control 
vector-transduced cells (control sh) in Nicoletti apoptosis assays. A significant 
decrease in intrinsic cell death could be observed in FAM96A-depleted cells after 
treatment with increasing doses of UV (Fig 3.6 B). Additionally, 8 shRNA constructs 
in the pGIPZ vector (Open Biosystems) were analyzed for their FAM96A knockdown 
potential and compared to the corresponding non-targeting vector control (Fig 3.6 
C). All of the constructs induced efficient protein reduction in early passages and the 
two most promising candidate cell lines were analyzed for their sensitivity towards 
intrinsic cell death. While the sh1 construct reduced FAM96A protein levels in low 
passages, FAM96A expression levels were restored as soon as passage five was 
reached after transduction (data not shown), although cells were cultured under 
constant selection pressure by puromycin. Long-term knockdown stability could be 
confirmed in sh5-FAM96A transduced RKO cells. These cells were compared to sh1 
and non-targeting (sh control) vector-transduced cells in a Nicoletti apoptosis assay. 
Cell death was induced via treatment of the cells with mitomycin C (Mito C) or UV 
irradiation. Here, a diminished susceptibility of the knockdown cells towards 
apoptosis induction could be observed (Fig 3.6 D), as described for the pLKO.1-
puro transduced RKO and NIH/3T3 cells. 
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Figure 3.6: Consequence of FAM96A depletion for cell death of RKO cells 
For stable lentiviral knockdown of FAM96A in the colon cancer cell line RKO, 5 
different shRNA constructs cloned in the vector pLKO.1-puro were analyzed for their 
efficiency to reduce FAM96A protein levels. The sh4 construct (hFAM96A sh) was 
most effective in FAM96A depletion (A). In a Nicoletti assay, the subG1 fraction of 
FAM96A knockdown (sh = sh4, passage 4 post transduction) cells was quantified by 
FACS and compared to non-targeting shRNA-transduced control cells (control sh) 6 
hours after irradiation (2 x 105 RKO cells, 70, 100, 120 and 150 mJ UV); n=6 (two 
independent transductions); * = p<0.05, unpaired student´s t-test; Mean ± SEM (B). 
8 different shRNA constructs cloned in the pGIPZ vector were investigated for their 
capability to induce efficient knockdown of FAM96A in passage two after 
transduction of RKO cells (C). Antibiotic selection was performed with 2 µg/ml 
puromycin. Cells transduced with the sh5 construct were investigated in a Nicoletti 
assay and compared to the sh1 knockdown cell line and the non-targeting pGIPZ 
control. 2 x 105 RKO were treated with 4 or 15 µg/ml mitomycin C for 20 hours, or 
with 150 mJ UV for 6 hours (D). Fixed cells were stained with PI prior to cell cycle 
profiling by flow cytometry; n=1. 
 
3.3 Functional investigations on the potential antagonistic role of the smaller 
isoform ΔN-FAM96A  
Due to an alternative in-frame startcodon 32 amino acids downstream of the first 
FAM96A translational start site, a second, N-terminally truncated isoform is 
generated. Previous studies were performed suggesting an antagonistic, anti-
apoptotic role for the smaller isoform of human FAM96A (Pick, 2006). This 
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assumption was further addressed in the course of this study. Therefore, RKO cells 
were transiently transfected with an efficiency of 60-70% with ectopic expression 
constructs (Fig. 3.7 A) for full length as well as the truncated isoform of human 
FAM96A in the pcDNA3.1(+) vector, and their effect on apoptosis was investigated 
(Fig 3.7 B). Transfected RKO cells were treated with mitomycin C (Mito C) and 
compared to wild type and empty vector-transfected controls. A pro-apoptotic 
influence could be observed, when either full-length or the smaller isoform of 
FAM96A were expressed (Fig 3.7 B). As the assumed antagonistic effect of the 
smaller FAM96A isoform could not be confirmed, further analysis of the functional 
role of ΔN-FAM96A and its interaction with APAF-1 was performed by Jennifer Jung 
(Jung, 2012).  
 
Figure 3.7: Influence of ΔN-FAM96A on mitomycin C-induced cell death 
2 x 105 RKO cells were seeded 24 hours prior to transient transfection with 
pcDNA3.1 expression constructs for full length and ΔN-FAM96A. 48 hours later, 
apoptosis was induced by treatment with 4 µg/ml mitomycin C (Mito C) for 24 hours 
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(B). Cells were then fixed in 70% ethanol for at least one day, followed by 
subsequent staining with propidium iodide and RNaseA treatment. The subG1-
fraction was quantified by flow cytometry (B); n=1.  
 
3.4 Consequences of ectopic FAM96A expression on the cell cycle profile 
A potential influence of FAM96A overexpression on the cell cycle distribution of 
cancer cells was investigated in Renca-lacZ cells. Additionally, the G1-arrest-
inducing chemotherapeutic agent Rad-001 (Everolimus) was added to the culture 
medium of Renca-lacZ cells in increasing concentrations. Everolimus belongs to the 
mTOR-pathway inhibitors, diminishes cellular proliferation and is used as a second-
line treatment of advanced and metastasizing renal cell carcinoma (George and 
Bukowski, 2009). An efficient G1-arrest was introduced in wild type, control vector- 
and FAM96A-transduced Renca-lacZ cells with Rad-001 at a concentration of 10nM. 
Although cells transduced with mFAM96A displayed a marginally increased G1-
arrest upon mTOR-inhibition, no significant changes due to upregulation of FAM96A 
in RLZ compared to wild type or empty vector-transduced cells could be observed 
(Fig. 3.8 A). mTOR-inhibition also increases apoptosis sensitivity in cancer cells by 
inhibition of the p53-target p21 (Beuvink et al., 2005). Therefore, Rad-001 was 
analyzed for its dose-dependent sensitization of Renca-lacZ cells to apoptosis. Due 
to G1-arrest induction, cell killing was reduced compared to untreated cells upon 
application of Rad-001 in different concentrations. No significant differences in 
apoptosis sensitivity upon cell-cycle inhibition of the renal cancer cells stably 
transduced with FAM96A could be observed compared to empty vector controls. 
However, intrinsic apoptosis was not triggered by combinatorial treatment with a 
DNA-damaging agent. 
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Figure 3.8: Analysis of cell cycle distribution and apoptosis of FAM96A over-
expressing Renca-lacZ following mTOR inhibition  
2 x 105 LeGoiG2mFAM96A or LeGoiG2-transduced and non-transduced Renca-
lacZ cells were seeded in 6 well plates. 24 hours later, G1-arrest was induced by 
increasing concentrations of Rad-001 (Everolimus) for 30 hours (A). Cells were fixed 
in ethanol for at least 24 hours, stained with PI, and cell-cycle distribution was 
analyzed by flow cytometry; n=1. Induction of apoptosis in the Rad-001-treated and 
untreated cells was quantified by PI-exclusion after 30-48 hours of treatment (B), 
data are presented as Mean ± SD; n=2. 
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3.5 Correlation of FAM96A expression with tumorigenicity  
Since a pro-apoptotic role for FAM96A was observed in vitro and a significant 
negative effect of increased FAM96A expression was observed on tumor growth in 
vivo, a tumor-suppressor function of the protein can be assumed. Mutation or 
deletion of the protein would increase the probability of tumor formation or 
progression. To investigate potential deletions within the FAM96A locus in tumors, 
an in silico analysis of a comparative genomic hybridization (CGH) database was 
conducted. CGH is a method to analyze chromosomal aberrations such as 
insertions or deletions within a certain locus in a genome wide manner (du Manoir et 
al., 1993; Kallioniemi et al., 1993).  
 
3.5.1 FAM96A is downregulated in gastrointestinal stromal tumors  
The progenetix database (http://www.progenetix.org/cgi-bin/pgHome.cgi) provides 
CGH data of 29,743 cancer patients and 364 distinct tumor entities. The most 
profound deletion of the FAM96A locus (chromosome 15q22.31) was observed in 
48.8 % of gastrointestinal stromal tumors (GIST). This in silico result about copy 
number aberrations (CNAs) was then further investigated by real time PCR analysis 
and immunohistochemistry of two different cohorts of GIST patient samples. In the 
first cohort, FAM96A mRNA levels were found to be diminished in 29 of 31 GIST 
independent of tumor grading (low risk, borderline, high risk or metastasis). 
Quantitative real time PCR with GIST material was performed in collaboration with 
Kurt Zatloukal (Institute for Pathology, University of Graz) (data not shown). 
Reduced protein levels were also observed when comparing 4 GIST samples to 
normal tissue from small intestine (material provided by Pathology department, 
University of Heidelberg; Pick, 2006). In a second cohort, FAM96A expression in 
biopsies from 53 different GIST cancer patients was investigated by 
immunohistochemistry by Dr. Abbas Agaimy (Institute for Pathology, Erlangen) (Fig. 
3.9 A). Tumor samples were derived from different areas of the gastrointestinal tract 
and, regardless of the cancer origin, none of the samples indicated positive staining 
for FAM96A. An example is represented by Figure 3.9 B. While normal liver tissue 
displayed strong cytosolic staining for FAM96A, GIST samples lacked protein 
expression.  
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When normal small intestine was analyzed by IHC, FAM96A protein was observed 
to be co-expressed together with the tyrosine kinase KIT in interstitial cells of Cajal 
(ICC), the precursor cells of GIST (Corless et al., 2011) (Fig. 3.9 C). FAM96A 
expression decreases at some point during gastrointestinal stromal tumor 
development. Independent of KIT expression, FAM96A was also highly represented 
in a KIT-negative interstitial cell (red asterisk, Fig. 3.9 C). In order to narrow down 
the time point of FAM96A loss during GIST tumorigenesis, mRNA levels were 
investigated via quantitative real time PCR in sorted ICC and ICC stem cells (ICC-
SC) from the gastric tunica muscularis of BALB/c mice (T. Ordog, Rochester, data 
not shown). The findings confirmed high expression of mFAM96A in both cell types 
compared to the unsorted cell population. Furthermore, a tumorigenic, 
immortomouse-derived clonogenic ICC-SC population that underwent malignant 
transformation was compared to its nontumorigenic precursor cell line for expression 
of mFAM96A, and decreased mRNA levels were observed in the transformed cells 
(T. Ordog, data not shown). According to these data, loss of FAM96A occurs 
simultaneously with malignant transformation of ICC stem cells.  
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Figure 3.9: Immunohistochemical analysis of FAM96A protein expression in 
GIST precursor cells and GIST patient material  
Immunostaining of normal small intestine gastric tunica muscularis tissue reveals 
co-expression of KIT (blue) and FAM96A (brown) in the precursor cells of GIST, the 
interstitial cells of Cajal (ICC) (A): double-labeled myenteric ICC (black arrowheads), 
intramuscular ICC in longitudinal muscle (black arrow), intramuscular ICC in circular 
muscle (red arrows) and ICC within intermuscular septa (blue arrows). FAM96A was 
also detected in some myenteric ganglion cells (black asterisk), intramural blood 
vessels (blue asterisk) and KIT– interstitial cells (red asterisk). Magnification: 400x. 
Expression of FAM96A was analyzed in tumor tissue samples from 53 GIST 
patients of various origins within the GI tract of which none stained positive, in 
contrast to liver tissue, which served as a positive control (B, C).  
 
3.5.2 Re-introduction of FAM96A into gastrointestinal stromal tumor cell lines  
As loss of FAM96A occurs during GIST tumorigenesis, the consequences of its re-
expression in established GIST cell lines were one focus of further studies. For this 
purpose, two GIST cell lines, GIST48 and GIST882, were kindly provided by S. 
Bauer (University hospital, Essen, Germany). While GIST882 is a tumorigenic, 
imatinib-sensitive cell line that harbors an uncommon, homozygous, primary 
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activating mutation in Exon 13 of the c-kit receptor which codes for the ATP-binding 
region (K642E), GIST48 was established from an imatinib-resistant GIST that, in 
addition to the usual primary, imatinib-sensitive, homozygous Exon 11 mutation 
(V560D), has acquired an additional, heterozygous, secondary Exon 17 mutation 
(D820A, within the activation loop) which resulted in imatinib resistance. The 
secondary mutation was acquired while the patient was treated with imatinib and 
confers therapy resistance. When endogenous FAM96A protein expression was 
investigated in these two cell lines, residual amounts of FAM96A could be detected 
via immunoblotting in the GIST48 cell line, whereas GIST882 cells completely lack 
FAM96A expression in contrast to a colon carcinoma (RKO) and two glioblastoma 
cell lines (U87, T98G) (Fig. 3.10).  
                                                 
Figure 3.10: Analysis of FAM96A protein expression in GIST cell lines 
FAM96A protein expression was explored in two different established GIST cell 
lines, GIST48 and GIST882, and compared to one colon cancer and two 
glioblastoma cell lines. 150 µg of total protein lysate were loaded on a SDS gel and 
analyzed by immunoblotting with a polyclonal anti-FAM96A antiserum. Anti-β-Actin 
was used as a control for protein loading.  
 
Upon transient or stable re-introduction of FAM96A, both GIST cell lines displayed 
increased susceptibility to induction of cell death with and without staurosporine or 
imatinib treatment (Fig 3.11 A, C, D).  
A modest increase in 7-AAD positive cells upon imatinib treatment was achieved in 
GIST882, and was enhanced in FAM96A expressing cells compared to controls 24 
hours after treatment (Fig. 3.11 A). When imatinib was incubated for 72 hours on 
GIST882 cells in a later passage post transduction, no difference between controls 
and cells that were expressing increased FAM96A amounts could be observed (Fig. 
3.11 B). Interestingly, when later passages of both GIST cell lines re-expressing 
FAM96A were investigated for their pro-apoptotic nature, no differences compared 
to controls could be observed although FAM96A expression was retained.      
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In case of GIST48, transient re-introduction of FAM96A increased “basal” cell death 
even without apoptosis induction. Unspecific kinase-inhibition by staurosporine 
significantly induced cell death in the imatinib-resistant GIST48 cells (Fig 3.11 C), 
whereas the state-of-the art treatment for KIT-positive GISTs, Imatinib Mesylate, 
had only a slight influence on cell killing, as expected (Fig 3.11 D). However, an 
increased susceptibility of GIST48 due to stable introduction of FAM96A again 
uncovered the pro-apoptotic nature of the protein. 
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Figure 3.11: Consequences of re-expressing FAM96A in GIST cell lines 
The effect of re-introducing hFAM96A in GIST cell lines was investigated in 
GIST882 and GIST48 cells. 1.5 x 105 GIST882 cells stably transduced with FAM96A 
or the empty LeGoiG2 vector were incubated with DMSO or 10µM Imatinib Mesylate 
for 24 hours. Cell death was analyzed by flow cytometry following 7-AAD staining; 
n=4; Mean ± SEM (A). Re-expression of FAM96A was confirmed by immunoblotting 
(inset). 1.5 x 105 GIST882 stably transduced with FAM96A or the empty LeGoiG2 
vector were incubated with DMSO or 10µM Imatinib Mesylate for 72 hours. Cell 
death was analyzed by flow cytometry following 7-AAD staining; n=3; Mean ± SEM 
(B). 1.5 x 105 GIST48 cells were transiently transfected with hFAM96A-pcDNA3.1  
and pcDNA3.1 as a control, and 48 hours later, apoptosis was induced by treatment 
with 1µM staurosporine for 18 hours. PI-staining of the cell population was analyzed 
by FACS (C). FAM96A expression was confirmed by immunoblotting (inset). *, p ˂ 
0.05; n=3; Mean ± SEM. 1.2 x 105 GIST48 were seeded following transduction with 
FAM96A or the empty LeGoiG2 vector prior to incubation with 10µM of imatinib or 
DMSO as solvent control for 48 hours. Subsequently, viability staining with 7-AAD 
and flow cytometric analysis were performed (D); n=1. 
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3.5.3 Re-establishment of FAM96A protein expression in GIST882 cells and its 
influence on tumor growth in vivo 
To further investigate the observed pro-apoptotic effects of FAM96A retrieval in 
GIST cell lines, a subcutaneous tumor xenograft experiment was performed in 
NOD/SCID mice using GIST882 cells. GIST882 cells stably transduced with the 
LeGoiG2 control vector or the LeGoiG2-hFAM96A construct were sorted for GFP 
expression by flow cytometry (Fig. 3.12 A). Stable expression of FAM96A in the 
transduced cells was further confirmed by immunoblotting (inset Fig. 3.11 A), and 
tumor propagation was monitored for 83 days following tumor cell injection. 
Interestingly, in the hFAM96A-transduced group, only 5 of the 9 injected tumors 
successfully engrafted, whereas 8 of 9 control tumors started growing. Upon re-
introduction of FAM96A, the tumor volume was significantly reduced compared to 
controls (Fig. 3.12 B). Additionally, only three of the expanding tumors ever reached 
a palpable tumor volume of 70 mm3 (day 0) during 83 days of monitoring (Fig. 3.12 
C). As a consequence, the relative tumor volume (tumor volume (tv) at day n/tumor 
volume at day 0), as presented by Fig. 3.12 C, was severely decreased, and growth 
deceleration is indicated by an increased time period of the FAM96A tumors before 
reaching a volume of 70 mm3 compared to the control tumors. The tumor burden of 
excised tumors at the end of the experiment was significantly reduced in hFAM96A-
expressing GIST882 compared to empty vector control tumors (Fig. 3.12 D). 
Tumors of both groups were GFP-positive at the last day of monitoring (data not 
shown). As a result, re-introduction of FAM96A significantly reduces GIST 
tumorigenicity in vivo.  
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Figure 3.12: Consequences of FAM96A re-introduction for tumorigenicity of 
the GIST882 cell line 
7.7 x 106 GIST882 cells lentivirally transduced either with FAM96A or empty 
LeGoiG2 vector (A) were subcutaneously xenografted into the right flank of 
NOD/SCID mice (B). Successful engraftment was detected in 8 of 9 mice injected 
with empty vector-transduced cells, and in 5 of 9 mice injected with FAM96A-
overexpressing cells. Tumor growth was significantly reduced in the hFAM96A-
group compared to the control at 39, 43, 47, 50, 56, 67, 70, 74 and 77 days post 
injection; *=p˂0.05; unpaired student´s t-test; Data are presented as Mean ± SEM 
(B). Relative tumor volume at day 0 (tumor volume (tv) of 70 mm3) was reached at a 
significantly increased latency when FAM96A was re-introduced. Only 3 of the 5 
engrafted tumors ever reached 70 mm3. Relative tumor volume (tv at day n/tv at day 
0) (day n = time point of measurement after day 0; tumors monitored twice during 
one week) (C). Tumor weight of hFAM96A tumors (n=5) compared with control 
tumors (n=6) at day 83 post injection; *=p˂0.05; unpaired student´s t-test (D). Data 
presented as Mean ± SEM.   
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3.5.4 Protein expression of FAM96A in tumor vs. normal tissue biopsies 
To further evaluate the general tumor-suppressive potential of the pro-apoptotic 
protein FAM96A, its expression was analyzed in multi-tumor tissue arrays by IHC. 
Biopsies of 2 mm in diameter from several tumor entities and normal tissue sections 
were incubated with a purified polyclonal anti-FAM96A antiserum. Tissue arrays 
were kindly provided by the NCT (National Center for Tumor Diseases, Heidelberg) 
and IHC was performed by R. Rieker (Institute for Pathology, Erlangen). 
 
3.5.4.1 FAM96A is reduced in several cancer entities  
Patient samples representing 18 different tumor entities were analyzed for FAM96A 
expression and compared to normal tissue material. Tumor biopsy punches of 2 mm 
in diameter were spotted on a microscope slide and incubated with an anti-FAM96A 
antiserum (Fig. 3.13 A). FAM96A protein levels were reduced in most of the tumor 
material investigated. Blue staining indicates weak expression (score 1) of the 
protein, whereas brownish staining suggests high tissue abundance (score 3). A 
strong expression in macrophages of lung and spleen was observed. This finding 
confirms existing microarray data on FAM96A mRNA expression (Chen et al., 
2012). All normal tissues displayed an intermediate (score 2) to strong (score 3) 
FAM96A expression, while the protein abundance was between weak (score 1) and 
intermediate in most tumor tissues analyzed (Fig. 3.13 B). Protein levels of FAM96A 
in patient samples were not changed in tumor material derived from colon, bile duct, 
prostate, uterus and ovary when compared to corresponding normal tissue.  
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Figure 3.13: IHC analysis of a multi-tumor array to compare FAM96A protein 
levels to normal tissue   
In a multi-tumor tissue array, several tumor entities were investigated for their 
FAM96A expression and compared to normal tissue samples. Punched biopsy 
samples of 2 mm in diameter were transferred to microscope slides and incubated 
with the respective antibody (A). 18 different tumor entities and nonmalignant 
precursor tissues were compared for their FAM96A expression (B). Mean values are 
presented; Scoring: 1: low, 2: intermediate, 3: strong expression, x: not analyzable 
 
3.5.5 FAM96A expression in kidney and bladder compared to transformed tissue 
The patient material analyzed in multi-tumor tissue arrays revealed a strong 
reduction of FAM96A protein expression in renal (RCC) and transitional cell 
carcinoma (TCC). 4 RCC samples were compared to 27 normal kidney punches and 
6 bladder samples to 3 TCC. As an example, high expression in the normal bladder 
epithelium is indicated by the brownish staining in the cytoplasm of cells (Fig. 3.14 
A), while the protein was hardly detectable in transitional cell carcinoma. Loss of 
FAM96A expression in tumor tissue compared to normal kidney was also observed 
for samples from renal cell carcinoma (Fig 3.14 B). A potential influence of FAM96A 
as a tumor-suppressor in renal cell carcinoma was investigated in Renca-lacZ cells. 
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Figure 3.14: Immunoreactivity of an anti-FAM96A-antiserum in renal and 
bladder cancers compared to their tissues of origin 
6 different bladder biopsies were incubated with anti-FAM96A antiserum and 
compared to 3 transitional cell carcinoma punches (A). Brownish staining indicates 
strong immunoreactivity of the polyclonal anti-FAM96A antiserum in the cytosol of 
the bladder epithelial cells. 27 normal kidney biopsies were compared to 4 renal 
carcinoma samples for their FAM96A expression levels. Representative pictures of 
the tumor and normal tissue sections are presented in B.  
 
3.6 The interaction of FAM96A with the cytosolic iron sulfur cluster assembly 
protein Ciao1  
In a global yeast-two hybrid screen for disease-associated genes, the interaction of 
human FAM96A and Ciao1 was first described (Rual et al., 2005). During the course 
of our investigations, the structure of FAM96A was resolved and its interaction with 
Ciao1 was verified by Chen et al. (Chen et al., 2012). Ciao1 is a 38 kDa, WD40 
repeat-containing protein that plays a major role in cytosolic iron sulfur cluster 
assembly and is assumed to be involved in DNA metabolism (Ito et al., 2010; 
Srinivasan et al., 2007; Stehling et al., 2012; van Wietmarschen et al., 2012). A 
polyclonal anti-Ciao1 antibody (Immunogen: SVLNSHTQDVKHVVWHPSQELLASA-
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SYDDTVKLYREEED-DWVCCATLEGH) was investigated for its specificity of 
detecting human and murine Ciao1 (Fig. 3.15 A). In case of murine Ciao1, 
background staining is higher than for its human homolog, as a second, unspecific 
band occurred for the NIH/3T3 lysate.  
The interaction of FAM96A with Ciao1 was confirmed by co-immunoprecipitation of 
Ciao1 by Flag-tagged FAM96A with an anti-Flag antibody (Fig. 3.15 B). An anti-
Cyclin D2 antibody of the same IgG subtype served as a negative control for the co-
immunoprecipitation. A “beads only” control was added to exclude potential 
unspecific protein interaction with the agarose beads.   
 
Figure 3.15: Overexpressed, Flag-tagged FAM96A interacts with endogenous 
Ciao1 
The specificity of a polyclonal anti-Ciao1 antibody for detection of the human and 
murine protein (38 kDa) was analyzed by immunoblotting. 100 µg of total protein 
lysate per lane were loaded on a SDS gel (A). 2 x 106 HEK293T cells were seeded 
24 hours prior to transfection of Flag-tagged FAM96A. After immunoprecipitation of 
overexpressed FAM96A via an anti-Flag antibody coupled to Protein A/G agarose 
beads, endogenous Ciao1 was successfully co-precipitated. An anti-Cyclin D2 
antibody of the same isotype and agarose beads served to ensure the specificity of 
the binding (IP control, beads only). n=4, one representative immunoprecipitation is 
depicted in B. 
 
3.7 A possible involvement of Ciao1 in the intrinsic cell death pathway 
As an interaction partner of FAM96A, an involvement of Ciao1 in the regulation of 
the mitochondrial cell death pathway can be envisioned. Ciao1 might facilitate 
apoptosome formation in collaboration with FAM96A, or it could intervene in the 
APAF-1/FAM96A interaction and thereby antagonize FAM96A function directly or 
indirectly. Therefore, apoptosis assays upon upregulation and reduction of Ciao1 
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were performed to investigate a potential role of Ciao1 in intrinsic apoptosis and a 
possible interplay of the two binding partners in apoptosis regulation.  
 
3.7.1 Co-expression of both interaction partners and consequences for 
apoptosis sensitivity 
 
In order to investigate a potential function of Ciao1 as an adaptor protein linking 
FAM96A to APAF-1 in vivo and facilitating intrinsic apoptosis, Ciao1 was transiently 
introduced into RKO cells which already stably overexpressed FAM96A (inset, Fig. 
3.16). Empty vector-transduced cells served as a negative control (RKO ctrl). An 
empty vector (pcDNA3.1) was transfected for comparison to transient Ciao1-
overexpression into the colon cancer cells. Intrinsic apoptosis was activated in RKO 
cells by UV-irradiation, mitomycin C treatment or incubation with staurosporine. 
Although a pro-apoptotic influence of FAM96A could be observed, a general 
reduction of cell death upon Ciao1 upregulation was obvious for all chosen apoptotic 
treatments (Fig. 3.16). This rather anti-apoptotic effect occurred independently of 
simultaneous FAM96A upregulation.  These findings indicate an antagonistic rather 
than a collaborative function of Ciao1 in FAM96A-regulated mitochondrial cell death.  
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Figure 3.16: Influence of Ciao1 on intrinsic apoptosis of FAM96A-
overexpressing colon carcinoma cells  
2 x 105 RKO cells transduced with hFAM96A or the empty LeGoiG2 vector were 
transfected with pcDNA3.1 (pcD) as a control or hCiao1. 24 hours later, apoptosis 
was induced by treatment of RKO cells with 100 mJ UV irradiation, 1µM of the 
kinase inhibitor staurosporine for 6 hours, or overnight treatment with 6 µg/ml 
mitomycin C (MMC). RKO cells were fixed with 70% ice-cold ethanol prior to PI-
staining and quantification of apoptosis by flow cytometry. SubG1 fractions of cells 
in three independent experiments are presented as Mean ± SD.  
 
3.7.2 Influence of a Ciao1 knockdown on FAM96A-influenced mitochondrial cell 
death  
To further investigate the observed antagonistic role of Ciao1 and whether its 
expression is of functional relevance for the FAM96A-induced increase in cell death, 
shRNA-mediated downregulation of Ciao1 in RKO cells was conducted. For this 
purpose, 5 different lentiviral shRNA constructs were analyzed for their capability to 
reduce Ciao1 levels following lentiviral transduction (Fig. 3.17 A). Severely 
diminished mRNA transcription was achieved by the pLKO.1-puro sh3 and sh5 
constructs. The sh5-vector-mediated Ciao1 knockdown, however, lost its stability 
during passaging of RKO cells (Fig. 3.17 B), while protein depletion in the sh3-
transduced cells remained stable under puromycin selection. Stable control cells 
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were generated via transduction of a non-targeting control shRNA and were 
compared to knockdown cells for their sensitivity towards apoptotic treatments.  
 
Figure 3.17: Ciao1 knockdown-stability in RKO cells between passage 2 to 
passage 6 post transduction 
2 x 105 RKO cells were stably transduced with 5 different shRNA constructs to 
achieve a Ciao1 knockdown. Reduction was most efficient in sh3 and sh5 
knockdown cells selected with 2 µg/ml puromycin (A). The long-term knockdown 
stability was investigated by immunoblotting with a Ciao1-specific antibody in 
passage 2 (A) and 6 post transduction (B). 80 µg of total lysate/lane were used for 
protein analysis, and Ezrin was chosen to verify equal loading. 
Human FAM96A or the empty vector pcDNA3.1 were transiently introduced into 
Ciao1-depleted cells, and cell death was analyzed by Nicoletti assays. An efficient 
increase in FAM96A protein levels upon simultaneous Ciao1 knockdown was 
confirmed by immunoblotting (inset Fig. 3.18). Cell death was induced by UV-
irradiation (120 and 150 mJ), mitomycin C (MMC), staurosporine or recombinant 
Flag-tagged Fas ligand (FasL) treatment. The result of two independent Nicoletti 
assays is depicted by Figure 3.18. FAM96A overexpression increased susceptibility 
towards intrinsic cell death induction via UV-irradiation or mitomycin C treatment in 
the non-targeting vector-transduced cells compared to pcDNA empty vector-
transfected controls. Ectopic expression of FAM96A had no such effects on the 
Ciao1 knockdown cell lines. Ciao1 reduction increased susceptibility towards cell 
death in untreated and treated cells in both knockdown cell lines compared to non-
targeting control cells, independently of simultaneous FAM96A upregulation. 
According to these data derived upon Ciao1 protein overexpression and reduction, 
the CIA protein Ciao1 exhibits an anti-apoptotic function. 
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Figure 3.18: Influence of Ciao1-reduction and simultaneous FAM96A 
overexpression on RKO cell death  
2 x 105 RKO cells with a Ciao1 knockdown were transfected with hFAM96A-
pcDNA3.1 or the empty pcDNA3.1 vector as a negative control. 24 hours after 
transfection, cell death was induced by 120 or 150 mJ UV irradiation for 6 hours, 
mitomycin C (MMC; 10 µg/ml) for 12 hours, staurosporine 1µM (6 hours) or 
recombinant Flag-tagged Fas ligand (40 ng/ml, together with 1µg/µl anti-Flag 
antibody and 0.1 µg/µl Cycloheximide for 6 hours). Cells were harvested, fixed in 
70% ethanol prior to PI-staining and analyzed by flow cytometry. Hatched bars = 
FAM96A-transfected; Data represent Mean ± SEM of two independent Nicoletti 
assays. 
 
3.8 Functional interplay of Ciao1 and FAM96A in the regulation of the 
transcription factor WT1? 
The transcription factor WT1 plays an important role during nephrogenesis and is 
mutated in childhood nephroblastoma. The interaction between WT1 and Ciao1, and 
the Ciao1-mediated inhibition of transcriptional activation was first described by 
Johnstone et al. (Johnstone et al., 1998). 
 
3.8.1 Can FAM96A interfere with the interaction of Ciao1 and WT1? 
Ciao1 binds to both proteins, FAM96A and WT1, and therefore, a simultaneous 
interaction of all three proteins cannot be excluded and was investigated during this 
study. As a first approach to analyze the potential cytosolic assembly of the three 
proteins, immunoprecipitations were performed. Ciao1 alone (0) or together with 
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FAM96A (1) were overexpressed in HEK293T cells to analyze whether FAM96A 
interferes with the WT1/Ciao1 interaction. A reduction of co-precipitated WT1 upon 
Ciao-1 immunoprecipitation was expected in the presence of FAM96A 
overexpression. Upon precipitation of Ciao1, no influence of simultaneous 
overexpression of FAM96A on the interaction with WT1 could be observed in two 
independent experiments (Fig. 3.19). As a control for specific interaction, an anti-
p15 antibody of the same isotype was used. Here, an unspecific precipitation of 
FAM96A with the p15 antibody was observed.  
 
Figure 3.19: Influence of FAM96A expression on the WT1/Ciao1 interaction 
Ciao1 only (0) or Ciao1 and FAM96A in a ratio of 1:1 (1) were introduced into 2 x 
106 HEK293T cells. 24 hours later, cells were harvested and co-immunoprecipitation 
of Ciao1 was performed via antibody-coupled protein A/G agarose beads. An anti-
p15 antibody served as a control for specific interaction. An unspecific precipitation 
of FAM96A occurred with the p15 antibody. n=2 
 
3.8.2 Ciao1-mediated modulation of the transcriptional activity of WT1 
The epidermal growth factor family member Amphiregulin (AREG) was described as 
a bona fide target of the transcription factor WT1 (Lee et al., 1999) and served as a 
readout for WT1 activity in Luciferase assays. The influence of Ciao1 and FAM96A 
on WT1 activity following overexpression of both proteins was investigated (Jung, 
2012). WT1-mediated activation of the AREG promoter was significantly increased 
upon transient Ciao1 upregulation. Synchronous FAM96A expression had only 
moderate antagonistic influence and -in 5-fold excess- reduced WT1 activity.  
                                                                                                                           Results 
	  
90	  
	  
The influence of Ciao1 and FAM96A on the regulation of WT1 target genes was 
further investigated on mRNA level by quantitative real time PCR. The WT1 
promoter is subjected to autoregulation by its own protein (Malik et al., 1994; 
Rupprecht et al., 1994). Therefore, a potential influence of Ciao1 and FAM96A on 
WT1 promoter-suppression and mRNA expression was investigated. The two 
different isoforms derived from alternative splicing of the WT1 transcription factor 
that are involved in transcriptional regulation (-KTS, WT1 B) and RNA processing 
(+KTS, WT1 D) were transiently overexpressed in HEK293T cells. Simultaneously, 
Ciao1 and FAM96A expression were increased and the overexpressed WT1 mRNA 
levels were quantified by real time PCR. A significant increase in WT1 mRNA upon 
expression of the –KTS as well as the +KTS isoform could be observed that was 
largely reduced in the presence of overexpressed Ciao1 alone and in collaboration 
with its binding partner FAM96A. Ectopic expression of FAM96A together with WT1 
resulted in slight, but insignificantly reduced mRNA expression of -KTS (Fig. 3.20), 
while mRNA-levels of the +KTS isoform were marginally increased. FAM96A 
exhibited only minor influence on the Ciao1-mediated reduction in WT1-mRNA 
levels of both isoforms.  
 
Figure 3.20: Analysis of WT1 mRNA levels following Ciao1 and FAM96A over-
expression  
2 x 105 HEK293T cells were seeded 24 hours prior to transfection with murine WT1 
-/+ KTS isoforms (B and D), Ciao1 and FAM96A. 30 hours after transfection, cells 
were harvested, and mRNA expression of transfected WT1 was investigated by real 
time quantitative PCR using total RNA preparations. The relative quantification was 
performed with mean expression levels of human GAPDH and HPRT. GFP-
transfected cells were used as a control (mock). –KTS, wt and mock: n=4, +KTS: 
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n=3; data are presented as Mean ± SD, one-way analysis of variance (ANOVA), 
Bonferroni post-test. 
 
3.9 Analysis of a conditional FAM96A knockout mouse model 
To study the physiological function of FAM96A, a conditional knockout mouse model 
(EUCOMM Project: 26229) was generated. The targeting vector construct is 
depicted below.  
 
 
Exon 3 of the FAM96A transcript was flanked by loxP-sites and after site-specific 
recombination due to activity of the Cre recombinase, a truncated FAM96A mRNA 
containing the first 2 Exons is left. The efficient trapping of this transcript is expected 
to be warranted due to the insertion of the En2 SA and a polyadenlyation signal 
within the reporter cassette (Skarnes et al., 2011; Testa et al., 2004). The lacZ gene 
is inserted to indicate FAM96A promoter activity within mouse tissues. The transcript 
produced originating from the first two remaining exons is predicted to give rise to a 
newly generated full length protein of 22.7 kDa (http://web.expasy.org/cgi-
bin/compute_pi/pi_tool; theoretical pI 8.67; and 19 kDa (pI 8.32) for the alternative, 
truncated protein sequence: MERVSGLLSWTLSRVLWLSGFSEHGAAWQPRIMEE-
KALEVYDLIRTIRDPEKPNTLEELEVVTESCVEVQEINEDDYLVIIKFTPTVPHCSLAT
LIGPRSRKPKKKNPNKEDKRPRTAFTAEQLQRLKAEFQTNRYLTEQRRQSLAQEL
GTRKIWTLENSAPLPPPPLTLLAEAAWNKAGVRLSICYFPPYCRLLAM (in red: 101 
putatively generated “nonsense” amino acids).  
In knockout mice generated from site-specific recombination from the FRT sites 
using the FLP recombinase, prior to Cre recombinase-mediated truncation of Exon 
3, a dedicated transcript of 102 amino acids is generated 
(MERVSGLLSWTLSRVLWLSGFSEHGAAWQPRIMEEKALEVYDLIRTIRDPEKPNT
LEELEVVTESCVEVQEINEDDYLVIIKFTPTVPHCSLATLIVGNLHF). The last 6 
amino acids are newly translated and derived from translocation of Exon 4. 
Importantly, a new in-frame stop codon is generated within the next to last exon 
(Exon 4) and the transcript is not recognized by non-sense mediated decay (NMD). 
As the novel stop codon is located within the last 50 bp of the second last exon, the 
exon junction complex cannot interact with the translation termination factors and 
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the protein is synthesized. The theoretical molecular weight of the newly translated 
protein is 11.697 kDa (pI 4.62, (http://web.expasy.org/cgi-bin/compute_pi/pi_tool) 
and the second and smaller putative protein derived from transcription from the 
alternative start codon (ΔN-FAM96A) has a predicted size of 8.04 kDa (pI 4.3). This 
mouse line was established, but not analyzed during this study.  
Heterozygous FAM96A mice containing one targeted allele were crossbred to CMV-
Cre mice on a C57Bl/6 background. The constitutively active CMV-promoter was 
chosen to achieve deletion of the floxed FAM96A Exon in every tissue of the 
progeny. In a second mating, heterozygous FAM96A+/-/lacZ mice expressing the Cre 
recombinase (FAM96A/lacZ) were inbred, resulting in homozygous FAM96A/lacZ 
Exon 3 knockout animals. As the complete knockout or knockdown of FAM96A is 
lethal in yeast (Peter Kötter, Frankfurt University), Drosophila melanogaster (Pascal 
Meier, University College London) and Danio rerio (Mathias Hammerschmidt, 
Cologne University) (unpublished data), embryonic lethality was also presumed for 
the homozygous knockout in mice. Surprisingly, mice were born and vital.  
 
3.9.1 Reporter gene expression within transgenic FAM96A/lacZ animal tissues  
No obvious phenotype was observed in the homozygous FAM96A/lacZ (FAM96A-/-) 
reporter animals. From homo- and heterozygous female Exon 3-knockout mice that 
contain a lacZ-reporter cassette in front of the targeted gene region, tissues were 
removed and analyzed for lacZ expression via X-Gal-staining (Fig. 3.21). A wild type 
C57Bl/6 mouse and a heterozygous FBP1/lacZ gene trap mouse served as controls 
for lacZ reporter-expression in tissues. The C57Bl/6 mouse served as a negative 
control, whereas the FBP1 gene trap mouse was chosen as a positive control for X-
Gal staining. While some background staining occurred in ileum, thymus, and uterus 
of wt animals, homozygous FAM96A-/- mice displayed the most intensive reporter 
activity in comparison to heterozygous animals in most tissues investigated. 
Intensive lacZ-activity was observed in lymphatic organs of homozygous animals 
(thymus and spleen, Fig. 3.21). A strong promoter activity of the FAM96A promoter 
was also observed within the ileum of FAM96A-/- animals compared to FAM96A+/-, 
FAM96A+/+ and the FBP1+/- tissue. FBP1 promoter activity in the murine brain was 
observed to be much higher compared to FAM96A promoter activity according to X-
Gal staining intensity (Fig. 3.21). Livers and mesenteric lymph nodes excised from 
wt C57Bl/6, heterozygous FAM96A/lacZ and FBP1/lacZ control mice compared to 
the homozygous FAM96A-/- animal displayed no difference in staining intensity due 
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to high background staining. No staining was observed in heart and lung of all the 
animals. According to these data, the FAM96A promoter is active almost 
ubiquitously in mouse tissues. Staining conditions should be improved, as overnight 
incubation in X-Gal solution yielded strong background staining in ileum, mesenteric 
lymph nodes, liver, uterus and thymus of the animals.     
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Figure 3.21: Analysis of lacZ reporter activity in FAM96A knockout mice via X-
Gal-staining of murine tissues 
Tissue samples prepared from a female wt C57Bl/6, heterozygous (+/-) and 
homozygous (-/-) FAM96A/lacZ knockout, and an FBP1/lacZ gene trap animal as a 
positive control were analyzed for lacZ expression following fixation and overnight to 
40 hours staining with X-Gal. Picture documentation followed washing of the stained 
tissues with DPBS. Afterwards, all tissues were bed in Roti Histofix for long-term 
storage. 
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4. Discussion 
Defects within the apoptotic pathways lead to severe pathologies in an organism, 
such as neurodegenerative diseases and cancer, or fundamental developmental 
defects during embryogenesis (Los et al., 1999; Schafer and Kornbluth, 2006). 
Oncogenic mutations in genes that regulate intrinsic apoptosis are common in 
malignancy and are responsible for initial neoplastic outgrowth, treatment failure and 
metastization (Lowe and Lin, 2000). Targeting of deregulated anti-apoptotic 
molecules involved in malignancy and restoration of pro-apoptotic activities are 
considered suitable approaches to induce cell death for cancer therapy (Lowe and 
Lin, 2000; Pick, 2006). The identification of novel pro- and anti-apoptotic effectors is 
indispensable from the development of further treatment strategies to overcome 
consistent mutational adaptations conferring malignant resistance.  
One aim of this project was to functionally characterize the APAF-1 binding protein 
FAM96A and to elucidate its pro-apoptotic potential that had been observed in 
preliminary investigations (Pick, 2006).  
 
4.1 Function of FAM96A in apoptosis and cancer 
4.1.1 FAM96A is involved in the intrinsic apoptosis pathway  
Evasion of the apoptotic program is a hallmark of cancer and the intrinsic apoptosis 
pathway is often deregulated in neoplasms (Hanahan and Weinberg, 2000). 
Reactivation of this cell death pathway is in the focus of current research. FAM96A 
was discovered as an APAF-1 interaction partner in a YTH screen for the C. elegans 
homolog of APAF-1, CED-4 and for several truncated versions as well as full length 
APAF-1S as baits (Völp, unpublished). The small protein FAM96A was observed to 
bind to APAF-1 in GST-pulldown experiments and preliminary co-immuno-
precipitation analyses (Pick, 2006; Mateus-Fernandez, unpublished). This study 
verified the interaction of the two proteins. Binding of FAM96A to APAF-1 could be 
confirmed for overexpressed as well as endogenous proteins within cellular lysates 
(Fig. 3.1). The binding site of FAM96A was mapped to the NOD of APAF-1S. If 
FAM96A would bind to the WHD (Fig. 4.1), or any other domain within the NOD of 
APAF-1 that is in close contact with the nucleotide-binding region, it could serve as 
a scaffold protein for conformational changes or facilitate nucleotide exchange on 
APAF-1 during apoptosome formation. Whether FAM96A binds only to the 
monomeric form or can interact with the apoptosome complex remains unresolved. 
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Upon induction of apoptosome formation in cellular lysates by the addition of 
Cytochrome c and dATP and subsequent size exclusion chromatography, FAM96A 
was found within high molecular weight fractions together with APAF-1, but this 
could also result from aggregation of FAM96A oligomers (data not shown). 
Furthermore, the stoichiometry of FAM96A bound to APAF-1 needs clarification. 
Oligomeric proteins such as FAM96A can co-exist in more than one state in vivo (Ali 
and Imperiali, 2005; Chen et al., 2012). Therefore, either one of the two different 
domain-swapped dimers, major or minor dimer, or the monomeric FAM96A protein 
might interact with APAF-1. Oligomerization of FAM96A could potentially occur in 
response to a certain stimulus, probably the release of mitochondrial factors during 
apoptosis, and increase the affinity of this conformational state of FAM96A for 
APAF-1. A transient interaction of FAM96A with APAF-1 is likely because the 
protein has not been identified as an integral part of the apoptosome so far (Fig 4.1. 
(1) and (2)). Recombinant co-expression of both interaction partners might reveal a 
potential scaffolding function of FAM96A on monomeric APAF-1. This function could 
have a significant influence on the drastic conformational changes within APAF-1 
during the initial steps of apoptosome formation (Fig. 4.1 (1)). Heptamerization of 
the platform for caspase activation can be triggered in vitro by addition of 
Cytochrome c and dATP to WD40-depleted APAF-1 (Riedl and Shi, 2004). The 
addition of FAM96A could facilitate or enhance oligomerization and thereby induce a 
stronger response to stimulation of the intrinsic pathway. The pro-apoptotic, cell-
cycle regulator Parcs (pro-apoptotic protein required for cell survival) has been 
suggested to maintain APAF-1 in an activatable conformational state, however, was 
not observed to be directly involved in apoptosome formation as an integral 
component (Sanchez-Olea et al., 2008).  
A model for a stabilizing function of monomeric FAM96A on APAF-1 is presented in 
Figure 4.1 (1).This stabilization could also be conferred by binding of one of the two 
different domain-swapped dimers. Furthermore, FAM96A might be able to stabilize 
the apoptosome complex as an integral part (3). Whether the protein is found within 
the heptameric complex can be analyzed in the future by induction of apoptosome 
formation and size exclusion analyses involving subsequent immunoprecipitation of 
complex proteins or functionally by monitoring of caspase activity in cellular lysates 
lacking FAM96A.  
In silico predictions and recent reports suggest a function for the DUF59 domain as 
an ATPase (Lezhneva et al., 2004; Schwenkert et al., 2010). This suggestion was 
addressed during this study using recombinantly expressed proteins in an ATPase 
activation assay. An intrinsic ATPase activity of FAM96A could not be observed in 
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one single experiment performed (data not shown). FAM96A could, however, serve 
as a nucleotide exchange factor during apoptosome formation (Fig. 4.1 (4), (5)). 
This assumption needs to be further addressed. It would be interesting to analyze 
whether the small protein can bind to radioactively labeled nucleotides. Unknown 
nucleotide exchange factors interacting with APAF-1 have been mentioned in recent 
reports (Bao et al., 2007; Bao and Shi, 2007), but have not been identified so far. 
Nucleotide exchange on APAF-1 in vitro is described to be enhanced by PHAPI, 
CAS and HSP70, but if this is due to facilitated apoptosome formation assisted by 
the three proteins, or whether one of them is a nucleotide exchange factor remains 
unresolved until now (Kim et al., 2008). The occurrence of additional adapter 
proteins complexed with APAF-1 has been frequently cited in literature (Benedict et 
al., 2000; Hill et al., 2004). Another pro-apoptotic APAF-1 interactor, NAC (NB 
domain and CARD) enhances caspase activation upon binding to the CARD domain 
of APAF-1 after unfolding of the autoinhibited protein during complex formation (Chu 
et al., 2001). Caspase-9 recruitment has been reported to be drastically enhanced 
by HCA-66, a protein that can bind to APAF-1 in its monomeric and oligomerized 
state, but has no influence on the oligomerization process per se (Piddubnyak et al., 
2007). Nucling is a pro-apoptotic molecule that binds to APAF-1 and is assumed to 
translocate the protein together with Caspase-9 from the cytoplasm to the nucleus 
(Sakai et al., 2004). Alpha-fetoprotein and acetylcholinesterase are pro-apoptotic 
proteins that can indirectly influence apoptosome formation (Schafer and Kornbluth, 
2006).  
                                                                                                             Discussion 
	  
98	  
	  
 
Figure 4.1: Model for the potential involvement of FAM96A during intrinsic 
apoptosis 
1: scaffolding function of FAM96A (monomer or dimers) on the activated APAF-1 
monomer; 2: short transient interaction facilitating conformational changes during 
oligomerization of the complex; 3: integral scaffolding function within the complex 
(pc-9: pro-Caspase-9); 4: nucleotide exchange factor function transferring ATP to 
the monomeric protein (before or after Cytochrome c binding); 5: nucleotide 
exchange factor bound to ADP; 6: ATP-bound apoptosome lacking FAM96A. 
Adapted from Reubold and Yuan et al., 2012.  
The in silico predicted molecular weight of FAM96A is 18.355 kDa. The fact that the 
protein is detected at a higher MW by immunoblotting implies that it might be 
subjected to posttranslational modifications which remain undefined until now. 6 
potential phosphorylation sites are located within FAM96A (Serine 124, Threonine 
46, 55, 84, Tyrosine 77, 117) as predicted by the NetPhos 2.0 Server 
(http://www.cbs.dtu.dk/services/NetPhos/). Two lysine residues (52, 113) are 
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predicted in silico for glycosylation (http://www.cbs.dtu.dk/services/NetGlycate/). 
Post-translational modifications also play an important role in regulation of the tumor 
suppressor p53, coordinating its interactions and subcellular localization (Green and 
Kroemer, 2009). Histone-deacetylase (HDAC) inhibitors were used to stabilize p53 
in preclinical experiments in cancer cells, but have not been established in clinical 
studies so far (Lane et al., 2010). Investigations about the posttranslational 
regulation of FAM96A might be of interest in the future.  
 
4.1.2 Functional investigations on the pro-apoptotic role of FAM96A  
This work aimed to characterize the physiological function of FAM96A. Preliminary 
results from transient FAM96A overexpression in RKO cells indicated a sensitization 
of cells towards stimulation of the intrinsic apoptosis pathway (Mateus-Fernandez, 
unpublished). This observation was further addressed by stable lentiviral FAM96A 
overexpression using the LeGoiG2 vector in several cancer cell lines. The pro-
apoptotic function of FAM96A could be confirmed in cell killing assays (Figs. 3.2 
and 3.3) upon stable overexpression of the protein. FAM96A upregulation 
successfully increased the sensitivity of cancer cells towards drug treatment with 
chemotherapeutics. Increased intrinsic apoptosis upon FAM96A overexpression 
could be verified in cell culture when RKO and Renca-lacZ cells were treated with 
mitomycin C or oxaliplatin. Both DNA crosslinking agents are currently in use or 
were used in the clinics to treat colorectal as well as renal cancer (Adrain et al., 
1999; Jin et al., 1992; Porta et al., 2004; Powles et al., 2008; Stein and Arnold, 
2012). The anticancer effects of oxaliplatin are optimized in combinatorial treatment 
with 5-fluorouracil and folic acid (FOLFOX) (Stein et al., 2012), nevertheless, 
significant pro-apoptotic effects were observed when the agent was used as 
standalone intervention together with simultaneous FAM96A overexpression. 
Statistically significant increases in cell death were observed for both 
chemotherapeutics in Renca-lacZ cells and for oxaliplatin-treated RKO cells when 
FAM96A expression was increased compared to empty vector-transduced control 
cells. The overexpression of FAM96A in Renca-lacZ cells was not stable, most 
probably due to the induction of apoptosis in cells expressing high levels of the 
protein.  
Vice versa, when murine fibroblast (NIH/3T3) and human colon cancer (RKO) cells 
were depleted of FAM96A via lentivirus-mediated shRNA transduction and 
compared to control vector-transduced cells, a significant desensitization towards 
UV-mediated killing could be detected (Figs. 3.5 and 3.6). Two separate vector 
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systems for the human FAM96A knockdown served to verify the apoptosis 
resistance-conferring consequence of FAM96A downregulation.  
In line with the FAM96A knockdown experiments, morpholino-mediated knockdown 
in zebrafish embryos also significantly reduced the sensitivity towards UV-induced 
cell death (M. Hammerschmidt, Cologne University, Fig. 4.2).  
 
 
Figure 4.2: TUNEL assay with morpholino-injected zebrafish embryos after UV 
irradiation 
Antisense morpholino oligonucleotides targeting zFAM96A (zFAM96A MO) or p53 
(p53 MO; positive control) were injected into 1-2-cell zebrafish embryos (0-1 hours 
post fertilization; hpf). Embryos injected with a morpholino bearing 5 mismatch 
mutations (zFAM96A 5mm MO) and uninjected embryos served as negative 
controls. At 4 hpf, the sphere-stage embryos were subjected to UV irradiation (20 s; 
50 mJ/cm2). (A) Apoptotic cells detected by TUNEL staining (dark brown dots) at 8 
hpf in representative whole embryos. (B) Apoptotic cells counted in 3 UV-irradiated 
zebrafish embryos. Data are means ± SD. Inset: Verification of knockdown 
efficiency by Western immunoblotting. To this end, zebrafish embryos were injected 
with an in vitro-transcribed Myc-tagged zFAM96A mRNA alone or in combination 
with zFAM96A MO or zFAM96A 5mm MO. Embryonic protein lysates prepared at 6 
hpf were analyzed using an anti-Myc antibody. Cadherin was used as a loading 
control. 
 
Increased protein levels of FAM96A were not observed to influence cell cycle 
distribution in one single experiment performed. Susceptibility towards G1-arrest 
induction by Rad-001 was observed to be moderately, but not significantly increased 
upon upregulation of FAM96A in Renca-lacZ cells (Fig. 3.8). Here, a combinatorial 
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treatment of the cells with an apoptotic stimulus, prior to G1-arrest induction will be 
useful in future experiments.  
 
An antagonistic, anti-apoptotic role for the smaller isoform of FAM96A has been 
suggested (Pick, 2006). However, preliminary results from this work (Fig. 3.7), 
together with other recent observations, suggest a rather pro-apoptotic function of 
ΔN-FAM96A (Jung, 2012). This supports the assumption that the C-terminus of the 
protein might be responsible for its pro-apoptotic function (Pick, 2006). It would be 
interesting to differentiate between the two FAM96A isoforms and their contributions 
to apoptosome formation. A specific interaction of the smaller isoform of FAM96A 
with APAF-1 is assumed, but could not be detected so far (Jung, 2012). The longer 
isoform was observed to be primarily involved in regulation of the intrinsic pathway 
and thereby with tumorigenicity. Differential expression of two different isoforms of 
ZO-2, another tumor-suppressor protein with the 2 isoforms ZO-2 A and C (which 
differ in 23 amino acids at the N-terminus) is assumed to play a role in pancreatic 
adenocarcinoma, where only the shorter isoform is expressed (Chlenski et al., 1999; 
Gonzalez-Mariscal et al., 2012). A rescue experiment performed by exclusive 
overexpression of the truncated isoform after an efficient FAM96A knockdown 
(removing both endogenous isoforms) would clarify the proposed pro-apoptotic 
function of ΔN-FAM96A.  
 
4.1.3 Conclusions about the potential tumor-suppressor function of FAM96A 
If FAM96A is considered to function as a pro-apoptotic protein with tumor-
suppressive potential, its expression should decrease or completely vanish during 
oncogenesis. Other tumor suppressor proteins such as p53, Rb, PTEN, BRCA1/2 or 
APC play key roles in development, tissue homeostasis and cancer inhibition and 
are frequently mutated in tumors (Berger et al., 2011). Here, the in vivo tumor- 
suppressive potential of the apoptosis-regulating protein FAM96A was initially 
investigated in subcutaneous xenograft experiments in NOD/SCID mice. The 
tumorigenicity of lentivirally transduced human colon and murine renal cancer cells, 
which displayed increased protein expression of FAM96A, was compared to empty 
vector- transduced cells. When these cells were injected subcutaneously into 
NOD/SCID mice, and tumor development was monitored over several weeks, an 
impaired tumor growth could be observed in human colon as well as murine renal 
cancer cells upon increased protein expression of FAM96A (Fig. 3.4). Additionally, 
mice were treated with mitomycin C. Overexpression of FAM96A compared to 
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control vector transduction successfully reduced resistance towards 
chemotherapeutic treatment in the colon cancer cell line and it decreased its 
tumorigenicity in vivo. The effect of simultaneous application of anticancer therapy 
and overexpression of FAM96A should however be investigated in more detail. In 
the case of the renal tumor xenograft, treatment with the cytostatic mitomycin C was 
started as soon as the tumor volume had reached 150 mm3, a value that can be 
considered as too high for these rapidly expanding tumors. In case of the RKO colon 
cancer tumor xenograft, only two mice of the seven animals within the mitomycin C-
treated FAM96A group showed engraftment of the cancer cells. The relative tumor 
volume of mitomycin C-treated RKO cells was reduced when FAM96A expression 
was simultaneously increased. Interestingly, the overall engraftment of RKO cells 
within the two groups of mice (treated and untreated, 7 animals per group) which 
overexpressed FAM96A was largely impaired. Only 5 out of 14 injected tumors 
successfully proliferated, while the 9 other mice did not display any engraftment post 
injection.  
 
4.1.3.1 Loss of FAM96A is important for GIST tumorigenesis, and its re-
introduction increases susceptibility to apoptosis of GIST cell lines 
A correlation of FAM96A expression with tumorigenicity was observed specifically in 
gastrointestinal stromal tumors, where FAM96A protein levels were found to be 
either poor or completely absent, as shown by immunoblotting and IHC (Figs. 3.9 
and 3.10). A loss of FAM96A in this tumor entity was initially observed by CGH, 
indicating deletions within the FAM96A locus with a frequency of around 50% for all 
GIST present in the CGH database. This was verified on mRNA as well as protein 
level in two separate GIST patient cohorts (Agaimy, Erlangen; Zatloukal, Graz, 
unpublished). The reduction of FAM96A in the different primary tumor samples, 
which were analyzed by quantitative real time PCR (data not shown) and IHC, was 
found to be independent of tumor grading or origin (Fig. 3.9). The precursor cells of 
GIST, ICC, were observed to express FAM96A as shown by immunohistochemistry 
(Fig 3.9). Real time PCR analysis of murine cell lines revealed loss of FAM96A to 
occur during GIST development, coincidental with malignant transformation of ICC 
stem cells (ICC-SC) (T. Ordog, unpublished). Although no experimental evidence 
exists, one can speculate that LOH of FAM96A might be one cancer promoting 
mutational event in GIST development, and loss of FAM96A obviously resembles a 
marker for GIST. A tumor xenograft experiment in which re-introduction of FAM96A 
in ICC-SC undergoing malignant transformation could potentially prevent GIST 
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development would be interesting to further confirm the tumor suppressor role of 
FAM96A in GIST. Another potential approach would imply deletion of FAM96A in 
ICC, and the investigation whether cells devoid of the tumor suppressor 
consequently undergo malignant transformation.  
Re-introduction of FAM96A into the established, imatinib-sensitive GIST882 cells 
that completely lack FAM96A protein expression as measured by immunoblotting 
(Fig.3.10), severely impaired tumor growth and the engraftment potential of these 
cells (Fig. 3.12). In the subcutaneous tumor xenograft experiment performed in 
NOD/SCID mice, only 5 of the 9 mice injected with GIST882 cells, in which FAM96A 
expression was re-established, developed tumors, as compared to empty vector-
transduced controls. Accordingly, an almost abolished engraftment potential of RKO 
cells was observed upon FAM96A overexpression. Thus, cell death of tumor-
initiating cells might result in decreased engraftment capacity and reduced 
oncogenic potential in both xenograft experiments.   
Furthermore, when GIST882 cells were treated with the tyrosine kinase inhibitor 
imatinib for 24 hours, simultaneous FAM96A re-expression enhanced cell killing, 
although no differences compared to control cells could be observed in later 
passages post transduction upon longer imatinib incubation (Fig. 3.11 B). 
Cell death of the imatinib-resistant GIST48 cell line was increased upon introduction 
of FAM96A, and additionally, significant pro-apoptotic effects were observed in 
FAM96A-transfected cells when apoptosis was induced by staurosporine compared 
to control vector-transfected cells (Fig. 3.11 C). The imatinib resistance of GIST48, 
acquired due to a secondary c-kit mutation, could not be overcome by 
overexpression of FAM96A (Fig. 3.11 D). 
Although FAM96A re-expression was maintained in later passages of the GIST cell 
lines 48 and 882, pro-apoptotic effects of FAM96A were lost, hinting towards 
unknown inhibitory or compensatory mechanisms within the cancer cells. This 
represents one major drawback of FAM96A re-establishment therapy.  
However, the results obtained from cell killing experiments upon FAM96A 
upregulation and depletion, and the three independent subcutaneous xenograft 
experiments imply that FAM96A exhibits a tumor-suppressive function. In support of 
this conclusion, reduction of FAM96A expression was observed for a variety of 
tumor entities in multi-tumor tissue arrays (Fig.3.13) and was drastic in the case of 
renal and transitional cell carcinoma (RCC and TCC) compared to normal tissue 
material (Fig. 3.14). This data derived from primary human renal cancer tissue 
samples is in accordance with the experimental data obtained from stable 
upregulation of FAM96A in the murine renal cancer cell line Renca-lacZ, when 
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overexpression of the protein diminished oncogenic potential (Figs. 3.3 and 3.4). An 
extensive analysis of FAM96A protein expression levels in primary tumor samples 
from human renal and bladder cancers compared to normal tissue is a focus of 
current investigations. RCC are strongly chemo- and radiotherapy-resistant, despite 
the fact that the apoptosome complex remains intact in these cells (Gerhard et al., 
2003). Signal transduction of intrinsic apoptosis has therefore been assumed to be 
disturbed at distinct sites in RCC.  
Reduction of oncogenicity upon FAM96A upregulation is not exclusively restricted to 
GIST, and a role for FAM96A as a novel universal tumor suppressor is suggested. 
Mechanistically, haploinsufficiency or, in some entities, obligate haploinsufficiency 
as observed for PTEN cannot be excluded (Berger et al., 2011). Obligate 
haploinsufficiency is present when cancer cells are strictly dependent on residual 
protein activity or expression of a tumor suppressor, and would succumb to 
senescence or cell death in the instance of TSG deletion (Berger et al., 2011). It 
would be of future interest if, besides from genomic deletions, other loss-of function 
mutations occur within the FAM96A gene, and if so, in which tumor entities and at 
which incidence. Restoration of the levels of the tumor-suppressor protein Par-4 
prevents neoplastic transformation. This tumor suppressor protein is inactivated by 
oncogenic Ras (Garcia-Cao et al., 2005; Qiu et al., 1999). FAM96A function could 
also be inhibited by anti-apoptotic oncogenes that are constitutively active at early 
stages of tumor development. Pathway and oncogene expression analyses in 
different tumor entities will shed light on this possibility. As another level of 
regulation of FAM96A gene expression in cancer, it would be interesting to analyze 
potential epigenetic influences that lead to silencing of the FAM96A promoter in 
tumors. The promoter of the pro-apoptotic, tumor cell specific suppressor Par-4 has 
been reported to be hypermethylated as an oncogenic event observed in a number 
of cancers (Hebbar et al., 2012). 
Furthermore, miRNAs regulating FAM96A expression could have important 
regulatory functions on the gene and should be investigated. Here, polymorphic 
variations in miRNA binding sites in cancer resulting from SNPs within the 3´UTRs 
or within the promoter region of FAM96A affecting transcription factor interaction 
could severely affect the regulatory network in tumor cells and with that the levels of 
protein expression of the TSG. Analysis of the miRNA/TSG interaction can indicate 
therapy response and is therefore important for patient prognosis (Berger et al., 
2011).  
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4.1.4 FAM96A as a potential therapeutic target for anticancer therapy 
FAM96A is lost or decreased in gastrointestinal stromal tumors, and its expression 
has been observed to be diminished in other cancer entities. Therefore, FAM96A 
loss can serve as a marker for tumorigenesis. Due to its positive influences on 
restoration and enhancement of apoptotic signaling, FAM96A represents a potential 
target for cancer therapy. As reconstitution of FAM96A protein expression strongly 
reduces the oncogenic potential, reintroduction of the protein into cancer cells would 
be a therapeutic option. In the case of FAM96A, gene therapy describes the most 
promising and efficient anti-cancer approach. Initially, gene therapy was designed 
for treatment of inherited diseases, however, expanded to the field of cancer 
research, and currently over 3249 clinical trials for gene therapy, of which 1291 are 
related to cancer, are ongoing worldwide ((Li et al., 2005) www.clinicaltrials.gov). 
Recombinant adenovirus-associated vectors (rAAV) represent a safe and efficient 
delivery system for gene therapy (Buning et al., 2008; Zentilin and Giacca, 2008). 
rAAV-mediated gene therapy approaches for cancer treatment include cytokines, 
antiangiogenesis genes, apoptosis inducers, suicide gene activation or oncogene 
downregulation (Li et al., 2005). In murine tumor xenograft experiments, tumor 
growth was strongly impaired following AAV2-mediated introduction of TRAIL (Mohr 
et al., 2004). Intratumoral AAV/p53 injection significantly reduced tumor growth in 
vivo in xenograft experiments. Increased expression of telomerase in tumor cells 
has also been targeted by AAV-vectors conferring siRNA-mediated knockdown of 
the enzyme (Li et al., 2005). Direct intratumoral application of a FAM96A-rAAV for 
overexpression in combination with radiation or chemotherapy would presumably 
exhibit tumor-suppressive effects. Due to its small size, the protein represents a 
suitable rAAV insert, as these vectors display limited coding capacity (4.5 kb). 
However, as for other TSGs, FAM96A therapy has some drawbacks due to the 
ubiquitous expression pattern of the protein and the expected potential side effects 
on nonmalignant cells upon viral infection. This can be overcome by specific 
identification of targeting peptides expressed by tumor cells (Büning et al., 2008). 
Here, an AAV peptide library of 7-mer peptides can be screened for selective 
targeting of GIST for example. ICC or normal tissue would be spared from infection 
with the GIST specific FAM96A-rAAV.  
Small molecule inhibitors and antisense approaches would be considerable if 
blockage of FAM96A by another protein would affect the function of the tumor 
suppressor as it is the case for p53 and Mdm2 or MdmX. Thus, the identification of 
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potential regulators of FAM96A should gain attention in future investigations (Lane 
et al., 2010). 
If recombinant FAM96A expression would yield high protein concentrations, another 
putative approach would imply the combination of the small protein with a protein 
transduction domain and intratumoral application of the fusion protein. The 
application together with a protein transduction domain has been described for 
Methallothionein fusion proteins before (Lim et al., 2010).  
Overall, cancer therapy approaches addressing the re-establishment of tumor 
suppressor function are not trivial because cancer cells harbor more than one 
oncogenic mutation and rapidly adapt to therapy by secondary mutations or 
oncogene upregulation.   
 
4.2 Involvement of FAM96A in cytosolic iron-sulfur assembly? 
As FAM96A efficiently binds the cytosolic iron sulfur cluster assembly protein Ciao1 
(Fig. 3.15), a potential role for FAM96A in CIA and vice versa, a role for Ciao1 in 
regulation of the intrinsic apoptosis pathway, cannot be excluded. The second 
mammalian DUF59 domain-containing protein, FAM96B, contains one conserved, 
hyperreactive cysteine residue and participates in the essential biogenesis pathway 
of iron-sulfur cluster biogenesis (Weerapana et al., 2010). Upon assembly of the late 
acting CIA complex which consists of FAM96B and Ciao1 together with MMS19, 
IOP1/NARFL and ANT2, a wide variety of Fe-S client proteins is loaded with Fe-S 
clusters for the execution of many cellular functions (Gari et al., 2012; Stehling et al., 
2012; van Wietmarschen et al., 2012). The contributions of ANT2 and IOP1 within 
this complex are currently under discussion. Recently, a DUF59 domain-containing 
protein has been characterized in Arabidopsis thaliana: AE7 (asymmetric leaves 1/2 
enhancer7). The DUF59 domain of the protein shares 58% identity with human 
FAM96B. AE7 is responsible for DNA integrity and exhibits a conserved function in 
CIA in plants (Luo et al., 2012). However, the FAM96B knockout phenotype in yeast 
could not be rescued by introduction of AE7, while the At-CIA1 (Arabidopsis 
thaliana) was able to protect Cia1 (the yeast Ciao1 homolog) deleted yeast from 
dying (Luo et al., 2012). DUF59 domain-containing proteins have been described to 
inhere several different functions across the biological kingdoms. In aerobic 
bacteria, two DUF59 domain-containing proteins are responsible for metal binding 
as subunits of the phenylactely-coenzyme A oxygenase complex PaaI (Song et al., 
2006). Furthermore, the first structure of a DUF59 domain-containing protein was 
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resolved from the anaerobic, hyperthermophilic bacterium Thermotoga maritima. 
The protein was suggested to be associated with Fe-S cluster assembly due to 
conserved cysteine and threonine residues within the proposed active site (Almeida 
et al., 2005). In Arabidopsis thaliana, the highly conserved, plastid localized DUF59 
domain protein HCF101 (high chlorophyll fluorescence 101) was initially described 
to be involved in Fe-S assembly in 2004 (Lezhneva et al., 2004). Five years later, 
Schwenkert et al. proved the functional contribution of HCF101 to Fe-S cluster 
assembly in Arabidopsis. The protein can bind and transfer Fe-S clusters to 
apoproteins, exhibiting a scaffolding function (Schwenkert et al., 2010). Fe-S 
clusters are bound by three cysteine residues in HCF101 of which one is essential 
for the binding and, consequently, highly conserved. FAM96A contains five cysteine 
residues, of which one is highly conserved (Cys90) and a C-X(7)-C motif that has 
been associated with metal and Fe-S cluster binding (Agnihotri et al., 2004; 
Schwenkert et al., 2010). Similar to its plant ortholog, FAM96A might potentially bind 
a Fe-S cluster, that is then transferred to apoproteins and thereby exhibit scaffolding 
functions during Fe-S biogenesis (Fig. 4.3 A). Thus, future investigations should 
address whether FAM96A is capable of transiently binding an Fe-S cluster, an event 
that can be analyzed by radiolabelling experiments, and especially, which of the 5 
cysteine residues would be responsible for the interaction with the Fe-S cluster. A 
sequential replacement of the cysteines by serine via site-directed mutagenesis 
would be one method to experimentally address this question.  
During CIA, FAM96A could act as a scaffold within an early CIA complex together 
with Ciao1 and IOP1/NARFL. This complex might be responsible for transport of the 
labile Fe-S cluster to the late CIA complex (Fig. 4.3. A1). Regarding the function of 
the FAM96A homolog, FAM96B, one would rather suggest a scaffolding function for 
the protein within the late acting CIA complex together with Ciao1 and probably also 
with MMS19 and ANT2 (Fig. 4.3. A2). The interaction of FAM96A with MMS19, 
ANT2 or IOP1 has not been investigated so far. Upon FAM96B deletion, DNA 
maintenance is impaired as various proteins involved in the preservation of genomic 
stability are dependent on Fe-S clusters (Gari et al., 2012; Stehling et al., 2012). 
Depletion of FAM96A would probably lead to an impaired loading of yet unknown 
target apoproteins and should be investigated in future experiments. The presence 
of a CIA-complex containing FAM96A, Ciao1 and potential novel target apoproteins 
can be analyzed by mass spectrometry-based immunoprecipitation proteomics (ten 
Have et al., 2011).  
On the other hand, due to its conserved cysteine residues, FAM96A could also be 
an apoprotein that is loaded with a Fe-S cluster during its interaction with Ciao1 and 
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which executes its functions upon integration of its prosthetic Fe-S group (Fig. 4.3 
B). That assumption appears less likely, referring to the described functions of 
DUF59 domain-containing proteins so far. A summary of the potential involvement 
of FAM96A in mammalian CIA is presented in Figure 4.3.  
 
Figure 4.3: Model for FAM96A function in CIA  
As a binding partner of Ciao1, FAM96A can contribute to cytosolic iron sulfur cluster 
assembly as a scaffold protein (A). It might either interact with Ciao1 and 
NARFL/IOP1 to facilitate the transport of Fe-S-clusters (A 1) to the late acting CIA 
complex or it can interact, like its homolog FAM96B, with proteins of this complex 
and thereby enable the loading of apoproteins (A 2). After loading, Fe-S proteins 
carry out their vital functions (A 3). Due to its conserved cysteine residues, FAM96A 
could exhibit apoprotein function and might be loaded with its prosthetic group by 
the CIA complex (B). Adapted from van Wiethmarschen et al., 2012. 
FAM96A might exhibit distinct functions in its different structural conformations. 
Chen et al. speculate that the two separate forms of the proposed dimer (major and 
minor dimer) fulfill different functions (Chen et al., 2012) in vivo. For example, one 
conformation might interact with APAF-1 or the apoptosome, another one with Ciao1 
as an integral part of a CIA complex. A conserved, ancient vital function of FAM96A 
independent of its regulatory function on PCD has been suggested earlier (Pick, 
2006). The potential participation of FAM96A in the ancient process of Fe-S cluster 
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biogenesis supports this hypothesis. Like Cytochrome c, which exhibits a conserved 
vital function in energy metabolism, FAM96A might have been integrated in the 
evolutionarily younger process of programmed cell death. 
 
4.3 A potential contribution of FAM96A and Ciao1 to intrinsic apoptosis and to 
the transcriptional activation of WT1 
A potential common contribution of FAM96A and Ciao1 to the regulation of the 
mitochondrial pathway of apoptosis was investigated. In overexpression and 
knockdown analyses, Ciao1 exhibited to some extend anti-apoptotic potential (Fig. 
3.16 and Fig. 3.18). Upon co-overexpression of Ciao1 and FAM96A, the decreased 
pro-apoptotic effects of FAM96A might potentially result from tethering by Ciao1 due 
to higher affinity of FAM96A for the CIA component. Assuming such a scenario, 
FAM96A would not be available to interact with APAF-1 and to facilitate apoptosome 
formation during intrinsic apoptosis. This should have been counteracted by 
simultaneous downregulation of Ciao1 and overexpression of FAM96A. However, 
when quantifying cell death, such a tendency could not be confirmed in the Ciao1 
knockdown experiments (Fig. 3.18). Reduced Ciao1 protein levels increased 
susceptibility of treated cells, independent of FAM96A expression. Therefore, it 
appears as if FAM96A and Ciao1 fulfill distinct functions in apoptosis regulation. It 
can be speculated that the observed anti-apoptotic nature of Ciao1 results from 
enhanced Fe-S loading of target apoproteins upon overexpression, and impaired 
CIA as a consequence of Ciao1 depletion, and the protein therefore has no direct 
influence on mitochondrial apoptosis.  
Ciao1 can bind to and regulate the transcriptional activity of WT1 (Johnstone et al., 
1998). It has originally been described as a transcriptional repressor, but recent data 
obtained in the group of Prof. M. Zörnig from luciferase assays report its activating 
role on WT1 (Jung, 2012). FAM96A function was analyzed in the context of Ciao1-
dependent regulation of WT1, investigating a potential antagonistic function for 
FAM96A. However, this weak antagonistic role of FAM96A on WT1 can be 
considered as inferior to Ciao1 function on WT1 and might result from formation of a 
putative trimeric complex on the WT1 target gene promoters (Jung, 2012). An 
interference of the Ciao1-WT1 interaction via simultaneous overexpression of 
FAM96A could not be observed in two independent competitive co-
immunoprecipitation analyses from cellular lysates (Fig. 3.19). Furthermore, 
diminished WT1 mRNA levels resulting from Ciao1 overexpression that were further 
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reduced by co-expression of FAM96A were only observed for the +KTS isoform of 
WT1 (Fig. 3.20). This isoform is involved in RNA processing and does not display 
transcription factor activity. The influence of FAM96A in this context was not 
significant, while the effect of Ciao1 on both isoforms of WT1, -KTS and +KTS was 
drastic (Fig. 3.20). One possible explanation for these conflicting results from 
luciferase reporter assays and WT1 mRNA quantification might arise from the fact 
that the WT1 protein is able to negatively autoregulate its own promoter (Malik et al., 
1994; Rupprecht et al., 1994). Unknown co-factors for negative autoregulation have 
been proposed, and Ciao1 could exhibit such a co-repressing function, conversely 
resulting in an increase in transcriptional activity of WT1 as the transcription factor is 
no longer subjected to autosuppression. In that way, Ciao1 would act as a fine-
tuning screw for transcriptional activity of WT1 due to inhibition of promoter 
suppression. The acquisition of further experimental evidence for this assumption 
should be in the focus of future experiments and here, electrophoretic mobility shift 
assays (EMSA), chromatin immunoprecipitations (CHiP) and luciferase assays 
would clarify the occurrence of a ternary WT1/Ciao1/FAM96A complex located on 
target gene promoters. Furthermore, a Ciao1-regulated activation of the WT1 
promoter could be investigated.  
 
4.4 Analysis of a conditional FAM96A knockout mouse model 
Knockout mouse models serve to analyze the physiological function of a gene, and 
conditional knockout mice can specifically serve to investigate pathological, 
developmental and a variety of other questions for a certain gene as they enable 
tissue specific gene deletion at will. 
 
4.4.1 Phenotyping of FAM96A/lacZ reporter mice 
To study the physiological function of FAM96A, a conditional knockout mouse model 
was established. Mice on a C57Bl/6 background, heterozygous for the expression of 
the FAM96A targeting cassette, were provided by EUCOMM, and matings with 
FLPeR deleter mice prior to CMV-Cre mice, or with CMV-Cre mice only were 
performed. Site-specific recombination mediated by the two recombinases FLP and 
Cre served to generate FAM96A Exon 3 knockout mice. Due to a newly generated 
Stopcodon by an Exon 4 frameshift within the mRNA transcript following FLP and 
Cre recombination, the RNA is predicted not to be recognized by nonsense-
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mediated decay (NMD), and a C-terminally truncated and modified protein of 11.4 
kDa is suggested to be generated. The knockout mouse strain was established but 
not analyzed during my PhD thesis. 
Following Cre-mediated recombination, the knockout alleles express a transgenic 
lacZ reporter cassette upstream of the deleted Exon 3 that serves as a reporter for 
endogenous FAM96A promoter activity. Due to a splice acceptor and a 
polyadenlyation signal, the remaining mRNA derived from the first two Exons of 
FAM96A is trapped, and a predicted putative novel protein of 22.7 kDa is generated 
(Skarnes et al., 2011; Testa et al., 2004). A knockout of Exons 3, 4 and 5 is 
generated at the RNA processing level. Additionally, the produced protein might be 
subjected to proteasomal degradation due to improper folding. Furthermore, a 
functional inactivation of the protein resulting from synthesis of the large new C-
terminus cannot be excluded and needs further investigations. Heterozygous 
FAM96A/lacZ knockout mice were inbred, and homozygous FAM96A-/- animals were 
preliminarily analyzed for the consequences of the C-terminal Exon 3, 4 and 5 
deletion. FAM96A-/- mice are born and vital, and they exhibit no differences in body 
weight compared to heterozygous and wt animals. Observations of BAK knockout 
mice also revealed no phenotype at all, and BAX-/- mice display only minor apoptotic 
defects, and show normal development. The double knockout (DKO) of these two 
functionally redundant genes BAX and BAK, however, exhibits severe 
developmental defects. Thymic selection is disrupted, lymphoid homeostasis is 
destroyed and 90% of DKO animals die perinatal (Ranger et al., 2001). 
Smac/DIABLO deficient mice are healthy, fertile and lack histological abnormalities 
(Okada et al., 2002). The existence of a functionally redundant substitutor in vivo or 
the participation of Smac in apoptosis only under specific circumstances or tissues 
was suggested as a potential explanation for the lack of phenotype of these mice. In 
analogy, functional redundancy of the two mammalian DUF59-containing proteins 
FAM96A and FAM96B might explain the viability of the FAM96A-/- mice, and 
FAM96A/B DKO mice might display more obvious phenotypes. A detailed 
phenotyping of FAM96A-/- mice might reveal defects in DNA-damage repair and 
chromosomal maintenance or other essential metabolic pathways, referring to the 
potential involvement of FAM96A in Fe-S biogenesis.  
Tissues from 6 week old female wt, FAM96A-/-/lacZ, FAM96A+/-/lacZ and a 
heterozygous FBP1+/-/lacZ mouse as a positive control were compared for their lacZ 
reporter gene expression by tissue staining with X-Gal, the substrate for β-
galactosidase. High activity of the FAM96A promoter was observed in lymphatic 
organs such as spleen and thymus (Fig. 3. 21). Data acquired during this thesis by 
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IHC report FAM96A to be highly expressed in macrophages of lung and spleen, and 
mRNA expression data on FAM96A expression in primary mouse macrophages by 
Chen et al. support this observation (Chen et al., 2012). Due to these findings, a 
potential immunomodulatory function of FAM96A in regulation of the immune 
system should be investigated in more detail.  
Furthermore, lacZ was observed to be highly expressed within the gastrointestinal 
tract of the FAM96A-/- mice (Fig 3.21, ileum). This finding suggests a significant 
FAM96A expression within the murine gastrointestinal tract and is in line with the 
immunohistochemical analysis of FAM96A protein expression in human ICC (Fig. 
3.9). The strong promoter activity might indicate requirement for FAM96A 
expression and thereby an increased susceptibility towards development of tumors 
associated with the GI tract, most probably gastrointestinal stromal tumors when 
FAM96A is lost. Long term observations and phenotyping of the knockout mice is 
necessary to monitor their potential spontaneous development of tumors, as it is 
observed in many other TSG knockout mouse models. 75% of p53-/- animals 
develop tumors (mainly T cell leukemia) at around 6 months of age (Hakem and 
Mak, 2001). Par-4 null animals do not suffer from embryonic lethality, but display 
age-associated pathologies, a significantly decreased survival, and increased 
susceptibility to chemically and hormonally induced cancers compared to 
heterozygous and wt animals (Garcia-Cao et al., 2005). Long-term investigations of 
spontaneous tumorigenesis in FAM96A-/-/lacZ mice and whether their average 
lifespan is decreased compared to FAM96A+/-/lacZ and FAM96A+/+ mice should be 
one focus of future investigations. Furthermore, mouse embryonic fibroblasts 
(MEFs) isolated from FAM96A knockout mice are assumed to exhibit increased 
resistance to apoptotic stimulation. Nucling-/- animals for example are viable and 
fertile, and their MEFs display severely increased resistance towards apoptosis 
induction via UV irradiation compared to wild type MEFs (Sakai et al., 2004).  
The tumor-suppressive role of FAM96A in vivo can be further investigated in the 
future by means of established knockout mouse models. Referring to the observed 
tumor suppressor function of FAM96A in GIST, FAM96A knockout mice can be 
inbred with homozygous Kit K641E animals, a mouse model for GIST (Rubin et al., 
2005). Consequently, homozygous knockout progeny might succumb to GIST 
development more rapidly than heterozygous FAM96A animals. Furthermore, 
tamoxifen-inducible transgenic mouse models such as inducible Cre mice represent 
a valuable tool for targeted induction of a gene knockout at specific time points 
during tumorigenesis for example (Feil et al., 2009; Saunders, 2011). Here, the time 
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point and dependency of FAM96A loss during GIST or development of other tumors 
such as RCC and TCC could be analyzed in vivo.  
As a model for the induction of bladder cancer, for which a significant decrease of 
FAM96A expression has been identified in this study, the carcinogen N-Butyl-N-(4-
hydroxybutyl)nitrosamine can be fed to the mice in drinking water (Garcia-Cao et al., 
2005). Monitoring of the animals would reveal whether the FAM96A-/- mice are 
predisposed to develop bladder cancer or whether tumorigenesis occurs with a 
decreased latency as compared to wt and FAM96A+/- mice.   
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6. Appendix 
6.1 Abbreviations 
7-AAD  7-Aminoactinomycin D 
17-AAG 17-N-Allylamino-17-demethoxygeldanamycin 
°C  degree Celsius 
aa          amino acids 
AGM  aorta-gonad-mesonephros region 
Akt  v-akt murine thymoma viral oncogene homolog 1 
APAF-1 Apoptotic protease activating factor-1 
APS        ammoniumperoxodisulphate  
ATCC        American type culture collection 
ATP  adenosine-5´triphosphate 
Bak  Bcl2-antagonist/killer 1 
Bax  Bcl2-associated X protein 
BCL-2  B-cell CLL/lymphoma associated 2 
BCLxL  Bcl2-like 1 
bp                   base pairs 
BSA        bovine serum albumine  
C. elegans Caenorhabditis elegans 
CARD  Caspase activation and recruitment domain 
Caspase aspartate-specific cystein proteases 
Casp-  Caspase 
Ciao1  cytosolic iron sulphur cluster assembly protein 1 
CD  cluster of differentiation 
Cdk  Cyclin-dependent kinase 
cDNA        complementary DNA 
CED-4  Cell death abnormality-4 
ChIP  chromatin immunoprecipitation 
Chk  checkpoint kinase 
CIP  calf alkaline phosphatase  
dATP        2 ́-deoxy adenosine-5triphosphate 
DD  death domain 
DED  death effector domain  
DIABLO direct IAP-binding protein with a low pI 
DISC  death-inducing signaling complex 
DMEM        Dulbecco ́s modified Eagle ́s medium  
DMSO        dimethyl sulphoxide 
DNA  deoxyribonucleic acid 
DPBS        Dulbecco ́s phosphate buffered saline  
DR  Death receptor 
DTT        dithiothreitol  
E. coli        Escherichia coli  
ECL        enhanced chemiluminescence  
EDTA        ethylenediaminetetraacetic acid 
e.g.  exempli gratia 
EGF   epidermal growth factor 
EMSA  electrophoretic mobility shift assay 
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EtOH        ethanol  
Etc  et cetera 
EtBr        ethidium bromide  
FACS        fluorescence-activated cell sorting 
FADD  Fas associated protein with a death domain 
FBP  FUSE binding protein 
FBS        fetal bovine serum 
FL  fluorescence 
FSC  forward scatter 
g         gravity 
GTE        glucose-Tris-EDTA  
GI  gastrointestinal 
GIST  Gastrointestinal stromal tumor 
h         hour(s) 
HEPES 2-(4-(2-Hydroxyethyl)-1-piperazinyl)-ethanolsulfonsäure 
HPRT   Hypoxanthine phosphoribosyltransferase 1 
HRP        horseradish peroxidase 
HSP  heat shock protein 
HTRA2 high temperature requirement protein A2  
IAP  Inhibitor of apoptosis 
ICC  Interstitial cells of Cajal 
Ig         immunoglobuline 
IHC  immunohistochemistry 
IP         immunoprecipitation  
ISCU  iron sulfur cluster scaffold homolog 
kb         kilobase  
kDa        kilo-Dalton 
l         liter 
LB         Luria-Bertani medium 
LOH  Loss of heterozygosity 
µg  microgramm 
µl  microliter 
µM  micromolar 
µm  micrometer 
M         molar 
MAP kinase mitogen-activated protein kinase 
MCS        multiple cloning site  
MEFs  Mouse embryonic fibroblasts 
min        minute(s) 
mJ  millijoule 
ml  milliliter 
mM  millimolar 
mRNA        messenger ribonucleic acid 
mTor  mechanistic target of rapamycin 
myc  v-myc myelocytomatosis viral oncogene homolog (avian) 
NaOAc       sodium acetate  
nm  nanometer 
NF1  neurofibromin 1 
NOD  Nucleotide binding and oligomerization domain 
Noxa  phorbol-12-myristate-13-acetate-induced protein 1 
OD  optical density 
P/S        penicillin/ streptomycin 
PAGE        polyacrylamide gel electrophoresis 
PBS        phosphate buffered saline 
PCD  programmed cell death 
PCR        polymerase chain reaction 
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PDGF   platelet-derived growth factor 
PDGFR platelet-derived growth factor receptor 
PEI        polyethyleneimine  
PI         propidium iodide 
PI3K  phosphoinositide-3-kinase 
pH  pondus Hydrogenii 
PMSF        phenyl-methyl-sulfonylfluoride 
qPCR  quantitative real time PCR 
Rb  Retinoblastoma protein 
RGD  Arginine-Glycine-Aspartic acid 
RNA        ribonucleic acid  
RCC  renal cell carcinoma 
RNase        ribonuclease 
rpm        revolutions per minute  
RPMI  Roswell Park Memorial Institute medium 
RT-PCR reverse transcriptase-PCR 
RTK  receptor tyrosine kinase 
SC  stem cell 
SD  standard deviation 
SDS        sodium dodecyl sulphate 
sec      second(s) 
SEM  standard error of the mean 
shRNA short hairpin RNA 
SMAC  second mitochondria-derived activator of caspases 
SSC  side scatter 
ssDNA  single-stranded DNA 
SDH  succinate dehydrogenase 
TAE        Tris-acetate-EDTA buffer 
TBE        Tris-borate-EDTA buffer  
tBid  truncated Bid 
TCC  transitional cell carcinoma 
TE        Tris-EDTA buffer  
TEMED    N, N, N ́, N, -tetramethylethylendiamine 
TNF-α  Tumor necrosis factor alpha 
TRAIL  TNF-related apoptosis-inducing ligand 
TRAILR TNF-related apoptosis-inducing ligand receptor 
Tris         tris(hydroxymethyl)aminomethane  
TSG  tumor suppressor gene 
UV  ultraviolet 
V  volt 
WHD  winged helix domain 
X-Gal  bromo-chloro-indoyl-galactopyranosidase 
XPD  xeroderma pigmentosum group D 
YTH  yeast two hybrid
                                                                                                                         Appendix 
	  
128	  
	  
 
6.2 Danksagung 
Diese Arbeit wurde am Georg-Speyer-Haus in Frankfurt am Main unter Betreuung 
von Herrn Prof. Dr. Martin Zörnig angefertigt. Bei ihm möchte ich mich hiermit 
herzlich für die Bereitstellung des interessanten Projektes, die freundschaftliche 
Zusammenarbeit und die stetige Möglichkeit eigene Ideen zu verwirklichen 
bedanken. 
Bei Frau Prof. Dr. Beatrix Süß und Herrn Prof. Dr. Bodo Laube bedanke ich mich 
recht herzlich für die Betreuung dieser Arbeit seitens des Fachbereichs Biologie der 
TU Darmstadt.  
Ein weiterer Dank gilt meinen Kooperationspartnern Dr. Abbas Agaimy, Prof. Dr. 
Volker Dötsch, Prof. Dr. Matthias Hammerschmidt, Prof. Dr. Ralf Rieker, Prof. Dr. 
Tamas Ordog, Prof. Dr. Kurt Zatloukal und zu guter Letzt Jan Heering für die 
konstruktive fachliche Zusammenarbeit im Rahmen dieses Projektes.  
Ich danke den Verantwortlichen und Organisatoren des Graduiertenkollegs 1172 für 
die fachliche Weiterbildung und den Einblick in die beruflichen Optionen nach der 
Promotion. 
Meinen aktuellen und ehemaligen Kollegen: Uta, Moritz, Katha, Susanne, Inga, 
Venkatesh, Marek, Frederic, Sabrina, Steffi W.,G. und H., Katharina, Rasa, Patrik, 
Giel, Dagmar, Bernd, Julia, Nanni und Jenny danke ich für die schöne Zeit im Labor, 
das außerordentlich gute Arbeitsklima, ihre Unterstützung und Hilfe. Bleibt so wie ihr 
seid, simply nonexpendable! Jenny danke ich für ihre motivierte Mithilfe am 
FAM96A-Projekt im Rahmen ihrer Diplomarbeit.  
Bei allen Mitarbeitern des Georg-Speyer-Hauses möchte ich mich für die 
angenehme Arbeitsatmosphäre und die interessante und lehrreiche Zeit bedanken. 
Last but not least möchte ich mich ganz herzlich bei meiner Familie und meinen 
Freunden, allen voran meinen Eltern und meinem Bruder, für ihre liebevolle 
Unterstützung bedanken.  
                                                                                                                         Appendix 
	  
129	  
	  
6.3 Curriculum Vitae          
Name 
 
Date/Place of birth 
 
E-Mail 
 
Address 
 
Bettina Schwamb   
 
08/03/1983 Worms, Germany 
 
bettina.schwamb@web.de 
 
Georg-Speyer-Haus, 
Paul Ehrlich-Str. 42-44,  
60596 Frankfurt am Main 
         
01/04/2009-today PhD student 
 
Research Group of Prof. M. Zörnig, 
Georg-Speyer-Haus, Frankfurt am Main, Germany;  
 
“Functional analysis of the APAF-1 binding protein 
FAM96A“ 
08/2009-03/2012 Associate member of GK1172 
 
Goethe University, Frankfurt am Main, Germany; 
 
Participation in the interdisciplinary program “Biologicals“ 
03/2010-03/2012 Speaker of FIRST (Frankfurt International Research 
Graduate School for Translational Medicine) 
05/2008- 03/2009 Junior scientist 
 
University Hospital Hamburg-Eppendorf,  
Department of Medical Microbiology, Hamburg, Germany;  
 
“Interaction studies on Cdc42-GAP “ 
05/2007-02/2008 
 
Diploma degree student 
 
Department of Medical Microbiology, University of Mainz, 
Germany;  
 
„Investigations on cytokine responses of C. parvum- 
infected immunocompromised mice“ 
10/2002-02/2008 
 
10/2002-09/2004 
 
 
 
Diploma studies in Biology 
 
Basic study period; intermediate diploma degree (University 
of Mainz , Germany) 
  
 
                                                                                                                         Appendix 
	  
130	  
	  
09/2004-07/2005 
 
 
 
07/2005-02/2008 
 
04/2007 
 
Academic year (3rd year student); Microbiology, 
Parasitology, Virology course (University of Glasgow, 
Scotland) 
 
Advanced study period (University of Mainz, Germany) 
 
Diploma examinations: Immunology, Microbiology, Zoology 
02/2006-04/2006 
 
Working student at Sanofi Aventis  
 
Department of Metabolism, Frankfurt Hoechst, Germany 
 
11/2005 and 
11/2006-12/2006 
 
 
02/2008-05/2008 
 
 
Research assistant  
  
Department of Microbiology (Group of Prof. G. Unden);  
 
Medical Microbiology, University of Mainz, Germany 
(Group of Prof. F. Petry) 
1993-2002 Secondary school, general qualification for university 
entrance, Gymnasium zu St. Katharinen Oppenheim, 
Germany 
Mother tongue German (native) 
Other languages English (fluent),  
French (good) 
Grants 
09/2004-06/2005 
 
01/07/07-31/12/07 
 
05/2008-03/2009 
 
ERASMUS scholarship, University of Mainz, Germany 
 
Diploma student scholarship, University of Mainz, Germany 
 
PhD student grant, Research Training Group 1459: “Sorting 
and interactions between proteins of subcellular 
compartments” 
Vocational training ÄKTA FPLC training course (GE Healthcare, Munich) 
Mouse experimental training (UKE, Hamburg) 
Publications:  
  
“Dynamics of gut mucosal and systemic Th1/Th2 cytokine responses in interferon-
gamma and interleukin-12p40 knock out mice during primary and challenge 
Cryptosporidium parvum infection”; Tessema TS, Schwamb B, Lochner M, Förster 
I, Jakobi V, Petry F; Immunobiology 2009 
 
 “Complexome profiling identifies TMEM126B as a component of the mitochondrial 
complex I assembly (MCIA) complex“; Heide H, Bleier L, Steger M, Ackermann J, 
Dröse S, Schwamb B, Zörnig M, Reichert AS, Koch I, Wittig I, Brandt U; Cell 
Metabolism 2012 
 
                                                                                                                         Appendix 
	  
131	  
	  
“A functional yeast survival screen of tumor- derived cDNA libraries to identify novel 
anti-apoptotic mammalian oncoproteins“; Eißmann M, Schwamb B, Moser J, Köhl 
U, Rieker R, Agaimy A, Herpel E, Gutschner T, Kögel D, Riberio V, Böhm S, 
Diederichs S and Zörnig M; 2013 (in revision) 
 
 
“FAM96A is a Novel Pro-Apoptotic Tumor Suppressor in Gastrointestinal Stromal 
Tumors”, Schwamb B, Pick R, Mateus Fernández S, Völp K, Heering J, Dötsch V, 
Hammerschmidt M, Nowak M, Bösser S, Dälken B, Jung J, Penzel R, Beinoraviciute-
Kellner R, Zörnig I, Rabenhorst U, Zatloukal K, Truss M, Joos S, Rieker R, Agaimy 
A, Söder S, Herpel E, Bardsley M, Hayashi Y, Asuzu D, Syed S, Ordog T and Zörnig 
M; 2013 (in preparation) 
 
 
Talks and Poster presentations 
 
“Influence of IL-18 on the systemic and local immune response to C. parvum 
infection in IFNγ-/- and IL-12-/- mice“; B. Schwamb, T. S. Tessema and F. Petry, DGP 
conference 2008, Hamburg; Germany; 05/03/2008  
 
 “CABY, a novel pro-apoptotic APAF-1 binding protein“ Embo Molecular Medicine 
Workshop, Cell death and disease: -“Death in the alps 3.0“-; B. Schwamb and M. 
Zörnig; Obergurgl, Austria; 10/03/11-14/3/11 
 
 “CABY in tumorigenicity of gastrointestinal stromal tumors“ LOEWE Oncogenic 
signalling; Frankfurt, Germany; 09/02/12 
 
 “Loss of the pro-apoptotic protein FAM96A is involved in tumorigenicity of 
gastrointestinal stromal tumors“ The 8th European Workshop on Cell Death; 
EWCD, Death à la carte; Le-Monêtier-les Bains, France; 03/06/12-08/06/12 
 
                                                    
 
 
